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Abstract 
Colorectal cancer is a major cause of cancer-related death in the UK, in part as a 
consequence of a failure to detect the disease at its early stages and also to 
treatment failure due to the development of drug and radiation resistance. 
MicroRNAs (miRNAs), small non-coding RNAs, regulate the expression of tumour 
suppressor genes and oncogenes including KRAS and may influence cancer 
development and drug and radiation response in colorectal cancer. MiRNAs 
therefore have potential as biomarkers of disease progression and treatment 
response.  
Quantitative real time PCR analysis, in the form of Taqman Low Density Array 
(TLDA) miRNA cards, was firstly used to prolife colorectal adenomas, cancers and 
matched normal mucosae and isogenic KRAS mutant and wild-type colorectal 
cancer cell lines to identify potential candidate miRNAs that regulate KRAS 
signalling and are involved in colorectal cancer progression.  
The over-expression of miR-224 was identified to be an early and persistent 
event in colorectal cancer as it was increased in colorectal adenomas and 
cancers compared to patient-matched normal tissue. MiR-224 expression was 
also increased in KRAS WT cells compared to mutant cells and in KRAS/BRAF WT 
colorectal cancers compared to BRAF mutant cancers.  MiR-224 knockdown in 
KRAS WT cells increased the amount of GTP-bound activated KRAS, increased 
ERK 1/2 phosphorylation and also increased cellular 5-FU sensitivity thus 
mimicking a KRAS mutant phenotype. MiR-224 knockdown also reduced cell 
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invasion in vitro and miR-224 expression was additionally increased in liver 
metastases compared to patient-matched primary colorectal cancers. 
To identify novel mechanisms of drug resistance, two colorectal cancer cell lines 
HCT116 and DLD-1 were made resistant to 5-FU or oxaliplatin, following 
continuous incremental drug selection, and chemosensitivity to the colorectal 
cancer drugs 5-FU, oxaliplatin and irinotecan were compared using MTT 
cytotoxicity assays. MiRNA and messenger RNA (mRNA) expression differences 
in paired drug sensitive and resistant cells were identified using TLDA miRNA 
cards and Illumina HT-12 BeadChip mRNA expression arrays. To identify miRNAs 
involved in KRAS-mediated radiation resistance, isogenic KRAS WT and mutant 
colorectal cancer cell lines were treated with 5 Gy of ionising radiation and 
profiled using TLDA miRNA cards.  
MiRNA target prediction databases (mirDB, miRANDA, miRBase, TargetMiner 
and  TargetScan) identified common candidate target genes for each 
differentially expressed miRNA, and Metacore analysis predicted key processes 
and pathways involved in drug and radiation resistance. 
In the paired drug sensitive and resistant cell lines, miRNA and mRNA profiling 
and bioinformatics analysis predicted cancer-related pathways and processes 
involved with cell invasion, cell cycle regulation and glycolysis as drug resistance 
mechanisms, which were then experimentally validated. I identified candidate 
drug resistance genes (ACTB, TUBB, ANGPTL4, MCM4, ALDOA, PGAM1, and 
AKR1C3) involved in the aforementioned cancer-related pathways and processes 
xxi 
 
 
 
as well as candidate drug resistance miRNAs predicted to regulate the 
expression of my candidate drug resistance genes.  
In radiation treated KRAS WT and mutant cells, the pathways and processes 
involved in radiation response were similar to those predicted in acquired drug 
resistance. I also identified a number of miRNAs, including miR-224, that were 
differentially expressed in irradiated KRAS WT and mutant cells and that may 
modulate KRAS-mediated radiation resistance. 
My data suggests that miR-224 could be a useful disease progression biomarker, 
in conjunction with other markers, to aid in determining patient prognosis. 
Furthermore, this study has identified novel candidate drug and radiation 
resistance signatures that could aid as additional markers of treatment 
response. 
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Chapter 1 
1. General Introduction 
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1.1. Introduction 
1.1.1. The nature of colorectal cancer  
Colorectal cancer is a disease characterised by cancerous growths within the 
colon and rectum. Initially, colorectal cancer presents as benign polyps 
(adenomas), some of which progress to colorectal adenocarcinomas and invade 
and metastasise to secondary sites within the body. Cases predominate in the 
left side of the bowel, with cancers in the sigmoid colon, recto-sigmoid junction 
and rectum accounting for 60% of colorectal cancer cases (CRUK, 2014; Figure 
1.1). Colorectal cancer can be categorised into sporadic and familial, the latter of 
which accounts for less than 10% of colorectal cancer cases (Söreide et al, 2006). 
 
Figure 1.1: The anatomical distribution of colorectal cancer cases. Data collected in the 
United Kingdom between 2007 and 2009 show that 60% of colorectal cancer cases were 
diagnosed on the left side of the bowel; namely in the descending colon, sigmoid colon, recto-
sigmoid junction, rectum and anus (CRUK, 2014). 
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According to Cancer Research UK (2014), colorectal cancer is the fourth most 
common type of cancer in the UK, with approximately 41,500 new cases 
diagnosed and about 16,000 deaths each year. The high number of deaths is 
attributed to the fact that patients tend to present with their cancers at 
advanced stages, thus reducing the 5 year survival success rate of current 
treatment (Wang & DuBois, 2009) and highlighting the importance of early 
detection and treatment of this disease.  
The incidence of colorectal cancer has been shown to increase with age, with 
84% of cases arising in people who are 60 years of age or older. Diet is also 
another major risk factor in the development of colorectal cancer. Countries 
such as Japan have recently seen an increase in the rate of colorectal cancers as 
they adopt a more ‘westernised’ lifestyle and diet rich in red meat and abandon 
the more traditional staple diets rich in fibre, fruit and vegetables (Tominaga & 
Kuroishi, 1997). It has also been shown that immigrants develop the same risk 
for colorectal cancer of their new country, often within one generation, most 
probably due to the adoption of the lifestyle and diet (Le Marchand, 1999). 
Furthermore, a meta-analysis by Ma et al (2013) of 54 studies reported a 
positive association with obesity (defined by body mass index or waist 
circumference) and a higher risk of developing colorectal cancer.   
This brings into question, amongst other factors, the link between diet, lifestyle 
and the development of cancer. Additionally, patients with pre-existing chronic 
inflammatory diseases such as ulcerative and Crohn’s colitis have a 70% higher 
4 
 
 
 
risk of developing colorectal cancer compared to the general population 
(Lutgens et al, 2013).  
1.1.2. The development of colorectal cancer  
 
As previously mentioned, some colorectal adenomas are precursors to the 
development of colorectal adenocarcinomas, although many remain benign. 
Colorectal adenomas histologically present as either tubular, tubulovillous or 
villous and increasingly change from displaying low to intermediate to high 
grades of dysplasia during colorectal cancer progression (Konishi & Morson, 
1982).  
Vogelstein et al (1988) initially proposed colorectal carcinogenesis to be driven 
by a progressive acquisition of genetic mutations and chromosomal deletions. 
Their initial study in 172 colorectal specimens at different stages of cancer 
development proposed that a mutation in the KRAS gene and allelic losses or 
mutations in chromosomes 5q, 17p and 18q which correspond to, among others, 
mutations in the APC, TP53 and DCC genes respectively were required for the 
transition from normal colorectal epithelium to colorectal adenocarcinomas.  
However, a number of groups have since shown that this proposed model does 
not represent the majority of colorectal cancers (Smith et al, 2002; Frattini et al, 
2004; Samowitz et al, 2007). Smith et al (2002), for example, found in a cohort of 
106 colorectal cancers, that there was variability in mutation burden. For 
instance, the TP53 gene was mutated in 61.3% of all cancers, whilst 56% and 
27.4% of the cancers had mutations in the APC and KRAS genes respectively. 
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Importantly, only 6% of all cancers had mutations in the KRAS, TP53 and APC 
genes whilst approximately 11% contained no mutations in the aforementioned 
genes. Interestingly, mutations in KRAS and TP53 were found to rarely occur 
together, suggesting that they were involved in different pathways that lead to 
cancer development. Thus the study concluded that the original colorectal 
cancer model proposed by Vogelstein in 1988 may not actually represent the 
vast majority of sporadic colorectal cancer cases as the progressive 
accumulation of multiple mutations in these genes is not a prerequisite for 
cancer development. 
Microsatellite instability (MSI) is an alternative mechanism of colorectal cancer 
development (Kinzler & Vogelstein, 1996), in addition to chromosomal instability 
(CIN) which accounts for approximately 85% of colorectal cancer cases and is 
characterised by allelic losses, chromosomal amplification and translocations. 
MSI occurs as a result of frame-shift mutations or base pair substitutions in 
microsatellites, short tandem-repeated nucleotide sequences present within the 
genome (Söreide et al, 2006). MSI is caused by failure of the mismatch repair 
mechanism, either because of germline mutations in one of the mismatch repair 
genes such as MLH1 (causing hereditary non-polyposis colorectal cancer; 
HNPCC) or through its epigenetic silencing (contributing to sporadic colorectal 
cancer; de la Chappelle, 2004). Colorectal cancers with MSI have also been 
shown to have mutations in a number of genes, including those coding for TGF-
βR2 and the pro-apoptotic protein BAX (Fernández-Peralta et al, 2005), as well 
as β-catenin (Kim et al, 2003; Figure 1.2). In contrast, mutations in KRAS and 
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TP53 are inversely associated with MSI (Samowitz et al, 2001). Familial 
adenomatous polyposis (FAP), another type of familial colorectal cancer in 
addition to HPNCC, develops as a result of inherited alterations in the APC gene 
(de la Chapelle, 2004).  
 
Figure 1.2: The genetic alterations in colorectal cancer. The genetic alterations characterised 
by chromosomal changes and mutations in key genes in the chromosomal instability 
(microsatellite stable) pathway and the genetic alterations characterised by defects in DNA 
mismatch repair in the microsatellite instability pathway that contribute to colorectal cancer 
development as depicted in Söreide et al (2006). As discussed, not all mutations are required for 
colorectal cancer development.  
1.1.3.  Limitations of current prognostic approaches to colorectal cancer 
 
The current methods of determining the staging of colorectal cancer is through 
the TNM classification (Edge et al, 2010), although the Dukes’ staging system is 
still used to a lesser extent and is referred to in earlier colorectal cancer studies.  
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This staging system describes the size of a primary cancer (T), whether the 
cancer has spread to any lymph nodes (N) and whether the cancer has spread to 
another part of the body or metastasised (M). Additionally, pathologists 
determine the grade (low grade, intermediate grade, high grade) of cancers by 
defining the extent of cancer differentiation and therefore aggressiveness. 
Tables 1.1 and 1.2 describe how colorectal cancers are classified or staged using 
the TNM classification system and Dukes’ staging respectively.  
Table 1.1: The TNM classification system (Edge et al, 2010) 
Stage Description 
Stage 
1 
Cancer has grown through the inner lining of the bowel, or into the muscle wall but no 
further. There is no cancer in the lymph nodes (T1, N0, M0 or T2, N0, M0). 
Stage 
2  
a No cancer cells in the lymph nodes, but the cancer has broken through the outer 
covering of the bowel (T3, N0, M0) 
 b Cancer has grown through the outer covering of the bowel wall and into tissues or 
organs (T4) next to the bowel. But no lymph nodes are affected (N0) and the cancer 
has not spread to another area of the body (M0). 
Stage 
3  
a Cancer is still in the inner layer of the bowel wall or has grown into the muscle 
layer, and between 1 and 3 nearby lymph nodes contain cancer cells (T1, N1, M0 or 
T2, N1, M0) 
 b Cancer has grown through the bowel wall or into surrounding body tissues or 
organs and between 1 and 3 nearby lymph nodes contain cancer cells (T3, N1, M0 
or T4, N1, M0) 
 c Cancer can be any size, has spread to 4 or more nearby lymph nodes, but there is 
no cancer spread to any other part of the body (any T, N2, M0) 
Stage 
4 
Cancer has spread to other parts of the body (such as the liver or lungs) through the 
lymphatic system or bloodstream (any T, any N, M1).  
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Table 1.2: The Dukes’ staging (Dukes, 1932) 
 
Stage Description 
Dukes 
A 
Cancer only affects the innermost lining of the colon or rectum or slightly growing 
into the muscle layer 
Dukes 
B 
Cancer has grown through the muscle layer of the colon or rectum 
Dukes 
C 
Cancer has spread to at least one lymph node in the area 
Dukes 
D 
Cancer has spread to somewhere else in the body, like the liver or lung 
 
These methods are problematic as they only correspond to the anatomical 
nature of the disease and, to a lesser extent, may be subjective depending on 
the assessing clinician. The current classification system is, however, important 
for determining the prognosis of patients. Figures from England between 1996 
and 2002 show that patients who were diagnosed at the earliest stage of 
colorectal cancer had a 93% five-year relative survival rate. This is vastly in 
contrast to patients who were diagnosed at the most advanced stages of 
colorectal cancer who were shown to have a 7% five-year relative survival rate 
(CRUK, 2014). This therefore highlights the importance of early detection and 
treatment of this disease. National screening programmes are in place where 
people in higher risk age groups (between 50 and 74 in Scotland) are sent faecal 
occult blood tests every two years to test for blood in their stool. These 
programmes aim to detect colorectal polyps or early stage colorectal 
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adenocarcinomas and, in Scotland, are reported to prevent at least 150 deaths 
from colorectal cancer each year (Scottish Bowel Screening Programme, 2014). 
However, despite these programmes, there is a need for molecular 
determinants that can further stratify patients into different risk categories and 
aid with prognosis and response to treatment. 
1.1.4. Current drug therapeutic approaches to colorectal cancer 
  
The first line of treatment for colorectal cancer patients is surgical resection, 
although this is only curative if the cancer is diagnosed at its early stages 
(Walther et al, 2009). In cases where the cancer has metastasised, neo-adjuvant 
(before surgery) or adjuvant (after surgery) chemotherapy is administered to 
patients in addition to surgical resection (Walther et al, 2009). Additionally, 
radiotherapy may also be administered, usually for the treatment of rectal 
cancer. 
5-Fluorouracil (5-FU) has been the mainstay treatment in colorectal cancer for 
over 50 years (Longley et al, 2003). 5-FU exerts its cytotoxic effects through its 
active metabolites (Figure 1.3). The main mechanism of action of 5-FU is through 
the active metabolite (FdUMP), which forms an irreversible complex with 
thymidine synthase (TYMS). This results in the depletion of thymidine 
triphosphate (TTP), one of the four nucleotide triphosphates used in the in vivo 
synthesis of DNA (Longley et al, 2003). Additionally, fluoro-deoxyuridine 
triphosphate (FdUTP) and fluorouridine triphosphate (FUTP) are active 
metabolites that are misincorporated into DNA and RNA (replacing uracil) 
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respectively, thus inhibiting DNA and RNA synthesis and consequently cell 
growth (Longley et al, 2003; Figure 1.3). 
 
Figure 1.3: The mechanisms of action of the active metabolites of 5-FU. 5-FU is metabolised 
to FdUMP, FdUTP and FUTP which respectively inhibits the action of TYMS, incorporates into DNA 
and incorporates into RNA (http://www.pharmgkb.org/pathway/PA165291507).   
5-FU or its pro-drug capecitabine is administered, either as bolus injections or by 
continuous infusion, with leucovorin (folinic acid). Leucovorin is co-administered 
to strengthen the binding of FdUMP to TYMS and thus potentiate the effect of 5-
FU. 5-FU or capecitabine are also co-administered with other drugs to increase 
efficacy in patients. The FOLFOX regimen consists of 5-FU, oxaliplatin and 
leucovorin whereas XELOX consists of capecitabine and oxaliplatin. Additionally, 
FOLFIRI consists of the administration of 5-FU, irinotecan and leucovorin. 
Current treatment guidelines in Scotland suggest that oxaliplatin should be used 
11 
 
 
 
as second line therapy following first line irinotecan therapy and vice versa 
(Scottish Intercollegiate Guidelines Network (SIGN), 2011). Response to 5-FU in 
colorectal cancer patients as monotherapy has been shown to be approximately 
10-15% (Johnston & Kaye, 2001). However, response rate has been shown to 
improve to up to 50% when 5-FU and folinic acid is co-administered with 
oxaliplatin or irinotecan (de Gramont et al, 2000; Douillard et al, 2000). 
Oxaliplatin is a platinum-based agent which binds preferentially to the guanine 
and cytosine moieties of DNA, leading to cross-linking of DNA and thus inhibiting 
DNA synthesis and function (Di Francesco et al, 2002). The active metabolite of 
irinotecan, SN-38 (Figure 1.4), inhibits DNA Topoisomerase I (TOPO1), a nuclear 
enzyme which functions by unwinding DNA for replication and prevents DNA 
strand breaks (Pommier et al, 2010).  
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Figure 1.4: The mechanism of action of irinotecan. Irinotecan is metabolised to SN-38 by 
butyrylcholinesterase (BCHE) and liver carboxylesterases (CES1 and CES2) and inhibits the action 
of topoisomerase 1 (TOP1). SN-38 thus prevents DNA unwinding (by inhibiting TOP1) and causes 
DNA damage leading to cell death. The action of SN-38 is deactivated by the action of UDP-
glucuronosyltransferase enzymes (e.g. UGT1A1; http://www.pharmgkb.org/pathway/PA2029). 
Recently, biological treatment such as humanised targeted monoclonal 
antibodies towards the epidermal growth factor receptor (EGFR) have been 
approved to treat colorectal cancer patients with metastatic disease, in 
combination with standard chemotherapy (SIGN, 2014). Studies have shown an 
improved efficacy for cetuximab in KRAS WT colorectal cancer patients (Lievre et 
al, 2006; Bokemeyer et al, 2008; Amado et al, 2008) compared to KRAS mutant 
patients. 
The inter-patient differences in response to chemotherapeutic drugs and 
biological therapy highlights the importance of identifying prognostic molecular 
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markers which may be used to select the most appropriate patients for adjuvant 
chemotherapy or to identify colorectal cancer patients at increased risk of 
disease progression. 
1.1.5. Molecular therapeutic biomarkers 
 
There is considerable interest in how somatic mutations and genetic alterations 
previously mentioned to play key roles in colorectal cancer development and 
progression could affect patient survival and response to treatment. KRAS 
mutation status, as previously mentioned, has been shown to play a role in 
patient response to anti-EGFR therapy.  
KRAS is one of three human RAS genes (the others being NRAS and HRAS) that 
code for small p21RAS G proteins which transduce signals across the plasma 
membrane and mainly activate the RAS/MAPK signalling pathway (Barbacid, 
1990). The proteins thus play key roles in the control of cell growth and 
differentiation through their intrinsic GTPase activity (Downward et al, 2003).  
KRAS in its active form binds guanosine triphosphate (GTP) allowing it to affect 
downstream signalling pathways. However, GTPase activating protein (GAP) 
triggers the hydrolysis of GTP to guanosine disphosphate (GDP), resulting in the 
inactivation of KRAS (Figure 1.5; Ellis & Clarke, 2000). The mutant form of KRAS 
is constantly activated as it is less sensitive to the hydrolysing action of GAP 
(Downward et al, 2003). Therefore, in its constitutively active form, KRAS 
induces unregulated cellular proliferation leading to malignant transformation.  
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Figure 1.5: The activation and inactivation of KRAS (Wicki et al, 2010). 
KRAS gene mutations, particularly in exon 1 (codon 12 and 13) and exon 2 
(codon 61) have been evaluated for their association with colorectal cancer 
outcome. Many groups have linked KRAS mutations in these regions with 
advanced cancer stage (Smith et al, 2002) and poor prognosis (Andreyev et al, 
1998; Andreyev et al, 2001; Conlin et al, 2005). Smith et al (2010) also identified 
a number of other KRAS mutations in addition to those in codons 12, 13 and 61. 
An alanine-to-threonine amino-acid substitution at codon 146 (A146T), in 
particular, was shown to occur as frequently as mutations in codon 13. In 
experiments using NIH3T3 mouse fibroblast cells stably transfected with various 
mutants of KRAS, cells with A146T  KRAS mutations were found to have a similar 
transforming phenotype to mutations in codon 13 (Smith et al, 2010). 
Many groups have also demonstrated that KRAS mutant colorectal cancer 
patients are less likely to respond to anti-EGFR therapy such as cetuximab and 
panitumumab compared to WT KRAS patients (Lievre et al, 2006; Bokemeyer et 
al, 2008; Amado et al, 2008). The binding of a specific ligand to EGFR activates a 
number of signalling cascades including the RAS/MAPK pathway (Figure 1.6). 
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Figure 1.6: The downstream effects of EGFR (Walther et al, 2009). 
Cetuximab and panitumumab exert their anti-cancer effects by targeting and 
blocking the extracellular domain of EGFR, which is up-regulated in 60-80% of 
colorectal cancer cases (Cunningham et al, 2004), and thus reducing oncogenic 
growth signalling. However, mutations in KRAS lead to the constitutive 
activation of downstream signalling pathways, rendering the vast majority of 
KRAS mutant patients nonresponsive to anti-EGFR therapy as EGFR no longer 
has regulatory control over KRAS.  
DiNicolantonio et al (2008) showed in a cohort of 113 metastatic colorectal 
cancer patients that a lack of response to cetuximab in KRAS WT patients was 
very strongly associated with the presence of a BRAF V600E mutation. KRAS and 
BRAF mutations have been found to be mutually exclusive events (Rajagopalan 
et al, 2002) and both genes could be important determinates of resistance to 
EGFR-specific therapies.  
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The role of KRAS mutation status in response to cytotoxic drugs such as 5-FU has 
also been studied. In vitro studies from Klampfer et al (2005) and work later  
presented in this study (Chapter 3) showed that cells with mutant or increased 
KRAS activity were more sensitive to 5-FU. However, large scale clinical studies 
have not reported any conclusive associations between KRAS mutation status 
and response to 5-FU-based therapy (Markowitz et al, 1995; Etienne-Grimaldi et 
al, 2008). 
1.1.6. Current radiotherapy approaches to rectal cancer 
 
Radiation therapy is used for the treatment of stage III rectal cancer patients and 
is delivered from the outside of the body through the pelvic area. Radiotherapy 
is delivered as neo-adjuvant or adjuvant therapy to shrink the size of the cancer 
before surgery or for easier removal of the cancer after surgery. Treatment 
options include pre-operative short course radiotherapy where patients receive 
25 Gy of radiation in 5 fractions over the course of 5 days (SIGN, 2014). 
Additionally, longer course pre-operative pelvic radiotherapy at doses exceeding 
30 Gy (administered in a number of fractions over 5-6 weeks) is another option 
possibly in combination with chemotherapy, before or after surgery (SIGN, 
2014).  
The division of radiation doses into smaller fractions allows for a compromise 
between killing cancers and limiting the toxicity to normal adjacent tissue. This 
allows for the repair, repopulation, redistribution and reoxygenation of normal 
and cancer cells in what is known as the ‘4 R’s of radiotherapy’ as described by 
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Withers in 1975. These factors, as well as the intrinsic radio-sensitivity of 
cancers, dictate response to radiation therapy.  
The repair and repopulation of cells between fractions allow for DNA damage 
repair and cell growth to occur in normal and cancer cells. This has been shown 
in breast cancer to be one of the possible mechanisms of radiation resistance as 
this has a negative effect on cancer shrinkage (Bese et al, 2005). Cells have been 
shown to be more sensitive to radiation during mitosis and the late G2 phase of 
the cell cycle (Pawlik & Keyomarsi, 2004). The redistribution of cells between 
fractions allows for the progression of cells that were originally resistant to 
radiation to the more radiation sensitive phases of the cell cycle (Withers, 1975). 
Hypoxic tissues were suggested to be more radiation resistant than normoxic 
tissues by Gray et al (1953). Reoxygenation describes the ability of hypoxic 
regions of cancers to become reoxygenated once the more normoxic, 
radiosensitive cancer cells have been killed (Semenza et al, 2004).  
Intrinsic radio-sensitivity of cancers was later described as the 5th ‘R’ of 
radiotherapy and is unaffected by fractionation (Steel et al, 1989). Although a 
number of factors may govern intrinsic radiation sensitivity, Chapter 5 discusses 
the role of the KRAS pathway in radiation resistance.  
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1.1.7. The nature of microRNAs 
 
Much work has been conducted to show how molecular characteristics of 
cancers could act as potential markers of patient prognosis and response to 
chemo- and radiotherapy. However, microRNAs (miRNAs) have in the last 15 
years emerged as additional regulators of gene expression. In light of this, it is 
necessary to gain better insights into the role of miRNAs in colorectal cancer 
development and regulating chemotherapy and radiotherapy response in 
patients.   
MiRNAs are small non-coding RNAs (18-25 nucleotides) which function by 
repressing protein translation by binding to target messenger RNAs (mRNAs; 
Bartel, 2004). MiRNAs were initially discovered when the lin-4 gene, which codes 
for a small non-coding RNA molecule, was found to regulate development in 
Caenorhabditis elegans (Lee et al, 1993). MiRNAs have since been identified in a 
number of species, including humans. It is suggested that miRNAs regulate up to 
30% of all human genes and that each miRNA has control over hundreds of gene 
targets (Lewis et al, 2005). MiRNAs therefore play an important regulatory role 
in processes such as development, cellular differentiation, proliferation and 
apoptosis and thus have wider roles in diseases such as cancer (Esquela-Kerscher 
& Slack, 2006).   
MiRNA genes are present throughout the genome and are transcribed from 
their own promoters by the action of RNA polymerase II or III to generate 
primary microRNA (pri-miRNA; Bartel, 2004). As shown in Figure 1.7, pri-miRNAs 
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are cleaved to precursor miRNA (pre-miRNA), a 70-nucleotide stem loop 
structure, by a microprocessor comprising Drosha (a ribonuclease) and DGCR8 (a 
double stranded RNA binding protein). Pre-miRNA is then transported from the 
nucleus to the cytoplasm by Exportin-5. In the cytoplasm, pre-miRNA is cleaved 
by a complex formed of the endonuclease enzyme Dicer and the double-
stranded RNA binding protein TRBP to form a double-stranded miRNA duplex. 
One of the strands, together with argonauate (Ago2) then incorporates into the 
RNA-induced silencing complex (RISC). The passenger miRNA star (*) strand (e.g. 
miRNA-18*) is usually degraded although it can also be incorporated into RISC. 
  
 
Figure 1.7: The classical pathway of microRNA processing (Winter et al, 2009). 
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Mature miRNAs are guided towards the 3’-untranslated region (3’-UTR) of an 
mRNA target and bind to imperfect complementary sites. This interaction leads 
to suppressed gene expression through mRNA cleavage, translational repression 
or mRNA de-adenylation (Winter et al, 2009). Imperfect complementarity results 
in one miRNA having the ability to repress the protein expression of hundreds of 
mRNA targets (Winter et al, 2009).   
Studies have shown that the ‘classical’ miRNA maturation steps described above 
are not universal to all miRNAs as once believed. For example, Drosha 
complexes containing multiple proteins including the RNA helicases p72 and p68 
have been suggested to process a subset of miRNAs, as evidenced by the 
reduced expression of certain miRNAs in homozygous p71 (-/-) and p68 (-/-) null 
mice, whilst the expression of other miRNAs remained unchanged (Fukuda et al, 
2007). Viswanathan et al (2008) have also shown that LIN28 regulates the 
processing of let-7.  
1.1.8. Role of miRNAs in carcinogenesis  
 
The differential expression of miRNAs has been implicated in a number of 
cancers and their precise role in carcinogenesis is influenced by whether they 
target key tumour suppressor or oncogenic genes (Esquela-Kerscher & Slack, 
2006; Volinia et al, 2006). The miRNAs differentially expressed in colorectal 
cancer are discussed further in Chapter 3. MiRNAs are reported to be 
differentially expressed due to chromosomal abnormalities, epigenetic changes, 
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the action of transcription factors, genetic mutations and abnormalities in 
miRNA biogenesis (Deng et al, 2008).  
Calin et al (2002) were the first to report the down-regulation of miRNA-15 (miR-
15) and miR-16 in over 70% of chronic lymphatic leukaemia (CLL) cases, 
suggesting their role as tumour suppressor genes in CLL.  Further studies 
mapping the chromosomal locations of all known miRNAs revealed that many 
miRNA genes are located in fragile chromosomal sites frequently deleted or 
amplified in many human cancers (Calin et al, 2004b). In colorectal cancer, 
Bandres et al (2006) observed a differential down-regulation of chromosome 
14q31 which contained a cluster of miRNAs, which were differentially decreased 
in colorectal cancer cell lines.   
Expression of miRNAs can additionally be affected by epigenetic changes, such 
as the methylation of the CpG islands of their promoters. CpG islands, which 
consist of a sequence of cytosine-guanine dinucleotides, are located in the 5’ 
region of many genes and are normally transcribed in the presence of the 
appropriate transcription factors (Croce, 2009). However, methylation of CpG 
islands by DNA methyltransferases (DNMTs) results in silencing of the gene and 
possible histone modifications (Croce, 2009). Thus, the methylation and 
silencing of miRNAs that normally have cancer suppressive functions, may 
contribute to its decreased expression and oncogenic cellular characteristics. 
Toyota et al (2008) identified 37 miRNAs that were significantly up-regulated by 
DMNT inhibition in HCT116 cell lines. The study focused on the miR-34b/c genes, 
due to their association with p53, and found that the CpG islands in these genes 
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were frequently methylated and under-expressed in colorectal cell lines and 
cancer samples compared to normal colorectal mucosa. This effect was reversed 
following the treatment with 5-aza-2'-deoxycytidine (DAC), a DNA methylation 
inhibitor. Additional studies (Brueckner et al, 2007; Bandres et al, 2009; Balaguer 
et al, 2010) identified different miRNAs to be methylated in colorectal cancer. It 
is likely that those differences were due to the inter-individual variability 
between the colorectal cancer genotypes.   
The expression of most miRNAs is controlled by transcription factors, and 
abnormalities in transcriptional regulation have been shown to contribute to 
differential miRNA expression in cancer. For example, the oncogenic miR-17-92 
cluster (which comprises miR-17, miR-20a, miR-18a, miR-19a, miR-19b, miR-92) 
is regulated by c-Myc. c-Myc is over-expressed in several human cancers and 
may be one of the mechanisms by which the miR-17-92 cluster is over-expressed 
in cancer (Chang et al, 2008). 
A study by Landi et al (2008) also revealed that single nucleotide polymorphisms 
(SNPs) exist within the 3’-UTR of the mRNA and thus affect miRNA-mRNA 
interaction. The study identified 2 polymorphisms, from 104 candidate 
colorectal cancer genes, that affected miRNA binding sites and increased risk of 
colorectal cancer. Similarly, SNPs affecting the proteins involved in miRNA 
biogenesis pathways have been associated with an increased risk of renal cell 
carcinoma (Horikawa et al, 2008; Lin et al, 2010) and lung cancer (Kim et al, 
2010). 
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Since their discovery miRNAs have been described to have roles in the 
development of cancer through the negative regulation of key oncogenes and 
tumour suppressor genes (Esquela-Kerscher & Slack, 2006) and to predict 
patient prognosis (Calin et al, 2004a). MiRNAs have also been reported to be 
differentially expressed in response to chemo- and radiotherapy and may play a 
key role in regulating and predicting cellular response to treatment and in drug 
and/or radiation resistance (Hummel et al, 2010).  
1.1.9. Aims and objectives   
 
The aims of the present study were therefore to explore the potential of miRNAs 
as markers and modulators of disease progression and treatment response in 
colorectal cancer by undertaking 3 separate approaches: 
Firstly, the present study aimed to explore how the inter-individual expression of 
miRNAs that regulate KRAS and its downstream pathways contributed to 
colorectal cancer progression and whether they could further sub-classify 
colorectal cancers at a molecular level (Chapter 3). 
Secondly, the study aimed to identify a miRNA and mRNA signature of drug 
resistance in colorectal cancer by profiling 5-FU and oxaliplatin resistant 
colorectal cancer cells that were created by incremental drug selection, to gain a 
better understanding into the mechanisms of acquired drug resistance (Chapter 
4).  
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Finally, the present study also aimed to use an in vitro model of radiation 
therapy to identify a miRNA radiation response signature that would help in the 
understanding of the cellular response to radiation and mechanisms by which 
KRAS signalling affects radiation sensitivity (Chapter 5).  
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Chapter 2 
2. Materials and Methods 
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2.1. Materials  
2.1.1. Chemicals and reagents 
 
Mammalian cell culture 
The following were purchased from Life Technologies: McCoy’s 5A medium, 
Dulbecco's Modified Eagle's Medium (DMEM; no phenol red), 0.25% 
Trypsin/EDTA with phenol red, foetal bovine serum (FBS), 
penicillin/streptomycin solution, mirVana™ microRNA inhibitors (miR-224 and 
negative control), mirVana™ microRNA mimics (miR-224 and negative control) 
and Lipofectamine 2000. MTT reagent and dimethyl sulfoxide (DMSO) were 
purchased from Sigma-Aldrich. The Calbiochem InnoCyte invasion assay was 
purchased from Merck Millipore.  
Drugs 
5-Flurouracil and oxaliplatin were purchased from Sigma-Aldrich. Sorafenib-
Tosylate was purchased from Selleckchem. 
Molecular biology  
The following were purchased from Life Technologies: pre-developed TaqMan® 
Small RNA Assays, pre-developed TaqMan® Gene Expression Assays, TaqMan® 
Reverse Transcription Reagents, TaqMan® Universal PCR Master Mix No 
AmpErase® UNG, TaqMan® Low Density Array microRNA cards (Card A), 
Megaplex™ Reverse Transcription Primers Human Pool A v2.1, Illumina® 
TotalPrep™ RNA Amplification Kit and RecoverAll™ Total Nucleic Acid Isolation 
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Kit for FFPE. The RNeasy Mini Kit and RNase free DNase Kit were purchased from 
Qiagen.  
Protein analysis 
The Bradford protein assay was purchased from Bio-Rad. The protease inhibitor 
phenylmethylsulfonyl fluoride (PMSF) was purchased from Sigma-Aldrich. The 
rainbow marker was purchased from Life Technologies. The Ras GTPase Chemi 
ELISA was purchased from Active motif. The PathScan Intracellular Signalling 
Array kit and 1X cell lysis buffer were purchased from Cell Signalling Technology. 
The ECL-chemiluminescence kit was purchased from GE Healthcare Life Sciences. 
Antibodies 
The anti-γ-H2AX (anti-mouse) was purchased from Cell Signalling Technology and 
β-actin antibody (anti-mouse) was purchased from Millipore. All secondary 
antibodies were purchased from Dako.  
Flow cytometry  
Propidium iodide and ribonuclease (RNase A) were purchased from Sigma-
Aldrich. The CellTrace Violet Cell Proliferation and SYTOX AADvanced Dead Cell 
Stain Kits were purchased from Life Technologies.  
Seahorse 
All reagents used in Seahorse glycolysis experiments were purchased from 
Seahorse Bioscience. 
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Chemicals 
All other chemicals were purchased from Sigma Aldrich unless otherwise stated. 
2.2. Methods 
2.2.1. Ethical approval 
 
All studies involving human tissue were approved by the Tayside Tissue Bank 
Research Ethics Committee, a devolved sub-committee of the Tayside 
Committee on Medical Research Ethics. 
2.2.2. Mammalian cell culture 
 
Six colorectal cancer cell lines were used for the present study. HCT116 and DLD-
1 cell lines were obtained from Cancer Research UK Cell Services (London 
Research Institute). HCT116 is one of 3 subpopulations of malignant cells that 
were isolated from a primary culture of a human colorectal carcinoma obtained 
during surgery (Brattain et al, 1981). Similarly, the DLD-1 cell line was derived 
from specimens of colon adenocarcinomas removed during normal surgery 
(Dexter et al, 1979).  
Additionally, isogenic HCT116 and DLD-1 lines specifically engineered to express 
the wild type (WT) or mutant form of KRAS were kindly donated by the 
laboratory of Dr Bert Vogelstein (John Hopkins University, Baltimore, MD). The 
parental HCT116 and DLD-1 lines have a WT KRAS allele and an allele with a 
G13D KRAS mutation (Jiang et al, 1989; Shirasawa et al, 1993). Isogenic cell lines 
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were created by deleting an allele by targeted homologous recombination to 
create KRAS mutant (KRAS G13D/-) and WT (KRASWT/-) HCT116 or DLD-1 colorectal 
cancer cell lines (Shirasawa et al, 1993; Torrance et al, 2001). 
Cells were cultured in McCoy’s 5A medium with 10% foetal bovine serum (FBS) 
and 1% antibiotics (penicillin and streptomycin). To ensure optimum growth, 
cells were routinely passaged or sub-cultured once they had reached 
approximately 70% confluence. Growth media was aspirated from the flask and 
the cells were washed once with phosphate buffered saline (PBS). The cells were 
then detached from the bottom of the flask by adding 2 ml 0.25% trypsin/EDTA 
and incubating at 37°C for 3-5 minutes. Growth media was then added to the 
flask to inhibit the effect of trypsin (media to trypsin ratio of 5:1) and cells were 
re-seeded in a fresh flask at a typical dilution factor of 1:10.  
Frozen cell stocks were created by trypsinising cells and centrifuging the cell 
suspension for 3 minutes at 1200 rpm. The cell pellet was then re-suspended in 
4 ml of freezing mixture (FBS and 10% (v/v) DMSO) and 1 ml of the cell 
suspension was transferred into cryovials. The cryovials were placed in a 
Nalgene Cryo freezing container containing isopropanol which freezes cells at a 
controlled rate of 1°C per minute. The container was initially stored at -80°C 
before the cryovials were transferred into liquid nitrogen for long term storage. 
2.2.3. Growth assays 
 
Growth assays were conducted to monitor the relative growth levels of different 
cell lines over a 48 hour time period. In order to calculate the number of cells in 
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a cell suspension a haemocytometer was used for cell counting. A cover slip was 
placed onto the haemocytometer ensuring that the gridlines used to count the 
cells were covered. A small volume of cell suspension (10 µl) was then pipetted 
between the cover slip and haemocytometer.  Observing under a microscope, 
the total number of cells in the four outer boxes was counted. The number of 
cells per ml of cell suspension was then calculated by determining the mean 
number of cells per box (dividing the total cell count by 4) and multiplying by the 
correction factor, 104. 
For growth assays, cells were seeded in 6 well plates (well diameter: 3.5 cm) at a 
density of 1 x 105 cells per well and incubated at 37°C and 5% CO2 for 24 hours 
to allow for attachment and growth. Cells were then detached from the plate 
using trypsin at alternate 16 and 8 hour intervals (16 h, 24 h, 32 h, and 48 h). The 
cell suspension was added to a universal tube containing growth media to make 
a cell suspension with a total volume of 3 ml. The total number of cells were 
then counted and plotted against the number of hours since seeding. The 
doubling time of cells was also calculated as shown in Box 2.1 using an 
exponential trend line and equation.   
Exponential equation: y = aebx 
Where a = number of cells at 0 hours, b = growth rate and x = doubling time 
Doubling time (x) = ln (2)/b 
Box 2.1: Method for calculating cell doubling time. 
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2.2.4. MTT assay 
 
The MTT assay is a colorimetric assay for determining cell viability (Mosmann, 
1983). It can therefore be used as a measure of relative cytotoxicity caused by 
drug treatment in different cell lines. MTT is a yellow tetrazolium salt which is 
reduced to purple formazan crystals by the mitochondrial enzyme succinate 
dehydrogenase in active and living cells. The amount of formazan crystals is 
therefore proportional to the number of viable cells present in a given sample 
and can be estimated using a spectrophotometer.  
Assays were conducted in sterile 96 clear flat-bottomed well plates. Cells were 
seeded at a density of 3000 cells per well, in a total volume of 100 µl growth 
media, and incubated at 37°C and 5% CO2 for 24 hours to allow for attachment 
and growth. Following incubation, growth media was removed from each well 
and replaced with media containing drug. For chemosensitivity studies, each cell 
line was plated in triplicate per drug concentration (Table 2.1).  
Table 2.1: MTT drug concentrations 
5-FU 
concentration 
(µM) 
Oxaliplatin 
concentration 
(µM) 
Irinotecan 
concentration 
(µg/ml) 
Sorafenib 
concentration 
(µM) 
Vehicle 
control 
(DMSO) 
Vehicle control 
(DMSO) 
Vehicle control 
(DMSO) 
Vehicle control 
(Water) 
1.25 1.25 0.625 0.94 
2.5 2.5 1.25 1.88 
5 5 2.5 3.75 
10 10 5 7.5 
20 20 10 15 
40 40 20 30 
80 80 40 60 
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Drug concentrations were previously determined in preliminary experiments to 
find an optimum drug concentration range for drug response. A vehicle control 
containing the agent that each drug was solubilised in was also included in 
triplicate. Cells were then incubated with drug (or vehicle control) for 72 hours. 
Growth media containing drug or vehicle control was then removed from each 
well and 100 µl of 5 mg/ml MTT dissolved in phenol red deficient DMEM growth 
media was added to each well and incubated for 3 hours. After removal of the 
MTT solution, 100 µl DMSO was added to each well to solubilise the formazan 
crystals which are insoluble in aqueous solutions. The absorbance was then read 
using a ThermoScan microplate reader at a wavelength of 570 nm.   
The mean absorbance for each drug concentration was calculated and 
represented as a percentage of the mean absorbance of the vehicle controls 
(designated 100%). The percentages were then plotted against the log[10] of the 
drug concentrations on GraphPad Prism version 6. The graphs were fitted with a 
best fit sigmoid curve and the IC50, the drug concentration at which 50% of cells 
are viable, was calculated.   
2.2.5. Transfection 
 
The function of miR-224 was investigated by the transient transfection of cells 
with a specific miRNA inhibitor or mimic. MiRNA inhibitors or antagomirs are 
chemically modified, single-stranded oligonucleotides which specifically bind to 
complementary endogenous mature miRNAs, thus competitively inhibiting the 
ability of miRNAs to bind to the 3’UTR of their target gene. MiRNA inhibitors are 
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designed to be more resistant to degradation than endogenous miRNAs within 
the cell. MiRNA mimics are modified double-stranded RNAs that mimic, or 
increase the effects of, endogenous miRNAs. The mature strand of the double 
stranded molecule is, like endogenous miRNAs, incorporated into the RNA 
induced silencing complex (RISC) by the Argonuate protein. The miRNA star (*) 
passenger strand is subsequently cleaved and expelled. In the present study, 
miRNA inhibitors and mimics were introduced into cells using Lipofectamine 
2000 (Life Technologies). This allows the formation of liposomes around the 
inhibitors or mimics, which binds to the plasma membrane and export their 
contents into the cytoplasm of a cell.   
Cells (1 x 105 per well) were seeded in six well plates and incubated for 24 hours 
to allow for attachment. For miR-224 knockdown experiments, HCT116 KRAS WT 
cells were transfected with a final concentration of 30 nM miR-224 inhibitor or 
miRNA inhibitor negative control (Life Technologies) in a total volume of 3 ml of 
growth media per well. A concentration-response optimisation experiment 
assessing the degree of knockdown caused by transfection with 10 nM, 15 nM, 
20 nM, 25 nM and 30 nM of miR-224 inhibitor or negative control was 
conducted to ascertain that 30 nM was the optimum concentration, giving a 
knockdown of 98% as later discussed in Section 3.3.4.  
To achieve this concentration for each well, 1.8 µl of 50 µM miR-224 inhibitor or 
negative control solutions (diluted in nuclease-free water) was diluted in PBS to 
make a total volume of 10 µl and was then added to 90 µl of serum-free media 
in an eppendorf tube. In a separate tube, 5 µl of lipofectamine was added to 95 
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µl of serum-free media. The contents of both tubes were combined and left to 
incubate at room temperature for 45 minutes. Growth media was aspirated 
from each well and replaced with 2.8 ml of serum-free media. The 200 µl mix 
was then added dropwise to each well. The cells were incubated at 37°C for 5 
hours before the transfection media was removed and replaced with fresh 
growth media containing FBS. The cells were left for 24 hours before further 
experiments were conducted. The success of knockdown was assessed using 
miRNA quantitative RT-PCR Taqman analysis (Sections 2.2.9.1 and 2.2.9.2).   
For miR-224 mimic experiments, HCT116 KRAS mutant cell lines were transiently 
transfected with final concentrations of 0.3 nM, 1 nM, 5 nM, 10 nM and 20 nM 
of miR-224 mimic or miRNA mimic negative control (Life Technologies) solution. 
To achieve these final concentrations, the miR-224 mimic or negative control 
solution was serially diluted in PBS according to Table 2.2 to make a total volume 
of 20 µl. In each well, 10 µl of the mimic or negative control and PBS mix was 
added to 90 µl of serum-free media in an eppendorf tube. The remainder of the 
procedure was then unchanged from transfection with miRNA inhibitors.  
Table 2.2:  MiRNA mimic dilutions in PBS 
Desired final 
miR-224 
mimic 
concentration 
per well (nM) 
Volume of 50 
µM miR-224 
mimic stock 
solution (µl) 
Volume of 5 
µM miR-224 
mimic stock 
solution (µl) 
Volume of 0.5 
µM miR-224 
mimic stock 
solution (µl) 
Volume of 
PBS (µl) 
20  2.4 - - 17.6 
10 1.2 - - 18.8 
5 - 6 - 14 
1 - 1.2 - 18.8 
0.3 - - 3.6 16.4 
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2.2.6. Generation of drug resistant cell lines  
 
Two colorectal cancer cell lines, HCT116 and DLD-1, were each made resistant to 
either 5-fluorouracil (5-FU) or oxaliplatin over the course of a year by continuous 
selection. This generated four novel drug resistant cell lines which, for further 
analysis, were then compared to their respective non drug resistant parental 
lines.  
Cells (2.5 x 105) were initially cultured in 5 ml McCoy’s 5A medium with 10% FBS, 
with a final 5-FU or oxaliplatin concentration of 0.1 µM, in a 25 cm2 flask. A 
concentration of 0.1 µM was selected as it was approximately 10% of the lowest 
concentration of drug used for MTT assays (Table 2.1). Starting at this very low 
concentration ensured that cells were not immediately killed and allowed the 
cells to gradually acquire resistance with incremental concentration increases. 
The cells were cultured at each concentration for 4 passages before the drug 
concentration was increased. During the initial months of selection, the media 
drug concentration was increased from 0.1 µM to 0.2 µM, 0.5 µM and 1 µM of 
either 5-FU or oxaliplatin. During the following months the drug concentration 
was increased as indicated in Table 2.3. The drug concentrations were increased 
until the cells reached the highest concentration at which they still remained 
viable and were able to grow in culture. During the first passage of each 
concentration period a MTT cytotoxicity assay (Section 2.2.4) was performed to 
determine how resistant the cells had become to the selection drug.  
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Table 2.3: Final concentrations of 5-FU and oxaliplatin  
Drug 
concentration 
(µM) 
Number of 
passages  
Viable cell lines after 4 
passages  
1.5  4 HF2, HO10, DF10, DO24 
2 4 HF2, HO10, DF10, DO24 
5 4 HO10, DF10, DO24 
10 4 HO10, DF10, DO24 
12 4 DO24 
24 4 DO24 
30 - - 
 
Final concentrations are in bold. HF2 – HCT116 5-FU resistant cells; HO10 HCT116 oxaliplatin 
resistant cells; DF10 – DLD-1 5-FU resistant cells; DO24 – DLD-1 oxaliplatin resistant cells. 
Once cells had reached their final drug concentration, single clone populations 
were isolated. Cells (5 x 104) were seeded onto 10 cm diameter plates in 5 ml 
McCoy’s 5A media, with the final 5-FU or oxaliplatin concentration. The plates 
were incubated at 37°C for two to three weeks to allow for single cell colonies 
(visible to the eye) to grow. Clones were isolated by placing cloning cylinders 
around individual colonies of cells. The cells were then trypsinised by adding 100 
µl of trypsin into the middle of the cylinder, incubating the plate at 37°C for 3 
minutes and then pipetting the trypsin up and down within the cylinder. 
Trypsinised colonies were then individually transferred into 24 well plates (1.56 
cm diameter per well). Once the cells had become confluent in 1.56 cm diameter 
wells they were gradually expanded by transferring them to 6 well plates (3.5 cm 
diameter per well) and then eventually into 25 cm2 flasks.  
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2.2.7. Invasion assay 
 
The Calbiochem InnoCyte invasion assay was used to model and quantify cancer 
cell invasion in vitro. The assay uses an invasion chamber consisting of a 24 well 
tissue culture plate and 12 cell culture inserts with an 8 µm pore sized 
polycarbonate membrane (Figure 2.1). The upper surface of the insert 
membrane is coated with a layer of dried basement membrane matrix (BMM) 
solution forming an extracellular matrix which prevents non-invasive cells from 
passing through the 8 µm pores. Invasive cells are able to degrade the matrix, 
pass through the pores and stick to the bottom of the polycarbonate membrane. 
The invasive cells can then be dissociated from the bottom of the polycarbonate 
membrane and fluorescently labelled to allow for quantification.  
 
Figure 2.1:  Diagrammatic representation of cell invasion assay.   
The cell invasion chamber (stored at 4°C) was initially left to warm to room 
temperature. The dried BMM in the cell culture inserts were then rehydrated by 
adding 400 µl of serum-free media and leaving for 30 minutes at room 
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temperature before it was discarded. Media (500 µl) containing 10% FBS was 
added to the lower chamber. Cells (1 x 106) were then added to the top chamber 
in a total volume of 350 µl of serum-free media. A negative control with no cells 
was also included. The cell invasion chamber was then incubated at 37°C and 5% 
CO2 for 24 hours. Following incubation, a cell staining solution was prepared by 
diluting the fluorescent dye Calcein-AM in cell detachment buffer by a factor of 
1:300. The upper chamber inserts were then placed into wells that had not yet 
been used, containing 500 µl containing cell staining solution and invasive cells 
were dislodged by gently tapping the inserts against the bottom of the lower 
chamber. The cell invasion chamber was incubated for 30 minutes at 37°C and 
then again after the removal of the inserts. The fluorescently labelled dislodged 
cell solution was then split into triplicate aliquots and transferred to a white, 
opaque 96 well plate (150 µl per well), and the fluorescence measured at an 
excitation wavelength of 485 nm and an emission wavelength of 530 nm. 
Invasion was therefore represented as relative fluorescence units (RFU) with a 
higher measurement representing increased invasion. The negative control 
reading was subtracted from the reading taken for cell samples. 
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2.2.8. RNA extraction 
2.2.8.1. RNA extraction from cell lines 
 
Once cells were 70% confluent in 75 cm2 flasks they were trypsinised, collected 
in a 15 ml falcon tube and centrifuged for 3 minutes at 1200 rpm to form cell 
pellets. Alternatively, for RNA extraction following transfection, drug treatment 
or single clone expansion of drug resistant cell lines, cells were seeded on, and 
trypsinised from, 6 well plates. Cell pellets could then be stored at -80°C for 
future RNA extraction.  
RNA was extracted from cell lines using a Qiagen RNeasy mini kit using spin 
technology by following the manufacturer’s protocol for mammalian cells. 
Briefly, cell pellets were disrupted using a denaturing buffer containing 
guanidine thiocyanate, thus ensuring the inactivation of RNases, and lysed using 
a QIAshredder spin column. Ethanol (70% v/v) was added to the cell lysate to 
precipitate RNA. The sample was then transferred to an RNeasy Mini spin 
column where RNA was able to selectively bind to a membrane. A number of 
subsequent wash steps ensured removal of contaminants and RNA was finally 
eluted in 50 μl RNase-free water. On column DNase digestion was performed 
using a Qiagen RNase free DNase kit to minimise genomic DNA contamination. 
2.2.8.2. RNA extraction from fresh frozen tissue 
 
RNA was extracted from fresh frozen tissue using a Qiagen RNeasy mini kit using 
spin technology by following the manufacturer’s protocol for animal tissue. 
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Fresh frozen samples of colorectal tissue were disrupted by placing the whole 
tissue sample (approximately 20 mg) in a small sterile tube and adding 1 ml lysis 
buffer containing guanidine thiocyanate. The tissue was then homogenised 
using a rotor – stator homogeniser (Polytron) until the sample was uniformly 
homogenised. Ethanol (70% w/v) was added to the homogenate to precipitate 
RNA. The remaining procedures following RNA precipitation was performed as 
detailed in Section 2.2.8.1. On column DNase digestion was also performed 
using a Qiagen RNase free DNase kit to minimise genomic DNA contamination. 
2.2.8.3. RNA extraction from formalin-fixed, paraffin-embedded (FFPE) tissue 
sections 
 
RNA was extracted from FFPE tissue sections using a RecoverAll Total Nucleic 
Acid isolation kit (Life Technologies) following the manufacturer’s protocol. 
Three 20 μm FFPE sections were placed into an eppendorf tube and 
deparaffinised by the addition of 1 ml xylene and heating at 50°C for 3 minutes. 
1 ml of 100% ethanol was then added to remove the xylene and accelerate the 
drying of tissue. The deparaffinised tissue was then subjected to protease 
digestion by the addition of 200 μl of digestion buffer with protease. RNA was 
precipitated by the addition of 790 μl of an ethanol/isolation buffer mix and the 
sample was transferred to a filter cartridge placed in a collection tube where 
RNA was able to selectively bind to a membrane. Following a series of wash 
steps, RNA was eluted in 60 µl of nuclease free water. On column DNase 
digestion was performed to minimise genomic DNA contamination.  
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2.2.8.4. Determination of RNA yield and integrity  
 
RNA yield and integrity was determined on a Nanodrop 1000 
spectrophotometer (Thermo Scientific). 2 µl of RNA sample was loaded onto the 
pedestal and absorbance readings were taken at 260 nm (A260) and 280 nm 
(A280). RNA concentration was represented in ng/µl and purity was estimated 
from the A260:A280 ratio. An A260:A280 ratio between 1.7 and 2.0 indicates high 
quality RNA. 
For human tissue samples and cells used for microarray analysis, RNA integrity 
was further assessed using an Agilent Bioanalyser 2100 and by using a RNA 6000 
Nano LabChip Kit (Agilent) following the manufacturer’s protocol. Briefly, 1 µl of 
RNA sample was loaded into a well on the LabChip. The chip was loaded onto 
the Bioanalyser which separated RNA by electrophoresis and detected the 
separated sample via laser-induced fluorescence. The Bioanalyzer 2100 software 
generates an electropherogram and a gel like image and displays the sample 
concentration, the 18s and 28s ribosomal subunit ratios, and RNA integrity 
number (RIN; Figure 2.2). The RIN, a uniform measure of RNA integrity, ranges 
from 0-10. RNA samples with a RIN value of over 7 are deemed high enough 
quality to be used for microarray and Taqman analysis. A RIN value of 10 
indicated that RNA was 100% intact whereas a lower RIN value indicated RNA 
degradation. The 18s and 28s ribosomal subunit ratios indicated the fragment 
length of RNA. The ideal ratio is approximately 2:1 indicating full length RNA.  
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Figure 2.2:  An electropherogram generated by the Bioanalyzer 2100 software. A 
representation of the electropherogram generated by the Bioanalyzer 2100 software, indicating 
RNA concentration, 18s and 28s ribosomal subunit ratios (rRNA Ratio [28s/18s]), and RNA 
integrity number (RIN). The RIN in A) is 10 indicating high quality RNA whereas the RIN in B) is 2.3 
indicating degraded RNA.  
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2.2.9. Taqman quantitative real time PCR Analysis  
 
Relative miRNA and mRNA expression was assessed by Taqman quantitative real 
time PCR analysis. Taqman quantitative real time PCR analysis is performed in 
two steps. In miRNA analysis, the initial reverse transcription (RT) reaction 
produces cDNA from total RNA using a small miRNA-specific, stem-loop RT 
primer (Figure 2.3). The PCR step amplifies products from cDNA samples using 
Taqman Universal PCR master mix and Taqman Small RNA Assays. In mRNA 
expression analysis, cDNA is reverse transcribed from total RNA using random 
primers. During PCR, products are then amplified from cDNA again using 
Taqman Universal PCR master mix and Taqman Gene Expression assays.  
 
Figure 2.3: Reverse transcription from a stem-loop miRNA primer (Life Technologies Taqman 
Small RNA Assays protocol). 
Taqman systems use fluorescent probe-based chemistry to allow quantification 
of the amplified PCR product. Taqman probes have a fluorescent reporter dye 
linked to the 5’ end and a non-fluorescent quencher (NFQ) dye linked to the 
3’end (Figure 2.4). The NFQ reduces the fluorescence emitted by the reporter 
dye by Fluorescence Resonance Energy Transfer (FRET) due to their proximity to 
each other. During PCR, the Taqman probe anneals specifically to a 
complementary sequence between the forward and reverse primer sites. DNA 
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polymerase degrades the probe that has annealed to the template leading to 
the separation of the reporter dye from the quencher dye and causing an 
increase in the fluorescent signal of the reporter dye. Therefore, with each PCR 
cycle, additional reporter dye molecules are cleaved resulting in an exponential 
increase in the fluorescent signal, which in turn is directly proportional to the 
amount of the amplified PCR product produced.  
The degradation and removal of the probe from the target strand also allows 
primer extension to continue to the end of template strand, thereby not 
interfering with the exponential accumulation of PCR product.  
 
Figure 2.4: Schematic diagram of Taqman chemistry and the process of gene amplification 
(Life Technologies Taqman Gene Expression Assays protocol). 
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2.2.9.1. Taqman Small RNA Assays - reverse transcription    
 
The initial RT step for miRNA expression analysis was performed using a specific 
miRNA stem-loop RT primer and reagents from the Taqman MicroRNA Reverse 
Transcription Kit in accordance with the manufacturer’s protocol. For each 
sample, 10 ng of RNA, diluted in a total of 5 µl of nuclease-free water, was 
added to 10 µl of reaction mix to make a RT reaction volume of 15 µl. The 
reaction mix consisted of 0.15 µl dNTPs, 1 µl reverse transcriptase, 1.5 µl reverse 
transcriptase buffer, 0.19 µl of RNase inhibiter, 4.16 µl nuclease-free water and 
3 µl of a miRNA specific primer.   
The RT reaction was then performed on a thermal cycler (MJ Research PTC-225 
Peltier) under the following conditions: 16°C for 30 minutes, 42°C for 30 minutes 
and 85°C for 4 minutes. 
2.2.9.2. Taqman Small RNA Assays – quantitative PCR analysis  
 
The PCR step amplified PCR products from cDNA samples using Taqman Small 
RNA Assays, containing a miRNA specific probe and primer mix and Taqman 
Universal PCR Master Mix II in a 96 well plate format. In each well, 1.33 µl of 
cDNA was added to 1 µl of a miRNA-specific probe mix, 10 µl of Taqman 
Universal PCR Master Mix II and 7.67 µl of nuclease-free water. Each cDNA 
sample was added to the plate in triplicate. The 96 well plates were sealed using 
a heated plate sealer and centrifuged at 1200 rpm for 10 seconds. The PCR 
reaction was then run on the standard Real Time PCR program on the 7900 
Taqman real-time system under the following conditions: 50°C for 2 minutes and 
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95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 
minute. 
The endogenous control used for all single Taqman Small RNA Expression Assays 
was U6 snRNA, one of the most common normalising genes in miRNA 
quantification (Peltier & Latham, 2008). 
2.2.9.3. Taqman mRNA Expression assays - reverse transcription  
 
The RT step for mRNA expression analysis was performed using a Taqman 
reverse transcription reagents kit. For each sample 200 ng of RNA, diluted in a 
total of 20 µl of nuclease-free water was added to 30 µl of reaction mix to make 
a RT reaction volume of 50 µl. The reaction mix consisted of 5 µl RT buffer, 11 µl 
magnesium chloride, 10 µl dNTPs, 1 µl RNase inhibitor, 1.25 µl reverse 
transcriptase and 2.5µl random hexamers. 
The RT reaction was then performed on a thermal cycler (MJ Research PTC-225 
Peltier) under the following conditions: 25°C for 10 minutes, 37°C for 60 minutes 
and 95°C for 5 minutes.  
2.2.9.4. Taqman Gene Expression assays – quantitative PCR analysis 
 
The PCR step amplified PCR products from cDNA samples using Taqman Gene 
Expression Assays, containing a specific probe and primer mix and Taqman 
Universal PCR Master Mix II in a 96 well plate format. In each well, 1 µl of cDNA 
was added to 1 µl of a gene specific Taqman probe mix, 10 µl of Taqman 
Universal PCR Master Mix II and 8 µl of nuclease-free water. Each cDNA sample 
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was added to the plate in triplicate. The 96 well plates were sealed and briefly 
centrifuged as previously described. The PCR reaction was then run on the 
standard Real Time PCR program on the 7900 Taqman real-time system (Applied 
Biosystems) under the following conditions: 50°C for 2 minutes and 95°C for 10 
minutes, followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 minute. 
The endogenous control used for all single Taqman Gene Expression Assays was 
18S ribosomal RNA. 18S ribosomal is universally used as a normalising gene in 
relative mRNA quantification. 
2.2.9.5. Taqman data analysis  
 
The data was analysed using SDS 2.3 software (Applied Biosystems) to 
determine a Ct (cycle threshold) value for each sample. The Ct value is described 
as the minimum PCR cycle at which fluorescence can be detected over 
background. The Ct value is therefore inversely proportional to the amount of 
the target gene in the PCR reaction. The relative expression of each gene and 
standard errors were then calculated. Firstly, the mean Ct of the endogenous 
control gene (i.e. U6 snRNA or 18S ribosomal RNA) was subtracted from the 
mean Ct of the target gene of interest to give the delta CT (δCt). Secondly, the 
standard deviation (sd) of δCt was calculated using the equation (sd target2 + sd 
control2)1/2. Thirdly, the relative expression was determined by calculating the   
2-δCT value, converting it from a log to linear scale. Finally, the positive and 
negative errors of relative expression were determined by calculating                   
2 (-δCt + sd δCt) and 2(-δCt – sd δCt). 
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2.2.9.6. Taqman Low Density Array (TLDA) microRNA Cards 
 
Taqman human miRNA arrays are 384 well plates pre-loaded with Taqman Small 
RNA Assays (Figure 2.5) allowing for the simultaneous quantification of 
hundreds of miRNAs. The arrays are split into an ‘A’ and ‘B’ card with a 
combination of 667 unique human miRNA assays. The ‘A’ card represents the 
miRNAs which were considered to be most well characterised at the time of 
manufacture, whereas the ‘B’ card were loaded with the lesser known miRNAs. 
At the time of writing, there are now over 2000 known unique human miRNAs 
(http://www.mirbase.org/). For the present study, card ‘A’, pre-loaded with 377 
unique human miRNA assays, 3 endogenous controls and one negative control, 
was used (Appendix A). 
 
Figure 2.5: The 384-well format Taqman Low Density Array miRNA cards with ports for 
sample loading. 
2.2.9.7. Megaplex reverse transcription  
 
The RT step was performed using Taqman reverse transcription reagents kit and 
Megaplex RT primers, a pool of 377 unique human miRNA RT primers.  For each 
sample 600 ng of RNA, diluted in a total of 3 µl of nuclease-free water was 
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added to 4.5 µl of reaction mix to make a RT reaction volume of 7.5 µl. The 
reaction mix consisted of 0.8 µl Megaplex RT primers, 0.2 µl dNTPs, 1.5 µl 
reverse transcriptase, 0.8 µl RT buffer, 0.9 µl magnesium chloride, 0.1 µl RNase 
inhibitor and 0.2 µl nuclease-free water.  
The RT reaction was then performed on a thermal cycler (MJ Research PTC-225 
Peltier) under the following conditions: 40 cycles of 16°C for 2 minutes, 42°C for 
1 minute and 50°C for 1 second followed by an additional 5 minutes at 85°C.  
2.2.9.8. Taqman Low Density Array miRNA cards – quantitative PCR analysis 
 
For each sample, 6 µl of megaplex RT product was added to 450 µl of Taqman 
Universal PCR Master Mix II and 444 µl of nuclease-free water to make a 900 µl 
PCR reaction mix. The TLDA card was then loaded by adding 100 µl of PCR 
reaction mix into each port. The plate was then centrifuged twice at 1200 rpm 
for 1 minute to evenly distribute the sample into each individual well. The card 
was then sealed using a TLDA card sealer (Applied Biosystems) before the 
sample ports were removed using scissors.  
The TLDA PCR reaction was then run on the standard Real Time PCR program on 
the 7900 Taqman real-time system (Applied Biosystems) under the following 
conditions: 50°C for 2 minutes and 94.5°C for 10 minutes, followed by 40 cycles 
of 97°C for 30 seconds and 59.7°C for 1 minute.  
Each individual sample was run in triplicate (3 different TLDA cards) and the data 
were analysed as detailed in Section 2.2.9.5.  
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2.2.10. Illumina HT-12 BeadChip mRNA expression arrays 
 
Illumina HT-12 BeadChip mRNA expression arrays provide a genome-wide, high-
throughput method of simultaneously quantifying the expression of thousands 
of well characterized genes, gene candidates and splice variants. The array uses 
a novel BeadArray technology where 3 µm silica beads self-assemble into micro-
wells. Each bead is covered with thousands of gene-specific probes which 
capture sequence specific antisense RNA.  
The RNA amplification steps (Figure 2.6) involve the generation of biotinylated, 
amplified antisense RNA for hybridisation with Illumina arrays. Firstly, single 
strand cDNA is generated from total RNA by reverse transcription using oligo 
(dT) primers to produce cDNA containing a T7 promoter sequence. This reaction 
is catalysed by ArrayScript, a reverse transcriptase enzyme engineered to 
produce a high yield of cDNA. Secondly, single stranded cDNA is converted to a 
double stranded cDNA (ds cDNA) template by the action of DNA polymerase, 
whilst RNA is simultaneously degraded by the action of an RNAse enzyme. The 
ds cDNA is then purified to remove enzymes, salts, RNAs and excess primers. 
Finally, T7 RNA polymerase catalyses the production of biotin labelled antisense 
RNA (cRNA) copies of each mRNA. In the present study, biotin labelled cRNA was 
generated using an Illumina TotalPrep RNA amplification kit (Life Technologies) 
by following the manufacturer’s protocol.  
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Figure 2.6: The process of RNA amplification. The synthesis of A) cDNA and B) double stranded 
cDNA; C) the purification of cDNA; D) the reverse transcription to biotin labelled cRNA and E) the 
purification of cRNA (modified from Life Technologies Illumina TotalPrep RNA amplification kit 
protocol). 
2.2.10.1. Reverse transcription to synthesise cDNA 
 
The initial reverse transcription step was performed using specific oligo (dT) 
primers to produce single strand cDNA bearing a T7 promoter. For each sample, 
500 ng of total RNA diluted in a total of 11 µl of nuclease-free water was added 
to 9 µl of reverse transcription master mix. The master mix consisted of 1 µl T7 
oligo (dT) primer, 2 µl first strand buffer, 4 µl dNTP mix, 1 µl RNAse inhibitor and 
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1 µl Array Script reverse transcriptase. The samples were incubated at 16°C for 2 
hours in a thermal cycler (MJ Research PTC-225 Peltier). 
2.2.10.2. Second strand cDNA synthesis  
 
Double stranded cDNA (ds cDNA) was then generated by adding 80 µl of second 
strand master mix to each sample to make a total reaction volume of 100 µl. The 
second strand master mix consisted of 63 µl nuclease-free water, 10 µl second 
strand buffer, 4 µl dNTP mix, 2 µl DNA polymerase and 1 µl RNAse H. The 
samples were then incubated at 16°C for 2 hours in a thermal cycler (MJ 
Research PTC-225 Peltier). 
2.2.10.3. In vitro transcription to synthesise cRNA 
 
To generate cRNA, 7.5 µl of in vitro transcription master mix was added to 
purified ds cDNA and eluted into 17.5 µl of nuclease-free water. The in vitro 
transcription mix consisted of 2.5 µl each of T7 reaction buffer, T7 enzyme mix 
and biotin-NTP mix. The samples were incubated at 37°C for 14 hours in a 
thermal cycler (MJ Research PTC-225 Peltier). The reaction was subsequently 
stopped by the addition of 75 µl nuclease free water. 350 µl of cDNA binding 
buffer was added to each cRNA sample. The cRNA was then precipitated by the 
addition of 250 µl 100% ethanol. The mixture was added to a cRNA filter 
cartridge placed in a collection tube. A number of subsequent wash steps using a 
wash buffer ensured removal of contaminants and cRNA was finally eluted in 
200 μl of RNase-free water pre-heated to 55°C.  
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2.2.10.4. Generation of mRNA expression array data 
 
cRNA samples were sent to the Wellcome Trust Clinical Research Facility, 
Western General Hospital, Edinburgh, where the gene expression array was 
performed according to the manufacturer’s protocol. Each sample was analysed 
in triplicate. Expression data was analysed as described in Section 2.2.17. 
2.2.11. Protein Determination and Western Blotting 
 
To extract cellular protein, cells were seeded in 6 well plates and incubated at 
37°C in McCoy’s 5A growth media and 10% FBS until 70% confluent. The cells 
were then washed once with PBS and incubated at 37°C in FBS free media for 5 
hours. Following incubation, the cells were washed again with PBS and 200 µl of 
1X cell lysis buffer (Cell Signalling Technology) and 1 mM PMSF (a protease 
inhibitor) was added to the cells and incubated on ice for 5 minutes. The lysed 
cells were then scraped from the plates using a cell scraper and transferred into 
an eppendorf tube. The cell lysate was then centrifuged for 10 minutes at 14000 
rpm at 4°C and the pellet was discarded. 
The protein concentration in the cell lysate was determined by performing a 
Bradford assay using the Bio-Rad protein assay. The Bio-Rad assay is based on 
the colour change of Coomassie brilliant blue G-250 dye in response to various 
concentrations of protein. The dye was diluted in water by a factor of 1:5 before 
use. 2 µl of each cell lysate sample was added to 200 µl of dye on a 96 well plate. 
A standard curve was also prepared using bovine serum albumin (BSA) at 
concentrations ranging from 0 mg/ml to 8 mg/ml. Each sample was added to the 
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96 well plate in triplicate. The absorbance was then read using a ThermoScan 
microplate reader at a wavelength of 595 nm.  
The mean absorbance of each BSA sample was plotted against the protein 
concentration. The protein concentration of the test samples were then 
calculated by using the equation of the line (y=mx + c), where m = slope of the 
dose response curve obtained from a BSA dilution series and c = the absorbance 
at 0 mg/ml.  
Western Blot analysis was performed on SDS-polyacrylamide gels which were 
prepared prior to the procedure. 10% resolving gels were prepared by adding 
together 4 ml water, 3.3 ml 30% acrylamide mix, 2.5 ml 1.5M Tris buffer, 100 µl 
SDS, 100 µl 10% ammonium persulfate (APS) and 4 µl TEMED and casting the 
mixture using the Bio-Rad Mini-PROTEAN II system. A 5% stacking gel was also 
prepared  by adding together 2.7 ml water, 670 µl 30% acrylamide mix, 400 µl 
1.0 M Tris, 40 µl 10% SDS, 40 µl 10% APS and 4 µl TEMED. The stacking gel was 
added on top of the resolving gel once it had set. A comb was placed into the 
stacking gel whilst it set to produce wells for loading protein samples.  
For Western blot analysis, 40 µg of protein was diluted in 5X SDS sample buffer 
(0.2 M Tris, 10% SDS, 0.05% bromphenol blue, 20% glycerol) to make a total 
volume of 20 µl. Samples were then denatured at 95°C for 5 minutes before they 
were loaded onto SDS-polyacrylamide gels. SDS-PAGE was run using the Bio-Rad 
mini-PROTEAN 3 Cell system and samples underwent electrophoresis at 100 
volts in Tris-glycine running buffer (25 nM Tris, 250 nM glycine, 0.1% SDS in 
water). Rainbow protein molecular weight marker was also loaded onto the gels. 
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Proteins were then transferred from gels onto nitrocellulose membranes in Tris-
glycine-methanol transfer buffer (48 mM Tris, 39 mM glycine, 0.037 (w/v) SDS, 
10% (v/v) methanol). The nitrocellulose membranes were then blocked in 5% 
milk supplemented with 0.05% Tween-20 for 2 hours at room temperature to 
prevent non-specific protein binding. The membranes were then incubated at 
4°C for at least 12 hours in primary antibody. In the present study γH2AX and β-
actin (loading control) anti-mouse antibodies were used as primary antibodies. 
In both cases the antibodies were diluted in milk by a factor of 1:1000. The 
membranes were washed 3 times for 5 minutes in PBS before incubation with an 
anti-mouse secondary antibody (diluted in milk by a factor of 1:1000) for 2 hours 
at room temperature. The blots were then developed using an ECL-
chemiluminescence kit (Millipore) and used to expose autoradiography films for 
an appropriate amount of time. The same procedure was repeated to develop 
blots for the loading control β-actin after bands for γH2AX had been successfully 
visualised.  
2.2.12. Ras GTPase Chemi ELISA - Quantification of GTP-bound activated KRAS 
 
KRAS activation or the amount of GTP bound KRAS in a cellular extract was 
determined using a RAS GTPase Chemi ELISA (Active Motif). The ELISA kit 
contains a glutathione-S-transferase (GST)-bound RAF-RBD protein that is coated 
on to a glutathione-coated 96 well plate by the interaction between GST and 
glutathione. Activated GTP-bound RAS in a cellular extract binds specifically to 
Raf-RBD, the Ras binding domain of RAF, whereas inactive GDP-bound RAS does 
not. Incubation with a primary HRAS antibody that specifically binds to KRAS in 
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human samples (or HRAS in mouse samples) followed by a secondary antibody 
conjugated to horseradish peroxidise (HRP) that binds specifically to the primary 
antibody allows the quantification of bound activated KRAS by luminescence. In 
the present study, the ELISA was used to compare the relative innate KRAS 
activation between cell lines or following miR-224 knockdown (Section 2.2.5). 
Cellular extracts were obtained from cells 24 hours after transfection with miR-
224 inhibitors and miRNA inhibitor negative controls or from cells that were 
seeded in six well plates and left to grow until 70% confluent. Cells were washed 
with ice cold PBS and lysed by adding 500 µl of complete lysis/binding buffer. 
The cell lysate was then incubated for 15 minutes at 4°C, centrifuged at 14000 
rpm for 10 minutes also at 4°C and the supernatant was collected. Protein 
concentration was determined by the Bradford assay (Section 2.2.11). 
The next steps were performed according the manufacturer’s protocol. Briefly, 2 
µg of GST-RAF-RBD protein diluted in 50 µl of complete lysis/binding buffer was 
added to each well and incubated for 1 hour at 4°C with mild agitation. 
Following wash steps, 40 µg of protein sample was diluted in 200 µl of complete 
lysis/binding buffer and added to each well. Each sample was added in triplicate 
and included a negative control (50 µl of complete lysis/binding buffer). The 
plate was then incubated for one hour at room temperature with mild agitation. 
The primary HRAS antibody (1:500 dilution in antibody buffer) was added to 
each well and incubated for 1 hour at room temperature. Following wash steps, 
the secondary antibody (1:5000 dilution in antibody buffer) was also added to 
each well and incubated for 1 hour at room temperature. Finally, 50 µl of 
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chemiluminescent working solution was added to each well, following final wash 
steps, and luminescence was measured using a Modulus II microplate 
multimode reader (Turner Biosystems). KRAS activation was therefore 
represented as relative luminescence units (RLU) with a higher measurement 
representing increased KRAS activation. 
2.2.13. PathScan Intracellular Signalling Array 
 
The PathScan intracellular signalling array is a slide based antibody array 
allowing for the simultaneous detection of 18 well characterised and important 
phosphorylated or cleaved signalling molecules (Figure 2.7). Each kit contains 
two slides with 16 nitrocellulose pads on which each target specific antibody has 
been spotted in duplicate. The array therefore allows for 32 samples to be 
tested. The assay was performed according to the manufacturer’s protocol.  
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Figure 2.7: The PathScan Intracellular Signalling Array.  A) A representation of one of the 
slides and the 16 nitrocellulose pads, and B) the names and positions of each target antibody 
(modified from Cell Signalling PathScan Intracellular Signalling Array protocol).  
A protein lysate was obtained as described in Section 2.2.11 and was diluted to a 
total protein concentration of 1 mg/ml. A multi-well gasket was fixed onto the 
slide to isolate each nitrocellulose pad. Each pad was incubated at room 
temperature with an array blocking buffer to prevent non-specific protein 
binding. The pads were then incubated at room temperature with protein lysate 
for 1 hour with mild agitation. Subsequently, the pads were incubated with a 
biotin-conjugated detection antibody cocktail (containing specific antibodies to 
each phosphorylated or cleaved signalling molecule) followed by a fluorescently-
linked antibody conjugated to streptavidin which binds biotin.  
Following a series of wash steps the slide was scanned using a LiCor Odyssey 
(LiCor Biosciences), a fluorescent digital imaging system. An image of the slide 
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was captured at an excitation wavelength of 680 nm and detecting wavelength 
of 700 nm and the relative fluorescent intensities of the spots were quantified 
by using the imaging program Image Studio Software (Li-Cor Biosciences).  
2.2.14. Fluorescence-activated cell sorting 
 
Fluorescence-activated cell sorting (FACS) is a specialised form of flow cytometry 
used to measure a number of parameters of individual cells within a 
heterogeneous population based upon the specific light scattering and 
fluorescent characteristics of each cell. In flow cytometry thousands of cells per 
second are passed individually in a stream of flowing fluid through a laser beam. 
Each individual cell can cause the scatter or refraction of light as it passes though 
the laser beam. The flow cytometer is able to detect the amount of light 
scattered in the direction of the laser beam (forward scatter) or light scattered 
at 90 degrees from the path of the laser beam (side scatter) and convert this 
information into voltage pulses. The intensity of the forward and side scattered 
light detected is proportional to the size of a cell and the inner structural 
complexity of a cell respectively. Additionally, targeted fluorescently-tagged 
molecules or fluorescent dyes, which bind to specific components or receptors 
of a cell, may be added to a cell sample. The fluorophore can be excited by the 
laser beam at the appropriate wavelength thus emitting a fluorescent signal that 
can also be detected by the flow cytometer and provide further insight into cell 
phenotype. The light scattering and fluorescent characteristics of cells can 
therefore be analysed graphically and can be represented in single dimensional 
histograms of two dimensional dot plots.  
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2.2.14.1. DNA cell cycle analysis using Propidium Iodide 
 
Propidium iodide (PI) is a fluorescent dye used to stain cells and quantify DNA 
content in cell cycle analysis. PI only permeates non-viable cells, which have 
been fixed in ethanol, and binds to both DNA and RNA. PI fluorescence is 
emitted at an excitation wavelength of 535 nm and emission wavelength of 617 
nm. The fluorescence emitted once PI is bound to DNA and excited by a laser 
source increases and the amount of fluorescence is proportional to the amount 
of DNA present in a cell. As PI does not discriminate between DNA and RNA, 
samples are also treated with a ribonuclease (RNase A) to eliminate RNA.  
DNA content is known to change during the cell cycle. As the DNA content of 
cells is duplicated during the synthesis or S phase of the cell cycle, the DNA 
content and thus the fluorescence of cells is assumed to be twice as high in cells 
in the G2/M phase than cells in the G0/G1 phase.  
In the present study, DNA cell cycle analysis was used to assess the effect of 
miRNA knockdown (Section 2.2.5), acute drug treatment or acquired drug 
resistance (Section 2.2.6) on the cell cycle. In miRNA knockdown and acute drug 
treatment analysis cells (1 x 106) were seeded on 5 cm diameter plates and were 
fixed at alternate 16 and 8 hour intervals (16 h, 24 h, 32 h, 48 h, 64 h and 72 h) 
within a 72 hour period. In the acquired drug resistance analysis cells (1 x 106) 
were seeded on 10 cm diameter plates and were fixed every 24 hours within a 
96 hour period. Each experiment was performed 3 times.  
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Each sample was fixed by adding 1 x 106 cells drop-wise into 2 ml of ice cold  
70% (w/v) ethanol and was stored at  -20°C for a minimum of 12 hours but for 
no longer than 7 days before analysis on the flow cytometer. On the day of flow 
cytometry analysis the fixed cell samples were left to warm to room 
temperature and then centrifuged at 1200 rpm. The pelleted cells were then 
washed with PBS and then resuspended in 950 µl PBS, 40 µl propidium iodide 
solution (1 mg/ml) and 10 µl RNase A (10 mg/ml). The samples were then 
incubated at 37°C for 30 minutes in darkness.  
Samples were analysed on a BD FACScan system (BD Biosciences) and the cell 
events were visualised using CellQuest Pro (BD Biosciences) software. The data 
was firstly represented in the form of a dot plot where the area (FL2-A) of the 
fluorescent light pulse, representing the total fluorescence of a cell, was plotted 
against the width (FL2-W), representing the time it takes for the cell to pass 
through the laser beam. This plot was used to distinguish between single cells 
and doublets, cells that have aggregated and have passed through the laser 
beam together and thus have larger FL2-A or FL2-W values than single cells 
(Figure 2.8 A). Single cells were therefore gated and an FL2-area histogram was 
generated to only show the events inside of the gated region (Figure 2.8 B). 
10,000 events were collected within defined gates during data acquisition. The 
histogram was used to assess the percentage of gated single cells in each 
defined phase of the cell cycle.   
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Figure 2.8: Analysis of DNA content using Propidium iodide analysis. A) A representation of a 
dot plot where FL2-A is plotted against FL2-W. The red dots represent the events that have been 
gated. B) A representation of an FL2-area histogram generated to assess the percentage of cells 
in the G0/G1, S and G2/M phases of the cell cycle.  
2.2.14.2. SYTOX AADvanced Dead Cell Stain Kit 
 
SYTOX AADvanced dead cell stain (Life Technologies) is a fluorescent stain that 
distinguishes live and dead cells by binding to nucleic acid after penetrating non-
viable cells with compromised plasma membranes. The dye emits fluorescence 
at an excitation wavelength of 488 nm, which is enhanced 500 fold upon binding 
to nucleic acid. In the present study, the SYTOX AADvanced Dead Cell Stain Kit 
(A) 
(B) 
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was used to assess changes in cell viability following treatment with ionising 
radiation (Section 2.2.16.3). Following treatment and 72 hours incubation (see 
Section 2.2.16.3), cells were trypsinised, collected in a 15 ml falcon tube and 
centrifuged for 3 minutes at 1200 rpm to form cell pellets. The cells were 
resuspended in 1 ml of PBS with a final stain concentration of 0.5 µM.  The 
samples were incubated on ice for 5 minutes to allow for the stain to bind 
nucleic acid. The samples were then analysed on an Attune Flow cytometer (Life 
Technologies) and the cell events were analysed using Attune Cytometric 
software (Life Technologies).  
The data was represented by plotting the total fluorescence of a cell detected to 
be side scattered (SSC-A) with cells detected to be forward scattered (FSC-A). 
This dot plot identified a population of cells emitting fluorescence at a 
wavelength of 625 nm (Figure 2.9 A). A BL3-area plot was also generated to 
calculate the percentage of gated cells that contained the dead cell stain dye 
and were therefore considered non-viable (Figure 2.9 B). BL3 represents the 
filter used to detect cells with the SYTOX AADvanced Dead Cell Stain (those 
emitting fluorescence at wavelength 625 nm). A negative control where cells 
were resuspended in 1 ml of PBS without the stain helped to identify the 
population of cells where the stain had permeated the membrane.   
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Figure 2.9: Analysis of viable cell number using the SYTOX AADvanced Dead Cell Stain kit. A) 
A representation of a dot plot where SSC-A has been plotted against FSC-A. R1 represents the 
total area that has been gated. B) A representation of the proportion of gated cells emitting 
fluorescence at a wavelength of 625 nm. R2 represents the proportion of cells that do not emit 
fluorescence whereas R3 represents the cells that do emit fluorescence at a wavelength of 625 
nm and are thus non-viable. 
 
 
 
 
(A) 
(B) 
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2.2.14.3. CellTrace Violet Cell Proliferation Kit 
 
CellTrace Violet is a dye that diffuses into cells where it is cleaved by intracellular 
esterases to yield a highly fluorescent compound. This compound covalently 
binds to intracellular amines, resulting in stable, well-retained fluorescent 
staining. The fluorescent signal emitted by this dye is halved at every cell division 
and is still detected after up to 10 generations or cell divisions.    
In the present study, the CellTrace Violet Cell Proliferation Kit was used to assess 
the effect of miRNA knockdown (Section 2.2.5) or acquired drug resistance 
(Section 2.2.6) on cell proliferation and doubling time. In miRNA knockdown 
analysis cells (1 x 106) were seeded on 5 cm diameter plates and labelled with 5 
µM CellTrace dye diluted in PBS (loading solution) as detailed in the 
manufacturer’s protocol according to the alternative method for labelling 
adherent cells. Cells were harvested at alternate 16 and 8 hour time points (16 
h, 24 h, 32 h, 48 h, 64 h and 72 h) within a 72 hour period. In the acquired drug 
resistance analysis cells (1 x 106) were seeded on 10 cm diameter plates and also 
labelled with 5 µM CellTrace loading solution as described above. Cells were 
harvested every 24 hours within a 96 hour period. Each experiment was 
performed in triplicate. The samples were then analysed on an Attune Flow 
cytometer (Life Technologies) and the cell events were analysed using Attune 
Cytometric software (Life Technologies).  
The data was represented by plotting the total fluorescence of a cell detected to 
be side scattered (SSC-A) with cells detected to be forward scattered (FSC-A; 
Figure 2.10 A). This dot plot identified a population of live cells. Further analysis 
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involved using ModFit LT (Version 4; Verity Software House) to create a 
proliferation model generating a visual representation in the changes in the 
proportion of cells within a particular generation at each time point (Figure 2.10 
B). The software calculated the proliferation index, the total number of divisions 
divided by the number of cells that went into division, which was plotted against 
time. The doubling time of cells was calculated as shown in Box 2.1 (Section 
2.2.3) using an exponential trend line and equation. 
 
 
 
Figure 2.10 
 
(A) 
(B) 
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Figure 2.10: Analysis of cell proliferation using the CellTrace Violet Cell Proliferation kit. A) A 
representation of a dot plot where SSC-A has been plotted against FSC-A. R1 represents the total 
area that has been gated. B) A representation of the proliferation model created using ModFit LH 
where the changes in the proportion of cells within a particular generation (indicated by different 
colours) at each time point can be visualised. ModFit LH then calculates the proliferation index.  
2.2.15. Measurement of glycolytic activity – Seahorse Bioanalyser 
 
The Seahorse Bioanalyser presents a way of investigating the metabolic 
behaviour of cells in real time in vitro. The set up consists of a sensor cartridge 
that can simultaneously measure changes in oxygen and proton (H+) 
concentration in a transient micro-chamber, with 24 solid state sensors that 
reside 200 µm above cells that are seeded in a 24 well plate. Each sensor is 
surrounded by four drug injection ports which allow for the injection of up to 
four drugs into each well. The rate of oxygen consumption (OCR) is proportional 
to mitochondrial respiration whereas the extracellular acidification rate (ECAR) is 
proportional to glycolysis. 
The XF glycolysis stress test kit is set up to assess three key parameters of 
glycolytic function: glycolysis, glycolytic capacity and glycolytic reserve (Figure 
2.11). These parameters are calculated by analysing the changes in ECAR 
following consecutive injection of glucose, oligomycin (an ATP synthase 
inhibitor) and 2-deoxy-D-glucose (2-DG; a glucose analogue). In the present 
study, due to time constraints, the effect of glucose on ECAR in parental and 
drug resistant cell lines was restricted to DLD-1 based cell lines.   
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Figure 2.11: The three parameters used to assess glycolytic function. The injection of glucose, 
oligomycin and 2-DG allows for the assessment of glycolysis, glycolytic capacity and glycolytic 
reserve respectively (XF glycolysis stress test protocol).  
DLD-1 parental, DLD-1 oxaliplatin resistant and DLD-1 5-FU resistant cells were 
seeded in a total of 100 µl of McCoy’s 5A medium at densities of 4 x 104, 4.23 x 
104 and 4.99 x 104 cells per well respectively in a XF24 24 well V7 cell culture 
plate (Seahorse Bioscience). The different densities were based on relative 
doubling times so that each cell line reached a similar level of confluence within 
the wells. Each cell line was seeded in 6 wells. Four control wells were left empty 
for background measurements. The XF24 plate was left at room temperature for 
one hour before it was incubated at 37°C for 24 hours.  
A cell number titration was performed to determine the optimal seeding density 
for the DLD-1 parental line. Cells were seeded at densities ranging from 1 x 104 
to 1 x 105 cells per well, left at room temperature for one hour and incubated at 
37°C for 24 hours, to determine the density at which there was a complete and 
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uniform monolayer of cells. The relative densities for the 5-FU and oxaliplatin 
resistant cell lines were determined based on their doubling times (Section 
2.2.14.3).     
The XF24 sensor cartridge (Seahorse Bioscience) was also hydrated prior to the 
assay by adding 1 ml of Seahorse Bioscience calibrant (pH 7.4) into each well of a 
utility plate and placing the sensor cartridge on top. The sensor cartridge and 
utility plate were then incubated at 37°C without CO2 for 24 hours.  
On the day of analysis, the McCoy’s 5A medium was removed from the adherent 
cells and the wells were washed with 1 ml of pre-warmed Seahorse DMEM (pH 
7.4; assay medium) containing no glucose or pyruvate. A final volume of 500 µl 
of assay medium was added to each well and the plate was then incubated at 
37°C without CO2 for 1 hour.  
A volume of 50 µl glucose (20 mM final concentration in well; pH 7.4) or assay 
media was added to injection port A of the XF24 sensor cartridge in triplicate 
resulting in triplicate glucose and control readings for each cell line. The sensor 
cartridge and cell culture plate were them equilibrated by incubating them for at 
least 15 minutes prior to analysis at 37°C without CO2.  
The Seahorse software was then used to calibrate the XF24 sensor cartridge in 
the Seahorse XF24 analyzer (Seahorse Bioscience), which was pre-warmed to 
37°C. Following calibration, the cell culture plate containing the adherent DLD-1 
cell lines was placed into the analyzer and the extracellular acidification rate 
(ECAR) was measured by the following protocol: five cycles of mix (3 minutes), 
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delay (2 minutes), measure (3 minutes); port A injection; five cycles of mix (3 
minutes), delay (2 min) and measure (3 minutes).  
Upon completion of the protocol, assay medium was removed from each well 
and 100 µl of 1X cell lysis buffer (Cell Signalling Technology) was added to each 
well and left on ice for 5 minutes. The cell lysis buffer was pipetted up and down 
in the well to dislodge the attached cells. The protein content of each sample 
was determined by the Bradford assay (Section 2.2.11), and the ECAR rates were 
normalised to protein content (mpH/min/µg protein).  
2.2.16. In vitro cell irradiation 
 
The laboratory irradiator was designed and constructed at the University of 
Dundee for studies led by Dr Ian Sanders and Professor Alastair Munro. The 
irradiator was originally used as an in vitro simulation of rectal intraoperative 
radiotherapy (IORT) to identify biological markers of IORT response. In the 
present study the laboratory irradiator was used to investigate the role of 
miRNAs in modulating response to radiotherapy in colorectal cancer cell lines.  
The laboratory irradiator was constructed using a photon radio-surgery system 
(PRS) x-ray source (Figure 2.12). The PRS x-ray source is attached to a stainless 
steel safe box lined with 3 mm of lead, with the x-ray probe pointing downwards 
into the box. An external response monitor (ERM) is also attached to the top of 
the safe box with its sensor inside the box which must measure radiation for the 
x-ray source to operate. Below the x-ray probe is a sample tray with an 
ionisation chamber and a shelving system which allows the distance between 
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the tip of the x-ray probe and the sample tray and ionisation chamber to be 
adjusted. The location of the ionisation chamber directly below the sample tray 
allows for a real time feedback of absorbed dose by a sample. The irradiator is 
made with a number safety interlocks to ensure the x-ray source is switched off 
if the safe box is opened or the x-ray source is lifted from the box during 
treatment.  
 
Figure 2.12: The laboratory irradiator. The photographs show A) the outside and B) inside of 
the laboratory irradiator (Sanders, 2011). 
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To deliver a target dose in Gray (Gy) to a sample, a dose in nano-Coulombs (nC) 
was calculated as shown in Box 2.2 for input into the dosemeter. The calculation 
was based on a number of preliminary experiments by the manufacturer to 
determine the PRS dose rate in air at each tray level and the attenuation factors 
of the culture dishes (Sanders, 2011). The calculation also involves correcting for 
changes in atmospheric pressure and temperature.  
Dose Limit (nC) = Target Dose (Gy) x Attenuation Factor  ÷     f.T.P                   
                                     Ion Chamber Conversion factor 
 
For example, for a 5 Gy irradiation at tray level 4 using a plastic circular 3.5 cm 
diameter dish (Temperature 21°C, Pressure 1000 mb):  
 
Dose Limit (nC) = 5 x 0.720           ÷      (273.15 + 21 x 1013.25) 
                                   1.279                           293.13            1000  
 
Dose Limit (nC) = 2.812 ÷ 1.017 
 
Dose Limit (nC) = 2.765 
Box 2.2: Equation for dose limit calculations. f.T.P – factor for temperature and pressure 
In the present study, cells were seeded onto 3.5 cm diameter plates for 
irradiation and placed 8.5 cm from the x-ray probe (tray level 4). Sanders (2011) 
report that this would ensure the homogenous delivery of x-radiation to the 
whole sample within an acceptable time frame, given the rapid attenuation of 
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PRS x-rays. Three different types of experiments with different endpoints were 
performed following irradiation to investigate the effect of ionising radiation on 
global miRNA expression, protein expression and cell viability.   
2.2.16.1. Taqman Low Density Array analysis  
 
Cells were seeded on 3.5 cm diameter plates at density of 2.5 x 105 cells per 
plate and incubated at 37°C for 24 hours. The cells were then irradiated in 
triplicate at 5 Gy and incubated at 37°C for 1 hour. The 1 hour incubation period 
was determined by performing an optimisation experiment whereby the 
expression of 3 miRNAs previously reported to be induced or inhibited by 
ionising radiation (miR-24, miR-100, miR-125b) was measured 10, 30, 60 and 180 
minutes after radiation. Following incubation, cells were harvested for RNA 
extraction (Section 2.2.8.1) for TLDA card analysis (Section 2.2.9.8).  
2.2.16.2. Western blot analysis  
 
Cells were seeded on 3.5 cm diameter plates at a density of 2.5 x 105 cells per 
plate and incubated at 37°C for 24 hours. The cells were then irradiated in 
duplicate at 5 Gy and incubated at room temperature for 5 minutes before 
protein samples were obtained as detailed in Section 2.2.11. Western blot 
analysis was then performed to blot for γH2AX. 
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2.2.16.3. Flow cytometry  
 
Cells were seeded on 3.5 cm diameter plates at a density of 2.5 x 104 cells per 
plate and incubated at 37°C for 24 hours. The cells were then irradiated in 
triplicate at 5 Gy. Changes in cell viability were then assessed using SYTOX 
AADvanced Dead Cell Stain on a flow cytometer (Section 2.2.14.2).  
2.2.17. Bioinformatics and statistics  
 
MicroRNA and mRNA expression data from TLDA miRNA cards and Illumina HT-
12 BeadChip mRNA expression arrays, in collaboration with Probir Chakravarty 
(CRUK Bioinformatics and Biostatistics Service, London), was analysed using 
Bioconductor 1.9 (Gentleman et al, 2004) running on R 2.6.0 (R Development 
Core Team, 2008).  
MiRNA expression data was normalised to MammU6 (the TLDA card equivalent 
of the single Taqman probe U6 snRNA). Statistically significant differentially 
expressed miRNAs were determined by using eBayes t-test from the limma 
package. P values were adjusted for multiple testing correction using the 
Benjamini-Hochberg method (Benjamini & Hochberg, 1995). MiRNAs that 
exhibited adjusted p values of less than 0.05 were then used to predict target 
genes that were predicted by at least 2 out of 5 of the following miRNA target 
prediction databases: mirDB (www.mirdb.org), miRANDA (www.microrna.org), 
miRBase (www.mirbase.org), TargetMiner (www.isical.ac.in) and TargetScan 
(www.targetscan.org). For each differentially expressed miRNA, a list of genes 
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was extracted, whereby a target gene was called if it was identified in at least 2 
of the 5 databases.  
Messenger RNA expression data was normalised using the Robust Multi-array 
Average (RMA) algorithm. Differentially expressed genes were then determined 
using eBayes t-test as described above. P values were also adjusted for multiple 
testing correction using the Benjamini-Hochberg method (Benjamini & 
Hochberg, 1995). Genes that exhibited adjusted p values of less than 0.05 and 
were differentially expressed by more than two-fold were then selected for 
further analysis.  
Pathway and biological processes enrichment analyses were performed using 
Metacore (http://thomsonreuters.com/metacore/). The analysis employs a 
hyper-geometric distribution to determine enriched gene sets.  
Independent T-tests were used to assess statistically significant (p ≤ 0.05) 
differences in the means of continuous variables in cell lines (e.g. relative gene 
expression). Mann Whitney tests were used to compare the median and 
distribution of continuous variables in patient groups. In all Figures, * denotes p 
≤ 0.05, ** denotes p ≤ 0.01, *** denotes p ≤ 0.001 and **** denotes p ≤ 0.0001.  
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Chapter 3 
3. The role of microRNAs in colorectal 
cancer progression 
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3.1. Introduction 
3.1.1. Colorectal cancer 
 
Sporadic colorectal cancer development, as discussed in Chapter 1, was initially 
proposed to be driven by the progressive acquisition of genetic mutations in key 
oncogenes and tumour suppressor genes (Vogelstein et al, 1988). However, 
subsequent studies have suggested that the original model may not represent 
the vast majority of sporadic colorectal cancers (Smith et al, 2002; Frattini et al, 
2004; Samowitz et al, 2007). For example, Smith et al (2002) reported that only 
6% of the cancers profiled from 106 colorectal cancer patients had simultaneous 
mutations in the KRAS, TP53 and APC genes, suggesting inter-patient variation in 
the mechanisms of development of colorectal cancer. Additionally, 
chromosomal instability, characterised by allelic losses, chromosomal 
amplification and translocation, and microsatellite instability, characterised by 
the epigenetic inactivation of DNA mismatch repair mechanisms, are proposed 
alternative mechanisms of colorectal carcinogenesis (Söreide et al, 2006). 
MicroRNAs are described as additional regulators of gene expression and have 
been presented as an additional level of complexity in the development of 
colorectal cancer (Bartel, 2004). As discussed previously, miRNAs may act as 
oncogenes or tumour suppressor genes through the negative regulation of key 
target genes involved in the development of colorectal cancer and metastatic 
disease.   
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3.1.2. Colorectal cancer miRNAs  
 
Calin et al (2002) first linked the differential expression of miRNAs with cancer 
by reporting the decreased expression of miR-15 and miR-16 in 70% of chronic 
lymphatic leukaemia (CLL) cases. Following this, Michael et al (2003) were the 
first to report that mature miR-143 and miR-145 expression levels were reduced 
in colorectal cancers compared to patient-matched normal mucosa, and 
speculated that they may play an important role in colorectal carcinogenesis.  
To date, a large number of studies have identified miRNAs differentially 
expressed in colorectal cancer. Table 3.1 summarises 20 studies in which 
miRNAs have been profiled in colorectal cancers and normal mucosa samples.   
One difficulty with attempting to collectively analyse the studies listed in Table 
3.1 is the inevitable variability between the patient samples and the profiling 
and statistical methodologies employed. For example, the number of miRNAs 
profiled ranged from 156 (Bandres et al, 2006) to 904 (Li et al, 2012). 
Additionally, some studies used RT-PCR technology whereas others used miRNA 
microarrays, while Schepeler et al (2008) used LNA-based oligonucleotide arrays 
and Li et al (2012) used miRCURY LNA Arrays. Furthermore, each study 
determined its own criteria for defining whether a particular miRNA was 
significantly differentially expressed meaning that they differed in the 
algorithms, statistical tests and cut offs employed.  
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Table 3.1: Studies assessing differential miRNA expression in colorectal cancers 
and normal colorectal tissue  
Study Tissue 
samples 
Technology Number 
of 
miRNAs 
profiled 
Number of 
differentially 
expressed 
miRNAs 
Bandres et al (2006) 12 matched 
cases  
qRT-PCR 156 30 up, 23 down 
Volinia et al (2006) 46 cancers, 8 
normal 
tissue 
miRNA microarray 228 21 up, 1 down 
Monzo et al (2008) 22 matched 
cases  
qRT-PCR  156 21 up, 7 down 
Schepeler et al (2008) 49 cancers, 
10 normal 
colon tissue 
LNA-based 
oligonucleotide 
arrays + qRT-PCR 
315 13 up, 6 down 
Schetter et al (2008) 84 matched 
cases (test) 
 
113 
matched 
cases 
(validation) 
miRNA microarray 
+ qRT-PCR  
389 26 up, 11 down 
Arndt et al (2009) 45 cancers, 4 
normal 
tissue 
qRT-PCR 169 21 up, 16 down 
Chen et al (2009) 13 matched 
cases 
qRT-PCR 200 8 up, 7 down 
Motoyama et al (2009) 69 matched 
cases 
miRNA microarray 
– 4/69 cases 
 
qRT-PCR validation 
in all 69 cases 
455 21 up* 
 
 
Sarver et al (2009) 80 cancers, 
29 normal 
colon tissue 
qRT-PCR 735 19 up, 20 down 
Earle et al (2010) 55 matched 
cases 
qRT-PCR 20 12 up, 9 down 
Wang et al (2010c) 3 matched 
cases 
miRNA microarray 
+ qRT-PCR 
723 12 up, 2 down 
Chang et al (2011) 20 matched 
cases 
qRT-PCR 380 20 up, 13 down 
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Table 3.1 continued 
Study Tissue 
samples 
Technology Number 
of 
miRNAs 
profiled 
Number of 
differentially 
expressed 
miRNAs 
Slattery et al (2011)  30 matched 
cases 
 
70 
additional 
colorectal 
cancers 
miRNA microarray 866 19 up, 16 down 
Faltejskova et al (2012) 8 matched 
cases 
qRT-PCR 667 4 up, 38 down 
Fu et al (2012) 40 matched 
cases 
miRNA microarray 
+ qRT-PCR 
- 16 up, 16 down 
Hamfjord et al (2012) 8 matched 
cases 
Illumina digital 
sequencing + qRT-
PCR 
- 18 up, 19 down 
Li et al (2012) 6 matched 
cases 
(rectal) 
miRCURY LNA Array 904 65 up, 25 down 
Mosokhani et al (2012) 60 matched 
cases 
miRNA microarray 
+ qRT-PCR 
723 7 up, 39 down 
Nishida et al (2012) 13 cancers, 
4 normal 
tissue 
miRNA microarray 
+ qRT-PCR 
- 127 up, 29 down 
Reid et al (2012) 40 matched 
cases 
qRT-PCR 621 43 up, 27 down 
 
* Indicates that decreased miRNAs were not mentioned in this study, 
 - Indicates that the number of miRNAs profiled not reported  
However, despite the aforementioned biological and methodology differences, a 
group of miRNAs were identified to be consistently differentially expressed in 
colorectal cancer (Table 3.2), among which miR-21, miR-135b, miR-183, miR-31, 
and miR-20a were increased, and miR-145 and miR-378 were decreased in 9 or 
more studies. 
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Table 3.2: The most consistently differentially expressed miRNAs in colorectal 
cancer as determined from the studies listed in Table 3.1. 
Increased in CRC Decreased in CRC 
miRNA  Number 
of studies  
miRNA Number 
of studies 
miR-21 10 miR-145 13 
miR-135b 9 miR-378 10 
miR-183 9 miR-143 6 
miR-31 9 miR-1 6 
miR-20a 9 miR-195 6 
miR-19a 8 miR-139-5p 6 
miR-93 7 miR-133a 5 
miR-96 7 miR-422a 5 
miR-17 7 miR-133b 5 
miR-203 7 miR-375 5 
miR-182 6 miR-10b 5 
miR-18a 6 miR-192 4 
miR-224 6 miR-215 4 
miR-25 6 miR-30a-3p 4 
miR-106a 6 miR-497 4 
miR-29b 6 miR-26b 3 
miR-106b 5 miR-30b 3 
miR-19b 5 miR-30c 3 
miR-424 5 miR-139 3 
miR-92 5 miR-363 3 
miR-223 5 miR-378* 3 
miR-130b 4 miR-551b 3 
miR-142-3p 4 miR-9 3 
miR-148a 4 miR-30e 3 
miR-29a 4 miR-125b 3 
miR-221 4 miR-137 3 
miR-15a 3 miR-204 3 
miR-17-5p 3 miR-30a 3 
miR-20 3 miR-150 3 
miR-200a* 3 
miR-27a 3 
miR-552 3 
miR-98 3 
miR-7 3 
miR-191 3 
 
MiR-224 has been highlighted as it was the focus of the present study, as discussed later. MiR-
224 expression was reported in six studies to be increased in colorectal cancers. 
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When the present study was established in October 2010, few studies had 
explored the expression of miRNAs in colorectal adenomas in an attempt to 
elucidate the role of colorectal miRNAs in the development of colorectal 
adenomas and progression of some of those adenomas to adenocarcinomas.  
Schetter et al (2008) showed that miR-21 expression was increased in colorectal 
adenomas compared to patient-matched adjacent normal mucosa and also in 
colorectal cancers compared to colorectal adenomas. This suggested that the 
aberrant expression of miR-21 was an early and persistent event in colorectal 
tumorigenesis. Schmitz et al (2009) also reported that the expression of miR-21, 
as well as miR-181b, was significantly higher in serrated adenomas than in 
normal mucosa.  
The six members of the miR-17-92 cluster (miR-17, miR-20a, miR-18a, miR-19a, 
miR-19b, miR-92) located on chromosome 13q31 had also been reported to be 
increased in colorectal cancers relative to both colorectal adenomas and normal 
mucosa (Disodado et al, 2009). The gain of chromosome 13q has also previously 
been characterised in colorectal cancers (Reid et al, 2009) and adenomas (Leslie 
et al, 2006). 
Furthermore, miRNAs are detectable in patient serum and plasma samples at 
stable and reproducible levels (Chen et al, 2008; Mitchell et al, 2008). Huang et 
al (2010) reported that the increased expression of miR-29a and miR-92a could 
distinguish between the 37 advanced adenoma and 59 healthy patients 
recruited to the study. Despite these advances, there was a need for more 
comprehensive miRNA profiling in colorectal adenomas.   
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3.1.3. The role of miRNAs in colorectal tumorigenesis  
 
The differential expression of miRNAs in colorectal cancer, as discussed in 
Chapter 1, is proposed to be caused by a number of factors including 
chromosomal abnormalities, epigenetic changes, the action of transcription 
factors and SNPs affecting miRNA biogenesis.   
Prominent tumour suppressor miRNAs in colorectal cancer such as miR-143, 
which has decreased expression in cancers compared to normal mucosa, have 
been shown to promote colorectal carcinogenesis by direct targeting of the 
oncogene KRAS. Chen et al (2009) showed in Lovo colon cancer cell lines that a 
specific miR-143 inhibitor increased cell proliferation, an effect that was 
reverted when miR-143 was overexpressed. The inhibition of KRAS by miR-143 
also inhibited the constitutive phosphorylation of ERK 1/2, an important 
intracellular protein kinase in the RAS/MAPK pathway.  
The oncogenic miR-21 has also been reported to drive colorectal carcinogenesis 
through the repression of the tumour suppressors PTEN, which regulates cell 
proliferation and the cell cycle (Xiong et al, 2013), and PDCD4 which plays a key 
role in apoptosis (Asangani et al, 2008). Furthermore, Asangani et al (2008) first 
reported that miR-21 drives colorectal cell invasion in vitro and that miR-21 and 
PDCD4 expression was inversely related in colorectal cancer specimens.  
Epithelial to mesenchymal transition (EMT) has also been implicated as a 
mechanism for the development of cancer metastasis, and miRNAs have since 
been shown to promote cancer metastasis through the regulation of EMT.  EMT 
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is the conversion of immotile epithelial cells into mobile mesenchymal cells. This 
process was first described for the remodelling of tissues during embryonic 
development. However it has since been described as a way by which cancers 
can detach, migrate and disseminate through blood and lymphatic vessels 
during cancer metastasis (Thiery, 2002; Acloque et al, 2008).  
Examples of miRNAs that have been established as regulators of EMT include the 
miR-200 family. The loss or down-regulation of epithelial (E-) cadherin, an 
adhesion molecule that forms adherin junctions and contribute to tissue 
structure and integrity, is a characteristic of EMT (Thiery, 2002). E-cadherin 
expression is repressed by the action of, amongst others, transcription factors 
known as zinc finger E-box binding homeobox (ZEB-) 1 and ZEB 2. Members of 
the miR-200 family, which include miR-200a, miR-200b, miR-200c, miR-141 and 
miR-429, directly target and negatively regulate the expression of ZEB 1/2 and 
thus induce EMT (Christoffersen et al, 2007; Hurteau et al, 2007). ZEB 1/2 
however, has been shown to directly repress the transcription of the miR-200 
family (Burk et al, 2008). ZEB 1/2 also promotes the transcription of vimentin, a 
type III intermediate filament protein expressed in mesenchymal cells that forms 
part of the cell cytoskeleton (Thiery & Sleeman, 2006). 
The down-regulation of the miR-200 family, therefore, leads to the up-regulation 
of ZEB 1/2 which consequently leads to a decrease of E-cadherin and increase in 
vimentin and thus promotes EMT. As ZEB 1/2 also represses the transcription of 
the miR-200 family, a feed-forward loop is created (Burk et al, 2008). This 
relationship between the miR-200 family, ZEB 1/2 and EMT has been reported in 
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colorectal cancer (Chen et al, 2012; Bojmar et al, 2013) and a decrease in their 
expression is associated with lower survival in colorectal cancer patients.  
MiRNAs may also contribute to colorectal progression and metastatic disease by 
regulation of angiogenesis. Cancers adapt to hypoxic conditions by increasing 
the induction of angiogenesis allowing for the exchange of oxygen and 
respiratory waste products and also providing a network by which cancer cells 
can disseminate and form metastases at secondary sites (Harris, 2002). One of 
the many transcription factors implicated in angiogenesis is vascular endothelial 
growth factor (VEGF; Harris, 2002). A recent study, in colorectal cancer, reported 
that epigenetic silencing of miR-126, which is under-expressed in colorectal 
cancer, contributed to cancer invasion and angiogenesis in vivo (Zhang et al, 
2013c). Restoration of miR-126, by 5-aza-CdR, inhibited cell growth, migration 
and invasion, an effect that was shown to occur through the miR-126 targeting 
and repression of VEGF.  
3.1.4. MiRNAs as biomarkers of disease progression  
 
There are now many examples where miRNAs that are commonly differentially 
expressed in colorectal cancer have been shown to be differentially expressed in 
different stages of colorectal cancer and to correlate with cancer staging and 
survival in colorectal cancer patients. Increased expression of miR-21, for 
example, is associated with advanced TNM staging and poor survival (Schetter et 
al, 2008; Liu et al, 2011).  
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Furthermore, miRNA expression profiles have been shown to discriminate 
between cancers on the basis of molecular characteristics such as microsatellite 
status or the mutation status of important oncogenes and tumour suppressors 
known to drive colorectal tumorigenesis. Given the multiple functions of miRNAs 
due to their imperfect complementarity with gene targets, the activation or 
repression of different cancer-related pathways may be caused or affected by 
miRNAs, thus leading to unique miRNA signatures and the mediation of variable 
phenotypes.  
Lanza et al (2007) were the first group to investigate the differences in miRNA 
expression between microsatellite stable (MSS) and microsatellite unstable 
(MSI) cancers where 14 miRNAs were identified as differentially expressed. 
Among the differentially expressed miRNA were members of the miR-17-92 
family that were significantly over-expressed in MSS cancers. In a similar study, 
Schepeler et al (2008) highlighted miR-142-3p, miR-212, miR-151 and miR-144 as 
miRNAs that could predict the microsatellite status of colon cancers with 
relatively high accuracy. MSI cancers have been suggested to have favourable 
clinical outcome compared to non-MSI cancers (Popat et al, 2005), and adds to 
the importance of identifying miRNA biomarkers to aid diagnosis.  
A series of studies led by Ju and colleagues identified 54 miRNAs that were 
differentially expressed in HCT116 p53-WT and null cell lines (Xi et al, 2006b). 
When a subset of these miRNAs was tested in a cohort of 24 colorectal cancer 
patients, the increased expression of miR-181b and miR-200c was strongly 
associated with a mutant p53 status in colorectal cancers, with high expression 
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of miR-200c also having a negative impact on patient survival (Xi et al, 2006a). 
This indicated that miRNAs that regulated, or were regulated by, p53 could 
discriminate between mutant and WT p53 cancers and also predict patient 
prognosis.  
Our research group has a particular interest in KRAS as a previous study 
published from within the group showed that colorectal cancer patients with 
KRAS mutations had a significantly lower survival than patients with WT KRAS, 
an effect that was not observed with APC and p53 (Conlin et al, 2005). The 
miRNAs that are able to discriminate between KRAS mutant and WT cancers and 
regulate the RAS/MAPK pathway may therefore be important in further 
classifying colorectal cancers based on patient prognosis.  
Ragusa et al (2010) reported that miR-146b-3p and miR-486-5p, miRNAs that 
were differentially increased following cetuximab treatment in HCT116 cells, 
were also increased in KRAS mutant cancers compared to KRAS WT cancers in 
colorectal cancer patients. However, the genetic background of the cancers 
apart from their KRAS mutation status was not considered. It is therefore 
necessary to identify novel regulators of KRAS and the RAS/MAPK pathway in a 
controlled, isogenic cell line background and test their potential in assisting with 
KRAS-based diagnosis in predicting patient prognosis.  
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3.2. Aims and objectives  
 
The aim of this study was therefore to extend the molecular sub-classification of 
colorectal cancers by investigating the extent to which individuality in miRNA 
expression influences oncogene expression. In particular, I sought to explore 
how the inter-individual expression of miRNAs that regulate KRAS and its 
downstream pathways may sub-classify colorectal cancers at a molecular level in 
terms of disease progression.   
To achieve this, my aim was firstly to analyse miRNAs that were differentially 
expressed in colorectal adenomas and cancers compared to normal mucosa. 
Secondly I sought to discover novel miRNA regulators of KRAS and the 
RAS/MAPK pathway by identifying differentially expressed miRNAs in isogenic 
KRAS mutant and WT cell lines.  
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3.3. Results 
3.3.1. MicroRNA profiling in human colorectal tissue 
 
Twelve colorectal cancer samples, previously profiled (Affymetrix mRNA gene 
expression profiles and mutation status) within our research group, were 
profiled for miRNA expression using TLDA cards, as described in Section 2.2.9.8. 
Figure 3.1 shows, using the first 55 miRNAs on the TLDA cards as an example, 
that inter-patient differences in miRNA expression were observed across the 
cancer cohort (full data set for all 377 miRNAs in Appendix B). This is of 
particular interest in the present study as the differences existing between the 
expression of certain miRNAs may have important phenotypic or clinical 
characteristics in a patient. The expression of miR-17, for example, (highlighted 
by red circles in Figure 3.1) is shown to be variable across the cohort of 12 
cancers. Heightened expression of miR-17, which is part of the miR-17-92 
cluster, has previously been shown to be associated with poor survival in colon 
cancer patients (Yu et al, 2012).  
The profiling data from the present study shows that of the 377 miRNAs 
profiled, 153 were not expressed in any of the cancers. The data also show that 
199 miRNAs (52.7%) were expressed in at least 2 of the 12 cancers and 108 
miRNAs (28.6%) were expressed in all 12 cancers (Appendix E, Table E1). The 
most abundantly expressed miRNAs were miR-200c, miR-222 and miR-24 
whereas miR-331-5p, miR-481 and miR-98 were the least abundantly expressed. 
The mean expression of miR-200c, relative to the control miRNA let-7a (using 
the method detailed in Section 2.2.9.5), was the arbitrary value of 60.5 whereas 
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the mean expression of miR-98 was 0.042, showing that there was a 1440-fold 
difference between the highest and lowest expressed miRNA.  
Furthermore, eighteen miRNAs (miR-193b, miR-323-3p, miR-324-3p, miR-331-
5p, miR-339-3p, miR-362-5p, miR-365, miR-374, miR-449b, miR-487a, miR-491-
5p, miR-494, miR-501, miR-532-5p, miR-574-3p, miR-671-3p, miR-744, miR-99b) 
not previously described in colorectal cancer were expressed in all 12 cancers. 
 
91 
 
 
 
 
92 
 
 
 
Figure 3.1: Inter-patient variability in the expression of individual miRNAs. TLDA miRNA ‘A’ 
cards (Life Technologies) were used to profile the expression of 377 miRNAs in 12 colorectal 
cancers, as detailed in Section 2.2.9.8. The expression of the first 55 miRNAs on the TLDA card, 
relative to the control gene let-7a, is shown and the full data set is presented in Appendix B. Each 
bar represents a single point determinant of relative expression. Red circles indicate the 
variability of expression of miR-17 across the 12 cancers. 
To investigate which miRNAs may drive the progression of colorectal cancer, 12 
normal colorectal mucosa samples, patient-matched to the colorectal cancers 
mentioned above, as well as 12 samples of mainly tubulovillous adenomas were 
obtained from Tayside Tissue Bank. The adenomas were split equally into those 
defined as displaying high grade or low grade dysplasia.  
To minimise the number of TLDA cards used in my initial screen, only 3 of the 12 
patient-matched normal mucosa samples and 6 of the 12 adenoma samples (3 
high grade, 3 low grade) were profiled for miRNA expression and compared to 
the profiling data from 3 of the 12 cancers that had already been profiled. The 
colorectal cancer and normal mucosa samples were matched from the same 
patient. The normal mucosa and adenoma samples used for TLDA miRNA 
profiling were chosen based on their high RNA yield and integrity (RIN) relative 
to other samples following RNA extraction, as assessed by the methods detailed 
in Section 2.2.8.4 (Appendix C and Appendix D).  
TLDA miRNA profiling identified that 111 miRNAs out of 377 (29.4%) were 
expressed in all of the normal, adenoma and cancer samples profiled (Appendix 
E, Table E2). The expression of seven miRNAs was significantly increased in low 
grade adenomas, high grade adenomas and colorectal cancers compared to 
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normal mucosa. Additionally, 6 miRNAs were identified to have a significantly 
decreased level of expression in all stages of colorectal cancer progression 
compared to normal mucosa (Table 3.3).  
All 13 miRNAs have subsequently been shown to be differentially expressed in 
colorectal cancers compared to normal mucosa. The data in the present study is 
consistent with Bartley et al (2011) who at the same time identified that the 
expression of miR-15b, miR-29c, miR-27a, and miR-500 was increased in 
colorectal adenomas and cancers compared to normal mucosa. Oberg et al 
(2011) found that miR-139-5p expression was decreased in colorectal adenomas 
and cancers compared to normal mucosa. Moreover, both Bartley et al (2011) 
and Oberg et al (2011) reported that miR-224 and miR-133a expression was 
increased and decreased respectively in colorectal adenomas and cancers 
compared to normal mucosa, consistent with the data in the present study. 
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Table 3.3: MicroRNAs differentially expressed in colorectal adenomas and 
cancers relative to colorectal normal mucosa 
 Normal vs LGA Normal vs HGA Normal vs cancer 
Fold change Fold change Fold change 
miR-15b 3.32 2.83 1.86 
miR-27a 5.45 8.35 6.83 
miR-29c 9.17 15.29 5.87 
miR-92a 3.72 4.66 4.01 
miR-93 3.15 3.46 4.25 
miR-224 7.41 5.86 5.15 
miR-500 2.22 7.29 3.13 
 
 Normal vs LGA Normal vs HGA Normal vs cancer 
Fold change Fold change Fold change 
miR-125b -7.28 -7.04 -2.12 
miR-127-3p -3.38 -2.85 -1.76 
miR-133a -3.75 -4.29 -27.26 
miR-139-5p -3.01 -3.19 -13.35 
miR-145 -3.32 -3.47 -9.42 
miR-149 -3.49 -2.16 -3.32 
 
The fold change in mean miRNA expression, calculated relative to the control miRNA let-7a, in 
low grade adenomas (LGA), high grade adenomas (HGA) and colorectal cancers compared to 
normal mucosa. All miRNAs listed are statistically significantly differentially expressed (p≤0.05) as 
determined using Mann Whitney tests. MiR-224, the later focus of the present study is 
highlighted.  
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3.3.2. MicroRNA profiling in colorectal cancer cell lines 
 
TLDA miRNA profiling was also used to identify miRNAs that were differentially 
expressed in HCT116 colorectal cancer cell lines, engineered to express either 
the WT or mutant form of KRAS, as described in Section 2.2.9.8. As the two cell 
lines are isogenic apart from their KRAS mutation status, the present study 
investigated whether differentially expressed miRNAs would have an influence 
on KRAS signalling or its downstream pathways. Twelve miRNAs were 
differentially expressed in KRAS WT cell lines compared to mutant cell lines 
(Table 3.4). Of the 12 miRNAs, 5 miRNAs were significantly decreased in KRAS 
WT cells relative to mutant cells whereas 7 miRNAs were significantly increased 
in KRAS WT cells compared to mutant cells. Interestingly, miR-193b has recently 
been experimentally validated to directly target KRAS (Gastaldi et al, 2014). 
Table 3.4: MicroRNAs differentially expressed in HCT116 KRAS WT and mutant 
cell lines 
microRNA Fold Change Adjusted p value 
miR-224 5.13 0.008 
miR-636 3.02 0.004 
miR-34a 2.57 0.011 
miR-193b 1.92 0.021 
miR-125a-5p 1.85 0.018 
miR-28-3p 1.83 0.022 
miR-139-5p 1.65 0.043 
miR-29a -1.89 0.021 
miR-494 -2.15 0.002 
miR-886-3p -2.34 0.013 
miR-29c -2.35 0.002 
miR-18a -2.47 0.003 
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Three miRNAs (miR-224, miR-29c and miR-miR-139-5p) were differentially 
expressed in HCT116 KRAS WT and mutant cells (Table 3.4) and additionally 
differentially expressed in colorectal adenomas and cancers (Table 3.3). The 
expression of miR-29c was increased in colorectal adenomas and cancers 
compared to normal mucosa and significantly decreased in KRAS WT cells 
compared to KRAS mutant cells. On the other hand, miR-139-5p was significantly 
increased in KRAS WT cells compared to KRAS mutant cells but was significantly 
decreased in colorectal adenomas and cancers compared to normal colorectal 
mucosa.  
The expression of miR-224, like miR-29c, was increased in colorectal adenomas 
and cancers relative to normal colorectal mucosa but, like miR-139-5p, was 
increased in KRAS WT cell lines. As miR-224 was also the most abundantly 
differentially expressed miRNA in the comparison between the KRAS WT and 
mutant HCT116 cells, this chapter investigates the association between miR-224, 
KRAS and its downstream pathways and also the potential role of miR-224 in 
colorectal cancer progression.  
To validate the results from the TLDA analysis described above, a single probe 
Taqman small RNA assay specific to miR-224 was used to confirm that miR-224 
expression was significantly increased (3.3-fold; p=0.0002) in HCT116 KRAS WT 
cells compared to KRAS mutant cells (Figure 3.2). 
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Figure 3.2: The validation of miR-224 expression in HCT116 KRAS WT and mutant cell lines. A 
miR-224 specific Taqman small RNA assay was used to assess the expression of miR-224 in 
HCT116 KRAS WT and mutant cell lines, relative to the expression of the control miRNA let-7a, as 
described in Section 2.2.9.2. MiR-224 expression was assessed in both cell lines in triplicate and 
errors were determined by calculating 2 
(-δCt + sd δCt)
 and 2
(-δCt – sd δCt)
, as detailed in Section 2.2.9.5. 
Statistical significance (p≤0.05) was determined by performing independent T-tests. 
3.3.3. MiR-224 expression in human cancers 
 
I next sought to confirm that miR-224 expression was increased in colorectal 
cancers relative to normal mucosa, and to investigate whether miR-224 
expression was influenced by KRAS or BRAF mutation status. Twelve colorectal 
cancers and their patient-matched normal mucosa samples were selected on the 
basis of cancer KRAS and BRAF mutation status (4 G13D KRAS mutant, 4 
BRAFV600E mutant and 4 KRAS and BRAF WT). G13D KRAS mutant cancers were 
chosen as the HCT116 KRAS mutant cell line harbours the same type of KRAS 
mutation. The cancers were otherwise variable for other factors such as the 
mutation status of other genes and cancer stage (Appendix F, Table F1). A 
marked inter-patient difference in miR-224 expression was observed across the 
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cohort of cancers and normal mucosa (Figure 3.3 A). The expression of miR-224 
was significantly increased in cancers compared to normal mucosa in 10 of the 
12 patients (Figure 3.3 B). Overall, across the cohort of 12 patients, the 
expression of miR-224 was significantly increased (p=0.005; Mann Whitney test) 
in colorectal cancers compared to normal mucosa, consistent with the initial 
screen in Table 3.3.  
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Patient Fold change p value 
1 12.25 p<0.0001 
2 2.79 0.002 
3 6.13 0.002 
4 10.75 p<0.0001 
5 1.10 0.042 
6 2.70 0.001 
7 16.78 0.002 
8 1.12 0.079 
9 1.25 0.025 
10 1.79 p<0.0001 
11 1.34 0.007 
12 -3.35 0.002 
 
Figure 3.3: MiR-224 expression in colorectal cancers and patient-matched normal mucosa. A) 
The expression of miR-224, relative to the control miRNA let-7a, was assessed in 12 colorectal 
cancers and patient-matched normal mucosa samples using a miR-224 specific Taqman small 
RNA assay, as detailed in Section 2.2.9.2. MiR-224 expression was assessed in all patient samples 
in triplicate and errors were determined by calculating 2 
(-δCt + sd δCt)
 and 2
(-δCt – sd δCt)
, as detailed in 
Section 2.2.9.5; B) Fold change of relative miR-224 expression in colorectal cancers compared to 
matched normal mucosa was calculated and statistical significance (p≤0.05) of miR-224 
expression in colorectal cancers compared to normal mucosa was determined by performing 
independent T-tests. 
(A) 
(B) 
(B) 
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Furthermore, to explore whether miR-224 could stratify colorectal cancers 
based on their KRAS or BRAF mutation status, the cancer series was extended to 
a cohort of 41 cancers including 14 KRAS and BRAF WT cancers, 9 BRAF mutant 
and 18 KRAS mutant cancers (Appendix F, Table F2). Compared to the KRAS and 
BRAF WT cancers, miR-224 expression was significantly decreased (p=0.012) in 
BRAF mutant cancers (Figure 3.4). In contrast, the expression of miR-224 was 
not significantly changed in KRAS mutant cancers compared to KRAS and BRAF 
WT cancers. An explanation for this could be that all 9 BRAF mutant cancers 
harboured a common BRAFV600E mutation. However, within the KRAS mutant 
cancers were a number of different KRAS mutations. Previous data within our 
group have shown using a NIH3T3 mouse fibroblast cell line model that other 
types of KRAS mutations cause varying cell phenotypes such as different 
sensitivities to 5-FU (see Section 3.3.6) and colony formation potential. This 
raises the question of whether miR-224 would be significantly differentially 
expressed in cell lines or cancers with only a G13D mutation, but we 
unfortunately did not have sufficient power to formally test this hypothesis.  
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Figure 3.4: MiR-224 expression in KRAS/BRAF WT colorectal cancers compared to BRAF 
mutant and KRAS mutant cancers: The expression of miR-224, relative to the control miRNA let-
7a, was assessed in 41 colorectal cancers, including 14 KRAS and BRAF WT cancers, 9 BRAF 
mutant and 18 KRAS mutant cancers. MiR-224 expression was assessed in all patient samples in 
triplicate and errors were calculated by using 2 
(-δCt + sd δCt)
 and 2
(-δCt – sd δCt)
, as detailed in Section 
2.2.9.5; statistical significance (p≤0.05) of miR-224 expression in BRAF mutant cancers compared 
to KRAS/BRAF WT cancers and KRAS mutant cancers compared to KRAS/BRAF WT cancers was 
determined by performing Mann Whitney tests. 
I also investigated whether miR-224 expression could stratify the 41 colorectal 
cancers based on correlations with gene expression data generated using 
Affymetrix profiling in previous studies within our laboratory. Spearman rank 
correlation was used to correlate the relative expression of miR-224 across the 
cohort of 41 colorectal cancers and each of the 3566 probes from the Affymetrix 
data targeted to the 1305 predicted gene targets of miR-224 (Appendix I) as 
determined by bioinformatics analysis described later in Section 3.3.8. The 
strongest positive correlation was seen with YIP1 (Yip1 domain family, member 
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6; correlation value: +0.629) whereas the strongest negative correlation was 
with TLR1 (Toll-like receptor 1; correlation value: -0.626; Appendix G). Neither 
YIP1 nor TLR1 have been previously associated with miR-224. The inverse 
correlation between miR-224 and TLR1 suggests that TLR1 could be a potential 
novel target of miR-224. No strong correlations however were seen with 
between miR-224 expression and the expression of the genes that have been 
experimentally validated to be direct targets of miR-224 such as SMAD4 (Wang 
et al, 2013; Zhang et al, 2013a) or API5 (Wang et al, 2008). This may indicate the 
limitations of correlating miRNA expression with mRNA expression as, in some 
cases, mRNA levels are unchanged following the binding of miRNAs to the 3’UTR 
of mRNA whereas protein translation is blocked.  This highlights the importance 
of correlating miR-224 expression with protein expression, a priority for future 
studies. Furthermore, this approach may have been further limited by the fact 
that the cohort of 41 colorectal cancers may have been too small, also 
highlighting the need to perform this type of analysis in a larger cohort.  
Pre-mir-224 is located on, and transcribed from, the q arm of the X chromosome 
to form the mature miR-224. It was therefore hypothesised that there could be a 
difference in the expression of miR-224 expression between male and female 
patients. The expression of miR-224 was not, however, significantly different 
between the 18 male and 23 female colorectal cancer patients (p=0.331; Mann 
Witney test) 
I also investigated whether miR-224 expression was higher in later staged 
cancers. Within the 41 cancers investigated, 4 were identified to be Dukes’ stage 
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A (T1/T2 N0 MX – by TNM staging), 20 as Dukes’ stage B (T3/T4 N0 MX) and 17 
as Dukes’ stage C (T3/T4 N1/N2 MX). There was no significant difference in miR-
224 expression between Dukes’ stage A and B (p=0.64), Dukes’ stage A and C 
(p=0.65) or between Dukes’ stage B and C cancers (p=0.48; Mann Whitney test). 
3.3.4. MiR-224 knockdown in HCT116 KRAS WT cells 
 
To investigate the functional role of miR-224, a specific miR-224 inhibitor was 
transiently transfected into HCT116 KRAS WT cell lines, as described in Section 
2.2.5. As miR-224 expression is higher in KRAS WT cells it was speculated that 
lowering the expression of miR-224 may show a KRAS mutant-like phenotype in 
KRAS WT cells by increasing KRAS activity. An initial optimisation experiment 
where final concentrations of 10 nM, 15 nM, 20 nM, 25 nM and 30 nM of miR-
224 inhibitor or a negative control was transfected into HCT116 KRAS WT cells 
showed that the degree of miR-224 knockdown ranged from 91% at 10 nM 
(p=1.5x10-8) to 98% at 30 nM after 24 hours (p=1.1x10-6; Figure 3.5). In contrast, 
the expression of miR-224 following transfection with negative control was not 
significantly changed between the lowest and highest concentration (p=0.12; 
ANOVA; Figure 3.5). A final concentration of 30 nM miR-224 inhibitor or negative 
control was therefore used for subsequent experiments.  
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Figure 3.5: MiR-224 inhibitor and miRNA inhibitor negative control optimisation. HCT116 
KRAS WT cells were transiently transfected with 10 nM, 15 nM, 20 nM, 25 nM and 30 nM of miR-
224 specific miRNA inhibitor and a miRNA inhibitor negative control, as described in Section 
2.2.5. The expression of miR-224, relative to the control let-7a, was assessed as described in 
Section 2.2.9.2. MiR-224 expression was assessed in each sample in triplicate and errors were 
calculated by using 2 
(-δCt + sd δCt)
 and 2
(-δCt – sd δCt)
, as detailed in Section 2.2.9.5; statistical 
significance (p≤0.05) of miR-224 expression in negative control transfected HCT116 KRAS WT cells 
compared to miR-224 inhibitor transfected cells was determined by performing independent T-
tests. 
The knockdown of miR-224 ranged from 96% ± 0.3% (p=1.1x10-5) 24 hours after 
transfection to 89% ± 0.8% (p=9.1x10-5) 96 hours after transfection (Figure 3.6). 
By 168 hours the knockdown of miR-224 had reduced to 51% ± 4.8%     
(p=8.6x10-3). This demonstrated that there was a window of at most 96 hours 
post-transfection where miR-224 expression was sufficiently diminished to allow 
for investigating the phenotypic consequences of its absence.  
105 
 
 
 
 
Figure 3.6: The knockdown of miR-224 over 168 hours. HCT116 KRAS WT cells were transiently 
transfected with a final concentration of 30 nM miR-224 inhibitor, as described in Section 2.2.5. 
MiR-224 expression was assessed, relative to the control miRNA let-7a, 24, 48, 72, 96 and 168 
hours after transfection in miR-224 knockdown cells and the untransfected HCT116 KRAS WT 
cells, as described in Section 2.2.9.2. The experiment was performed 3 times and the error bars 
represent the SEM. Statistical significance (p≤0.05) of miR-224 expression in untransfected 
HCT116 KRAS WT cells compared to miR-224 knockdown cells at each time point was determined 
by performing independent T-tests. 
3.3.5. The effects of miR-224 knockdown on KRAS activation  
 
As miR-224 was significantly differentially expressed in HCT116 KRAS WT and 
mutant cells, the effect of miR-224 knockdown on the amount of GTP-bound 
activated KRAS was next investigated using a RAS ELISA, as described in Section 
2.2.12. KRAS activation, as expected, was inherently higher (2.5 fold, p=0.0017) 
in KRAS mutant cells compared to KRAS WT cells (Figure 3.7). The knockdown of 
miR-224 in HCT116 KRAS WT cells significantly increased KRAS activation (1.9 
fold, p=0.0012) compared to the untransfected KRAS WT cells. Consistent with 
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my hypothesis, this suggests that the knockdown of miR-224 may convert the 
KRAS WT phenotype to a more active or KRAS mutant-like phenotype.   
 
Figure 3.7: The effect of miR-224 knockdown in HCT116 KRAS WT cells on KRAS activation. A 
Ras ELISA was used to assess the effect of miR-224 knockdown in HCT116 KRAS WT cells on the 
amount of GTP-bound activated KRAS (measured in relative luminescence units) in a cellular 
extract compared to untransfected HCT116 KRAS WT and mutant cells, as described in Section 
2.2.12. Each sample was assessed in triplicate and the errors represent the SEM of relative 
luminescence units. Statistical significance (p≤0.05) of KRAS activation in miR-224 knockdown 
HCT116 KRAS WT cells compared to untransfected HCT116 KRAS WT and mutant cells was 
determined by performing independent T-tests.  
 
 
 
 
 
107 
 
 
 
To investigate the effect of miR-224 knockdown in HCT116 KRAS WT cells on 
downstream signalling pathways, a PathScan intracellular signalling array which 
detects the phosphorylation or cleavage of 18 well characterised signalling 
molecules was used as described in Section 2.2.13. The array firstly suggested 
that, consistent with KRAS activation, the phosphorylation of ERK, an important 
downstream intracellular protein kinase in the RAS/MAPK pathway, was 
increased (1.6 fold) in HCT116 KRAS WT cells after miR-224 knockdown and thus 
also exhibited a KRAS mutant-like phenotype (Figure 3.8). 
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Figure 3.8: The effect of miR-224 knockdown on ERK 1/2 phosphorylation. A) The PathScan 
intracellular signalling array and LiCor Odyssey fluorescence imaging system was used to assess 
the effect of miR-224 knockdown in HCT116 KRAS WT cells on the phosphorylation or cleavage of 
18 signalling molecules compared to untransfected HCT116 KRAS WT and mutant cells, as 
detailed in Section 2.2.13; highlighted in red is pERK 1/2. Each signalling molecule is represented 
in duplicate. B) The fluorescent signals at wavelength 680/700 nm as determined by LiCor Image 
Studio are represented graphically. Experiment was performed once and error bars represent the 
technical replicates.  
(A) 
(B) 
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Secondly, the array suggested that the phosphorylation of AKT at tyrosine 308 
and serine 473 was significantly higher (1.4 and 1.3 fold respectively) in HCT116 
KRAS WT cells after miR-224 knockdown compared to untransfected KRAS WT 
cells and KRAS mutant cells suggesting that miR-224 knockdown may also affect 
the pro-survival Ras-Akt-PI3K pathway. Surprisingly, there was no difference 
between the KRAS WT and mutant cells (Figure 3.9).  
 
 
 
 
Figure 3.9 
(A) 
(B) 
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Figure 3.9: The effect of miR-224 knockdown on AKT phosphorylation. A) The PathScan 
intracellular signalling array and LiCor Odyssey fluorescence imaging system was used to assess 
the effect of miR-224 knockdown in HCT116 KRAS WT cells on the phosphorylation or cleavage of 
18 signalling molecules compared to untransfected HCT116 KRAS WT and mutant cells, as 
detailed in section 2.2.13; highlighted in purple is AKT Thr 308 and highlighted in blue is AKT 
Ser473. Each signalling molecule is represented in duplicate. B) The fluorescent signals at 
wavelength 680/700 nm as determined by LiCor Image Studio are represented graphically. 
Experiment was performed once and error bars represent the technical replicates.  
Thirdly, the PathScan array identified a number of signalling molecules that were 
significantly increased in HCT116 KRAS WT cells post-miR-224 knockdown 
compared to untransfected KRAS WT cells indicating the variety of pathways 
that may also be affected by miR-224. These included Stat1, Stat3, AMPK, 
HSP27, PRAS40 and p38 (Figure 3.10). A specific association with miR-224 and 
the activation of these pathways have not been previously reported. However, 
these results would need to be validated by performing Western blots for native 
and phosphorylated forms of each protein. 
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Figure 3.10: The effect of miR-224 knockdown on the phosphorylation of other signalling 
molecules. A) The PathScan intracellular signalling array and LiCor Odyssey fluorescence imaging 
system was used to assess the effect of miR-224 knockdown in HCT116 KRAS WT cells on the 
phosphorylation or cleavage of 18 signalling molecules compared to untransfected HCT116 KRAS 
WT, as detailed in Section 2.2.13. Each signalling molecule is represented in duplicate. B) The 
fluorescent signals at wavelength 680/700 nm as determined by LiCor Image Studio are 
represented graphically. Experiment was performed once and error bars represent the technical 
replicates.  
(A) 
(B) 
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To further investigate why miR-224 knockdown increased KRAS activity, other 
than through GTP-bound activation, the expression of KRAS and two other 
human Ras genes, NRAS and HRAS was compared in HCT116 KRAS WT miR-224 
knockdown cells and untransfected KRAS WT and mutant cells by Taqman RT-
PCR as detailed in Section 2.2.9.4. There was no significant change in KRAS gene 
mRNA expression between the KRAS WT and mutant cells. However, consistent 
with the KRAS activation data presented above, miR-224 knockdown 
significantly increased (1.7-fold, p=0.007) KRAS expression in KRAS WT cells 
(Figure 3.11 A). This suggests that an increase in KRAS expression may contribute 
to the mutant-line phenotype in KRAS WT cells following miR-224 knockdown. 
This appears to be a KRAS specific rather than a general Ras effect as there was 
no significant change in NRAS (p=0.12) or HRAS (p=0.09) expression due to miR-
224 knockdown (Figure 3.11 B, C), although NRAS and HRAS expression was 
significantly increased in KRAS mutant cells (NRAS: 1.3 fold, p=0.04; HRAS: 1.7-
fold, p=0.007). Future studies would be directed towards confirming these 
results using Western blots. 
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Figure 3.11: The impact of miR-224 knockdown on KRAS, NRAS and HRAS mRNA expression. 
A) KRAS mRNA expression was assessed, relative to the control gene 18S ribosomal RNA , in miR-
224 knockdown HCT116 KRAS WT cells and untransfected KRAS WT and mutant cells as detailed 
in Section 2.2.9.4. B) NRAS and C) HRAS mRNA expression was also assessed in miR-224 
knockdown HCT116 KRAS WT cells and untransfected KRAS WT cells. Each sample was assessed 
in triplicate and the errors were determined by calculating 2 
(-δCt + sd δCt)
 and 2
(-δCt – sd δCt)
, as detailed 
in Section 2.2.9.5. Statistical significance (p≤0.05) was determined by performing independent T-
tests. 
(A) 
(B) 
(C) 
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3.3.6. The effect of miR-224 knockdown on drug sensitivity 
 
The MTT cytotoxicity assay was used to investigate the effect of miR-224 
knockdown on drug sensitivity, as detailed in Section 2.2.4. Cell sensitivity to 5-
FU and oxaliplatin was investigated as these are drugs commonly used in 
colorectal cancer treatment. I also intended to investigate cetuximab, the EGFR 
inhibitor which has been approved for the treatment of KRAS WT colorectal 
cancer and which has little or no effect in KRAS mutant colorectal cancer. 
However, in contrast to antimetabolites or DNA damaging drugs, it is difficult to 
study the in vitro effects of cetuximab as its efficacy depends on the presence of 
EGFR on the cell surface and the presence of a receptor ligand, and is therefore 
difficult to evaluate in cell line models. Sorafenib is a small molecule BRAF 
inhibitor that inhibits the RAS/MAPK pathway downstream of KRAS and was 
therefore used as an alternative to cetuximab.  
The knockdown of miR-224 increased the sensitivity of HCT116 KRAS WT cells to 
5-FU. The IC50, the concentration of drug where 50% of cells are no longer viable, 
was significantly decreased 1.9-fold (p=0.04) in miR-224 knockdown KRAS WT 
cells compared to untransfected KRAS WT cells (Figure 3.12). In contrast, miR-
224 knockdown had no significant effect on the sensitivity of HCT116 KRAS WT 
cells to sorafenib (Figure 3.13) or oxaliplatin (Figure 3.14).  
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Figure 3.12: The effect of miR-224 knockdown on HCT116 KRAS WT cell sensitivity to 5-FU. A) 
MTT cytotoxicity assays were used to compare 5-FU sensitivities of miR-224 knockdown HCT116 
KRAS WT, negative control transfected and untransfected HCT116 KRAS WT cells, as detailed in 
Section 2.2.4. B) The IC50 for each cell line was calculated on GraphPad Prism version 6 and 
presented graphically as a fold change from the IC50 of the untransfected HCT116 KRAS WT cell 
line. The errors represent the SEM of three separate experiments. Statistical significance (p≤0.05) 
was determined by performing independent T-tests. 
 
 
(A) 
(B) 
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Figure 3.13: The effect of miR-224 knockdown on HCT116 KRAS WT cell sensitivity to 
sorafenib. A) MTT cytotoxicity assays were used to compare sorafenib sensitivities of miR-224 
knockdown HCT116 KRAS WT, negative control transfected and untransfected HCT116 KRAS WT 
cells, as detailed in Section 2.2.4. B) The IC50 for each cell line was calculated on GraphPad Prism 
version 6 and presented graphically as a fold change from the IC50 of the untransfected HCT116 
KRAS WT cell line. The errors represent the SEM of three separate experiments. Statistical 
significance (p≤0.05) was determined by performing independent T-tests. 
 
(B) 
(A) 
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Figure 3.14: The effect of miR-224 knockdown on HCT116 KRAS WT cell sensitivity to 
oxaliplatin. A) MTT cytotoxicity assays were used to compare oxaliplatin sensitivities of miR-224 
knockdown HCT116 KRAS WT, negative control transfected and untransfected HCT116 KRAS WT 
cells, as detailed in Section 2.2.4. B) The IC50 for each cell line was calculated on GraphPad Prism 
version 6 and presented graphically as a fold change from the IC50 of the untransfected HCT116 
KRAS WT cell line. The errors represent the SEM of three separate experiments. Statistical 
significance (p≤0.05) was determined by performing independent T-tests. 
 
 
(A) 
(B) 
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The observation that a KRAS mutant-like increase in KRAS activity or activation 
caused by miR-224 knockdown is associated with increased sensitivity to 5-FU is 
consistent with previous data generated by Dr. Simone Weidlich in our research 
group using a NIH3T3 mouse fibroblast cell line model. NIH3T3 cells were stably 
transfected with WT KRAS, 17 mutants of KRAS, WT BRAF or the V600E mutant 
of BRAF to generate 20 novel cell lines (Figure 3.15).  
 
Figure 3.15: The stable transfection of WT and various mutants of KRAS and BRAF in NIH3T3 
cells. NIH3T3 cells were previously stably transfected with WT KRAS, 17 mutant KRAS, WT BRAF 
and mutant (V600E) BRAF constructs. A Western blot was performed to confirm the protein 
expression of WT and the various mutants of KRAS and BRAF, relative to the expression of β-
actin. 
Consistent with my miR-224 knockdown data, the mutant KRAS (G12V and G13D 
mutants used as examples) and BRAF (V600E) NIH3T3 cells were more sensitive 
(lower IC50) to 5-FU (Figure 3.16 A). Conversely, the mutant KRAS and BRAF cells 
were more resistant to sorafenib (Figure 3.16 B), an effect that what not 
observed following miR-224 knockdown in HCT116 KRAS WT cells. Consistent 
with the miR-224 data presented above, the KRAS or BRAF mutation status of 
the cells had no effect on their sensitivity to oxaliplatin (Figure 3.16 C).   
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Figure 3.16: KRAS and BRAF mutation status and drug sensitivity in stably transfected 
NIH3T3 cells. MTT cytotoxicity assays were used, previous to the present study, to compare the 
sensitivities of A) 5-FU B) sorafenib and C) oxaliplatin in KRAS WT and KRAS mutant (G12V and 
G13D) and BRAF WT and BRAF mutant (V600E) NIH3T3 mouse fibroblast cells. G12V and G13D 
KRAS mutants are presented here as representative examples. The IC50 for each cell line was 
calculated on GraphPad Prism version 6 and presented graphically as a fold change from the IC50 
of the KRAS WT cell line. The errors represent the SEM of three separate experiments. Statistical 
significance (p≤0.05) was determined by performing independent T-tests. 
 
(B) 
(C) 
(A) 
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3.3.7. The effect of miR-224 expression on drug metabolism genes 
 
Differences in chemosensitivity could relate to differences in cell proliferation or 
differences in drug metabolism. Given the effect of miR-224 on the sensitivity of 
5-FU, we sought to investigate whether the knockdown of miR-224 affected the 
expression of a number of enzymes that have been extensively investigated for 
their ability to predict response to 5-FU - Thymidylate synthase (TYMS), 
thymidine phosphorylase (TYMP) and dihydropyrimidine dehydrogenase (DPYD). 
As discussed in Chapter 1, TYMP is involved in the conversion of 5-FU to one of 
its active metabolite, fluorodeoxyuridine monophosphate (FdUMP). FdUMP 
inhibits TYMS, an enzyme involved in the synthesis of thymidine triphosphate 
(TTP), one of the four nucleotide triphosphates used in the in vivo synthesis of 
DNA. DPYD inactivates 5-FU to FDHU for excretion.  
Although contentious in the literature, a 5-FU sensitive phenotype has been 
associated with low expression of DPYD as this increases the amount of available 
and active drug available for the target cancers (Goto et al, 2012). Similarly, a 
low expression of TYMS is associated with 5-FU sensitivity as the resulting lower 
levels of TTPs negatively affect DNA synthesis. Elevated expression levels of 
TYMP have also been associated with 5-FU sensitivity as more FdUMP is 
produced leading to greater inhibition of TYMS (Goto et al, 2012). 
The expression of TYMS, TYMP and DPYD was assessed by Taqman qRT-PCR 
analysis in HCT116 KRAS WT miR-224 knockdown and untransfected cells, as 
described in Section 2.2.9.4. The knockdown of miR-224 in KRAS WT cells 
121 
 
 
 
significantly increased the expression of TYMS (1.96-fold; p=7.65x10-6), TYMP 
(1.48-fold; p=0.007) and DPYD (1.53-fold; p=0.045) compared to untransfected 
KRAS WT cells (Figure 3.17 A, B, C). If however, miR-224 induced changes in drug 
metabolism and sensitised HCT116 KRAS WT cells to 5-FU, it would be expected 
that the expression of TYMS and DPYD would be decreased.  
Additionally, miR-224 knockdown significantly increased the expression of 
ERCC1 (1.52-fold; p=0.01), which codes for a protein involved in DNA damage 
repair (Figure 3.17 D). The increased expression of ERCC1 is associated with 
resistance to oxaliplatin (Seetharam et al, 2010). However, ERCC1 induction 
caused by miR-224 knockdown had no effect on oxaliplatin resistance.  
The aforementioned effects on gene expression would need to be validated at a 
protein level using Western blots. However, the effect of miR-224 knockdown on 
the regulation of drug response enzymes is of interest given the aforementioned 
marked inter-patient differences in miR-224 expression in colorectal cancers 
(Figure 3.3).  
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Figure 3.17 
(A) 
(B) 
(C) 
(D) 
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Figure 3.17: The effect of miR-224 knockdown on the expression of drug response enzymes.  
A) TYMS, B) TYMP, C) DPYD and D) ERCC1 mRNA expression was assessed, relative to the control 
gene 18S ribosomal RNA, in miR-224 knockdown HCT116 KRAS WT cells and untransfected KRAS 
WT cells as detailed in Section 2.2.9.4. Each sample was assessed in triplicate and the errors were 
determined by calculating 2 
(-δCt + sd δCt)
 and 2
(-δCt – sd δCt)
, as detailed in Section 2.2.9.5. Statistical 
significance (p ≤ 0.05) was determined by performing independent T-tests. 
3.3.8. MiRNA target prediction databases 
 
A single miRNA is known to regulate a large number of genes due to the 
imperfect complementarity between the miRNA sequence and the seed 
sequence of the 3’ UTR of target genes. There are now many readily available 
online miRNA target prediction databases which use unique algorithms to 
predict targets. The targets are ranked within each database based on the 
predicted affinity of the miRNA to the target gene, although it is important to 
note that the majority of predicted targets have not been experimentally 
verified. 
In the present study, in collaboration with Probir Chakravarty (CRUK 
Bioinformatics and Biostatistics Service, London), five well characterised miRNA 
target prediction databases, mirDB (www.mirdb.org), miRANDA 
(www.microrna.org), miRBase (www.mirbase.org), TargetMiner 
(www.isical.ac.in) and TargetScan (www.targetscan.org) were used to predict 
the targets of the 12 miRNAs (Table 3.2) differentially expressed in HCT116 KRAS 
WT and mutant cells, as described in Section 2.2.17. A total of 4083 and 3612 
predicted targets were identified for the over and under-expressed miRNAs 
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respectively. In order to limit the number of false positives, the predicted targets 
that were common to at least two of the five databases were selected for 
further analysis. Therefore, 2305 unique predicted targets for the 7 up-regulated 
miRNAs and 1859 for the 5 down-regulated miRNAs were selected (Appendix H).  
The bioinformatics tool, Metacore was then used to identify pathways and 
processes that were enriched and significantly associated with the predicted 
targets of the over and under-expressed miRNAs, as described in Section 2.2.17. 
As shown in Tables 3.5 and 3.6, several common cancer-related processes and 
pathways involved in development of epithelial to mesenchymal transition 
(EMT), cell adhesion, cytoskeleton remodelling and cell proliferation were 
prominent. However, processes and pathways associated with cardiac 
development or neurogenesis, for example, were also identified further 
demonstrating the wide ranging effects of differential miRNA expression.  
Within the Tables, the ratio indicates the number of genes found to be in our 
target list compared to the number of genes identified by the program to be 
involved in a particular process or pathway. In this initial analysis, although 
significant associations were identified, less than 50% of the genes in our target 
list appeared in the genes involved in the vast majority of the processes and 
pathways identified (Tables 3.5 and 3.6).  
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Table 3.5:  Pathways and processes associated with 7 miRNAs differentially 
increased in HCT116 KRAS WT cells relative to HCT116 KRAS mutant cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pathway name p value Ratio 
1 Cytoskeleton remodeling_TGF, WNT and cytoskeletal remodelling 5.84E-19 54/111 
2 Cytoskeleton remodeling_Cytoskeleton remodelling 7.98E-18 50/102 
3 Development_Thrombopoietin-regulated cell processes 3.96E-16 30/45 
4 Cell adhesion_Chemokines and adhesion 2.02E-14 45/100 
5 Development_HGF signaling pathway 2.58E-14 29/47 
6 Development_Regulation of epithelial-to-mesenchymal transition (EMT) 7.41E-14 34/64 
7 Transcription_CREB pathway 2.56E-13 28/47 
8 Cardiac Hypertrophy_NF-AT signaling in Cardiac Hypertrophy 9.36E-13 33/65 
9 Reproduction_GnRH signalling 9.93E-13 35/72 
10 Development_TGF-beta-dependent induction of EMT via MAPK  2.33E-12 27/47 
 
Process name p value Ratio 
1 Signal transduction_WNT signalling 5.26E-12 85/177 
2 Development_Neurogenesis_Axonal guidance 2.73E-10 99/230 
3 Proliferation_Positive regulation cell proliferation 6.91E-10 95/221 
4 Development_EMT_Regulation of epithelial-to-mesenchymal transition 2.73E-09 97/232 
5 Signal Transduction_Cholecystokinin signalling 2.95E-09 54/106 
6 Signal transduction_NOTCH signalling 3.48E-09 98/236 
7 Development_Blood vessel morphogenesis 1.13E-08 94/228 
8 Development_Neurogenesis_Synaptogenesis 1.55E-08 78/180 
9 Cell adhesion_Cadherins 1.55E-08 78/180 
10 Reproduction_Feeding and Neurohormone signaling  1.74E-08 88/211 
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Table 3.6: Pathways and processes associated with 5 miRNAs differentially 
decreased in HCT116 KRAS WT cells relative to HCT116 KRAS mutant cells 
 
Pathway name p value Ratio 
1 Development_Regulation of epithelial-to-mesenchymal transition (EMT) 4.07E-13 31/64 
2 Development_WNT signaling pathway. Part 2 2.26E-11 26/53 
3 Signal transduction_PKA signaling 5.62E-11 25/51 
4 Cytoskeleton remodeling_Role of PKA in cytoskeleton reorganisation 3.82E-10 21/40 
5 Cytoskeleton remodeling_TGF, WNT and cytoskeletal remodeling 3.98E-10 38/111 
6 Transport_Clathrin-coated vesicle cycle 4.13E-10 29/71 
7 Development_TGF-beta-dependent induction of EMT via SMADs  1.08E-08 18/35 
8 Cell adhesion_Chemokines and adhesion 1.62E-08 33/100 
9 Cytoskeleton remodeling_Cytoskeleton remodeling 2.81E-08 33/102 
10 Proteolysis_Role of Parkin in the Ubiquitin-Proteasomal Pathway 5.82E-08 14/24 
 
 
 
 
 
 
 
 
 
 
 
 
 
Process name p value Ratio 
1 Development_EMT_Regulation of epithelial-to-mesenchymal transition 8.67E-11 92/232 
2 Development_Hedgehog signaling 1.74E-09 95/254 
3 Development_Neurogenesis_Synaptogenesis 1.68E-08 71/180 
4 Cell adhesion_Synaptic contact 1.97E-08 72/184 
5 Cytoskeleton_Regulation of cytoskeleton rearrangement 9.03E-08 70/183 
6 Signal transduction_WNT signaling 1.14E-07 68/177 
7 Development_Neurogenesis_Axonal guidance 1.21E-07 83/230 
8 Cytoskeleton_Actin filaments 2.11E-07 67/176 
9 Cardiac development_FGF_ErbB signaling 3.87E-07 51/124 
10 Signal transduction_NOTCH signaling 4.31E-07 83/236 
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To further investigate the phenotypic consequences of miR-224 knockdown, a 
similar bioinformatics approach was used to analyse HCT116 cells before and 
after miR-224 knockdown. TLDA miRNA profiling of HCT116 KRAS WT cells after 
miR-224 knockdown identified that, compared to untransfected HCT116 KRAS 
WT cells, 35 miRNAs (3 up, 32 down) were differentially expressed (Table 3.7) 
 Table 3.7: MicroRNAs differentially expressed in HCT116 KRAS WT and miR-224 
knockdown HCT116 KRAS WT cells 
 
 
 
 
 
 
 
 
 
 
 
microRNA  Fold Change 
Adjusted 
p value   microRNA Fold Change 
Adjusted  
p value 
miR-532-5p 3.53 0.0044 
 
miR-636 -3.04 0.0097 
miR-34a 2.54 0.0250 
 
miR-744 -3.27 0.0086 
miR-342-3p 1.98 0.0469 
 
miR-375 -3.52 0.0076 
miR-19a -1.71 0.0475 
 
miR-642 -3.63 0.0076 
miR-31 -1.81 0.0475 
 
miR-532-3p -3.79 0.0038 
miR-222 -1.91 0.0387 
 
miR-197 -4.17 0.0029 
miR-140-5p -1.92 0.0469 
 
miR-331-3p -4.17 0.0095 
miR-103 -2.00 0.0338 
 
miR-125b -4.21 0.0057 
miR-132 -2.01 0.0296 
 
miR-193b -4.75 0.0029 
miR-93 -2.13 0.0271 
 
miR-320 -5.18 0.0044 
miR-29c -2.23 0.0469 
 
miR-671-3p -5.63 0.0469 
let-7d -2.23 0.0275 
 
miR-574-3p -5.98 0.0076 
let-7e -2.37 0.0340 
 
miR-92a -6.09 0.0044 
miR-149 -2.58 0.0076 
 
miR-181a -6.86 0.0029 
miR-345 -2.68 0.0126 
 
let-7b -10.20 0.0102 
miR-324-3p -2.72 0.0336 
 
miR-210 -15.00 0.0003 
miR-183 -2.84 0.0436 
 
miR-328 -22.98 0.0029 
miR-99b -2.92 0.0336 
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The same five miRNA target prediction databases were also used to identify 
predicted targets for these over and under-expressed miRNAs. Metacore 
bioinformatics analysis showed that cytoskeleton remodelling, cell adhesion, 
development of EMT, cell cycle regulation and cell proliferation again were 
prominent processes and pathways (Tables 3.8 and 3.9). In this analysis there 
was a marked enrichment of the genes involved in the processes and pathways 
identified, with the majority now within the 95% to 100% range. This is likely to 
be because our target lists for this analysis was a lot larger; therefore they were 
more likely to contain target genes identified by the program to be involved in a 
particular pathway. I next went on to experimentally validate the phenotypes 
identified by bioinformatics analysis. 
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Table 3.8: Pathways and processes associated with 3 miRNAs differentially 
increased in HCT116 KRAS WT miR-224 knockdown cells relative to 
untransfected HCT116 KRAS WT cells 
  Pathway name p value Ratio 
1 Cytoskeleton remodeling_TGF, WNT and cytoskeletal remodeling 3.10E-21 82/111 
2 Cell adhesion_Chemokines and adhesion 1.16E-17 72/100 
3 Cytoskeleton remodeling_Cytoskeleton remodeling 4.89E-17 72/102 
4 Immune response_IL-15 signaling 8.38E-13 48/64 
5 Development_EGFR signaling pathway 1.18E-11 50/71 
6 Development_Regulation of epithelial-to-mesenchymal transition (EMT) 2.60E-11 46/64 
7 Development_Gastrin in cell growth and proliferation 2.60E-11 45/62 
8 Immune response_Gastrin in inflammatory response 2.85E-10 47/69 
9 Chemotaxis_CXCR4 signaling pathway 3.09E-10 29/34 
10 Development_TGF-beta-dependent induction of EMT via MAPK  3.19E-10 36/47 
 
 
Process name p value Ratio 
1 Cytoskeleton_Regulation of cytoskeleton rearrangement 7.33E-08 128/183 
2 Signal transduction_NOTCH signaling 7.33E-08 158/236 
3 Development_Neurogenesis_Synaptogenesis 2.33E-07 124/180 
4 Cell adhesion_Synaptic contact 2.34E-07 126/184 
5 Development_EMT_Regulation of epithelial-to-mesenchymal transition 4.39E-07 149/226 
6 Reproduction_FSH-beta signaling pathway 1.43E-05 107/160 
7 Cell cycle_G1-S Growth factor regulation 2.21E-05 126/195 
8 Development_Neurogenesis_Axonal guidance 2.57E-05 145/230 
9 Development_Skeletal muscle development 4.26E-05 96/144 
10 Cytoskeleton_Actin filaments 4.26E-05 114/176 
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Table 3.9: Pathways and processes associated with 32 miRNAs differentially 
decreased in HCT116 KRAS WT miR-224 knockdown cells relative to 
untransfected HCT116 KRAS WT cells 
  Pathway name p value Ratio 
1 Cytoskeleton remodeling_TGF, WNT and cytoskeletal remodeling 1.74E-24 107/111 
2 Cytoskeleton remodeling_Cytoskeleton remodeling 1.10E-19 96/102 
3 Cell adhesion_Chemokines and adhesion 3.59E-18 93/100 
4 Development_Regulation of epithelial-to-mesenchymal transition (EMT) 7.42E-16 63/64 
5 Transport_Clathrin-coated vesicle cycle 4.24E-15 68/71 
6 Immune response_HSP60 and HSP70/ TLR signaling pathway 7.84E-15 54/54 
7 Development_TGF-beta receptor signaling 1.08E-13 50/50 
8 Development_WNT signaling pathway. Part 2 6.36E-13 52/53 
9 Cell adhesion_ECM remodeling 1.11E-12 51/52 
10 Immune response_IL-18 signalling 2.65E-12 57/60 
 
  Process name p value Ratio 
1 Development_Neurogenesis_Synaptogenesis 2.04E-11 180/180 
2 Cytoskeleton_Actin filaments 6.58E-10 175/176 
3 Transcription_mRNA processing 5.77E-09 159/160 
4 Cell cycle_G2-M 5.92E-09 202/206 
5 Cytoskeleton_Regulation of cytoskeleton rearrangement 1.64E-08 180/183 
6 Cytoskeleton_Cytoplasmic microtubules 1.70E-07 115/115 
7 Cell adhesion_Integrin-mediated cell-matrix adhesion 2.96E-07 207/214 
8 Signal transduction_NOTCH signaling 3.27E-07 227/236 
9 Development_Skeletal muscle development 3.35E-07 142/144 
10 Proliferation_Positive regulation cell proliferation 4.03E-07 213/221 
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3.3.9. The effect of miR-224 on cell proliferation and the cell cycle 
 
The impact of miR-224 knockdown in HCT116 KRAS WT cells on cell proliferation 
was investigated, firstly, by flow cytometry using the CellTrace Violet Cell 
Proliferation Kit as detailed in Section 2.2.14.3, and secondly by a growth assay, 
as described in Section 2.2.3.  
The knockdown of miR-224 in HCT116 KRAS WT cells significantly increased their 
doubling time (from 19.8 hours to 27.5 hours, p=0.01) over a 48 hour period as 
determined by the CellTrace Violet Cell Proliferation Kit (Table 3.10).  
Table 3.10: Doubling time of HCT116 KRAS WT miR-224 knockdown cells 
compared to negative control and untransfected KRAS WT and mutant cells as 
determined by the CellTrace Violet Cell Proliferation Kit 
 
 
 
 
 
 
 
 
Cell line  
Doubling time 
(hours)  
p value  
(compared to HCT116 
KRAS WT – miR-224 KD) 
HCT116 KRAS WT – miR-224 KD  27.5 ± 1.39 - 
HCT116 KRAS WT – negative control KD  21.5 ± 2.60 0.113 
HCT116 KRAS WT  19.8 ± 0.93 0.010 
HCT116 KRAS mutant  19.1 ± 0.31 0.471 
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This result was confirmed by an independent cell growth assay where the 
knockdown of miR-224 in HCT116 KRAS WT cells significantly increased their 
doubling time from 23.5 hours to 26.1 hours (p=8.7x10-4) over a 48 hour period 
(Figure 3.18). Surprisingly, in contrast, there was no significant difference in 
doubling time between the KRAS WT and KRAS mutant cells in both experiments 
(CellTrace Violet Cell Proliferation Kit, p=0.51; growth assay, p=0.07; 
independent T test). This may be an effect of using immortalised cell lines which 
have been in culture for long periods and where the biology has been altered in 
the process. It was expected that the KRAS mutant cells, which have a 
constitutively activated RAS/MAPK pathway, would proliferate at a faster rate 
and have a lower doubling time than the KRAS WT cells.  
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Figure 3.18: Cell growth after miR-224 knockdown in HCT116 KRAS WT cells. A) Cells were 
seeded at a density of 1x10
5
 cells per 3.5 cm diameter well  and counted at 5 different time points 
over a 48 hour period as detailed in Section 2.2.3. Errors bars represent the SEM of cell number 
over 3 separate experiments. B) The doubling times were then calculated as detailed in Section 
2.2.3 (Box 2.1). Statistical significance (p≤0.05) was determined by performing independent T-
tests. 
 
Cell line  Doubling time (hours)  
p value  
(compared to HCT116 
KRAS WT – miR-224 KD) 
HCT116 KRAS WT – miR-224 KD  26.1 ± 0.14 - 
HCT116 KRAS WT – negative 
control KD  23.1 ± 0.17 1.8x10-4 
HCT116 KRAS WT  23.5 ± 0.26 8.7x10-4 
HCT116 KRAS mutant  22.5 ± 0.31 0.06 
(A) 
(B) 
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The effect of miR-224 knockdown on cell cycle kinetics was then investigated by 
staining cells with propidium iodide and analysing DNA content using a flow 
cytometer, as described in Section 2.2.14.1. 
Figure 3.19 shows progression through the different stages of the cell cycle and 
suggests that KRAS mutant cells inherently remained in the G0/G1 phase for 
longer at 36 and 48 hours after seeding compared to KRAS WT cells. This was a 
surprising result as this suggests that the KRAS mutant cells did not progress 
through the cell cycle at the same rate as the KRAS WT cells. As mentioned 
previously Table 3.10 and Figure 3.18 suggest that the KRAS mutant and WT cells 
did not have significantly different doubling times. Due to time constraints this 
experiment could only be performed once and further analysis will shed better 
light on this observation. The knockdown of miR-224 or transfection with a 
miRNA inhibitor negative control, however, had no effect on the cell cycle 
kinetics of KRAS WT cells, an effect that has also been shown in HepG2 human 
liver carcinoma cells (Li et al, 2010), suggesting that there is not a direct 
association between doubling time and cell cycle progression.  
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Figure 3.19: The effect of miR-224 knockdown in HCT116 KRAS WT cells on cell cycle kinetics.  
Cells were seeded at a density of 1x10
6
 cells per 5 cm diameter plate, harvested at 3 time points 
over 48 hours and labelled with Propidium iodide. DNA content was then analysed by flow 
cytometry to determine the percentage of cells in the defined phases of the cell cycle, as 
described in Section 2.2.14.1. Experiment was performed once. 
 
136 
 
 
 
To investigate whether the above result would be different in response to 
cellular stress, the cells were treated with 10 µM 5-FU for 12, 24 and 48 hours. 
5-FU caused an S-phase arrest particularly from 24 hours post drug exposure 
(Figure 3.20), an effect that commonly occurs in response to drugs to halt the 
cell cycle and repair damaged DNA. In response to drug, KRAS mutant cells once 
again remained in G1 phase for longer than KRAS WT cells. However, the 
knockdown of miR-224 in KRAS WT cells did not affect the cell cycle kinetics 
compared to untransfected KRAS WT cells.  
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Figure 3.20: The effect of miR-224 knockdown in HCT116 KRAS WT cells on cell cycle kinetics 
in response to cellular stress.  Cells were seeded at a density of 1x10
6
 cells per 5 cm diameter 
plate and treated with 10 µM 5-FU for 12, 24 and 48 hours. Cells were harvested at these 3 time 
points over 48 hours and labelled with Propidium iodide. DNA content was then analysed by flow 
cytometry to determine the percentage of cells in the defined phases of the cell cycle, as 
described in Section 2.2.14.1. Experiment was performed once. 
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3.3.10. The effect of miR-224 on the development of EMT and cell invasion  
 
To explore the predicted association between miR-224 and EMT, the expression 
of a panel of well-known EMT genes, CDH1 (E-cadherin), CDH2 (N-cadherin), 
TWIST1 (Twist-related protein 1) and VIM (Vimentin) was compared in 
untransfected KRAS WT cells and miR-224 knockdown KRAS WT cells, by Taqman 
qRT-PCR analysis as described in Section 2.2.9.4. E-cadherin has previously been 
shown to be down-regulated during EMT whereas N-cadherin is known to be up-
regulated.  
CDH1 expression was significantly increased (1.12 fold; p=0.005) in miR-224 
knockdown KRAS WT cells compared to the untransfected KRAS WT cells (Figure 
3.21 A). Vimentin was also decreased (1.7 fold; p=0.04) in miR-224 knockdown 
KRAS WT cells compared to untransfected WT cells (Figure 3.21 B), while CDH2 
was not expressed in HCT116 KRAS WT and mutant cells (data not shown).  
TWIST1, when activated, causes the indirect down-regulation of E-cadherin or 
up-regulation of vimentin and is associated with up-regulation of matrix 
mellatoproteases (MMPs; Zhao et al, 2011). The knockdown of miR-224 
significantly increased (2.3 fold; p=0.008) the expression of TWIST1 (3.21 C). An 
important extension of this work would therefore be to confirm the above gene 
expression changes using Western blots and immunohistochemical analysis and 
to explore the effect of miR-224 knockdown on both MMP mRNA and protein 
expression. 
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Figure 3.21: The effect of miR-224 knockdown on the expression of EMT genes. The mRNA 
expression of A) CDH1, B) VIM and C) TWIST1 was assessed, relative to the control gene 18S 
ribosomal RNA, in miR-224 knockdown HCT116 KRAS WT cells and untransfected KRAS WT cells 
as detailed in Section 2.2.9.4. Each sample was assessed in triplicate and the errors were 
determined by calculating 2 
(-δCt + sd δCt)
 and 2
(-δCt – sd δCt)
, as detailed in Section 2.2.9.5. Statistical 
significance (p ≤ 0.05) was determined by performing independent T-tests. 
(A) 
(B) 
(C) 
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To investigate possible changes in cell invasion caused by miR-224 knockdown, a 
Calbiochem InnoCyte invasion assay was used to model and quantify cancer cell 
invasion in vitro, as detailed in Section 2.2.7. The invasion assay showed that 
miR-224 knockdown in KRAS WT cells significantly reduced (1.75 fold; p=0.009) 
its invasive capabilities (Figure 3.22 A). HCT116 KRAS mutant cells were 
significantly less invasive (1.2 fold; p=0.04) than HCT116 KRAS WT cells, 
suggesting that again miR-224 knockdown in KRAS WT cells exhibited a mutant 
KRAS-like phenotype.  
However, in the NIH3T3 model, previously discussed in Section 3.3.6, where WT 
or mutant KRAS was stably transfected into mouse fibroblast cells, NIH3T3 G13D 
KRAS mutant cells were significantly more invasive (4.6 fold; p=0.002) compared 
to NIH3T3 KRAS WT cells (Figure 3.22 B). This suggests that in this case the input 
of a dominant oncogenic mutant KRAS drives an invasive phenotype and further 
highlights the limitations of using immortalised cell lines as previously discussed.   
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Figure 3.22: The impact of miR-224 knockdown and KRAS mutation status on cell invasion. 
The Calbiochem InnoCyte invasion assay was used to model and quantify cancer cell invasion in 
vitro, as detailed in Section 2.2.7. A) The effect of miR-224 knockdown in HCT116 KRAS WT cells 
was compared to untransfected HCT116 KRAS WT and mutant cells. B) The effect of stable 
transfection of KRAS WT and G13D mutant KRAS constructs into NIH3T3 cells was also compared. 
Each sample was analysed in triplicate and errors represent the SEM of three separate 
experiments. Statistical significance (p≤0.05) was determined by performing independent T-tests. 
  
(A) 
(B) 
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3.3.11. The expression of miR-224 in cancer metastases 
 
As the present study shows that miR-224 affects cell invasion, in vitro, I next 
investigated whether miR-224 was also differentially increased in cancer 
metastases compared to patient-matched primary colorectal cancers. In the 
present study, 15 matched lymph node metastases and primary colorectal 
cancer samples and 20 matched liver metastases and primary colorectal cancer 
samples from 24 patients were selected for analysis by Professor Frank Carey 
(Consultant pathologist, Ninewells Hospital, Dundee). The expression of miR-224 
was compared within each matched pair by Taqman qRT-PCR analysis as 
described in Section 2.2.9.2.  
MiR-224 expression was significantly decreased in lymph node metastasis 
samples compared to primary colorectal cancers in 11 patients and significantly 
increased in 1 patient (Figure 3.23). There was no significant change in 4 
patients.  
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Patient Fold Change p value 
3 -1.89 0.005  
6 -1.69 0.0004  
7 -1.35 0.004 
9 -1.83 3.1E-05  
10 -2.10 0.003  
11 2.21 2.9E-05  
12 -3.11 0.0004  
13 -1.92 0.005  
15 -1.19 0.01  
20 -2.23 0.003  
21 -2.29 0.0001  
23*  -1.28 0.0004  
 
Figure 3.23: Differential miR-224 expression in primary colorectal cancers and patient-
matched lymph node metastases. A) The expression of miR-224, relative to the control miRNA 
let-7a, was compared in 15 primary colorectal cancers and patient-matched lymph node 
metastases as detailed in Section 2.2.9.2. Each sample was assessed in triplicate and the errors 
were determined by calculating 2 
(-δCt + sd δCt)
 and 2
(-δCt – sd δCt)
, as detailed in Section 2.2.9.5 B) Fold 
change represents the change of relative miR-224 expression from colorectal cancers to lymph 
node metastases. Statistical significance (p ≤ 0.05) was determined by performing independent T-
tests. 
(A) 
(B) 
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The expression of miR-224 was significantly increased in liver metastases 
samples compared to primary colorectal cancers in 13 patients and significantly 
decreased in 8 patients. There was no significant difference in 2 patients (Figure 
3.24). However, miR-224 expression was increased in 9 of the 13 patients where 
there was a differential expression greater than 1.5-fold.  
In collaboration with Professor Frank Carey, we assessed whether there was any 
association between increased, decreased or unchanged miR-224 expression in 
each matched case with patient gender, cancer differentiation (e.g. aggressive 
and poorly differentiated compared to less aggressive and well differentiated) 
and cancer origin (i.e. left colon and rectum versus right colon), but found no 
significant association. The patient cohort size in the present study was perhaps 
too small to look for these types of associations and therefore a larger patient 
cohort may allow for better interpretation.  
In the present study I hypothesised that miR-224 expression may be increased in 
lymph node or liver metastases compared to primary colorectal cancers. A 
recent study reports that high miR-224 expression drives colorectal cancer cell 
invasion in vitro and is associated with lower survival and greater risk of relapse 
in colorectal cancer patients (Zhang et al, 2013a). In contrast, Yuan et al (2013) 
showed that miR-224 inhibited colorectal cancer cell invasion in vitro and was 
under-expressed in colorectal lung metastases compared to primary cancers and 
inversely correlated with patient survival. This highlights the dual role miR-224 
may have in the development of cancer metastasis in different organs and 
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tissues by affecting different pathways and its possible role of reflecting the 
aggressiveness of the disease. 
In the present study, there was insufficient information available on patient 
survival to determine any correlation with increased or decreased miR-224 
expression, particularly in patients with liver metastases.  
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Patient Fold change p value 
1 -1.32 0.04  
2 1.57 0.0007  
3 -1.68 0.008  
4 -3.48 0.0003  
6 -3.92 1E-05  
8 3.84 0.0008  
9 2.48 3.7E-05  
10 2.86 0.001  
11 (i) 3.48 0.003  
11 (ii) 2.16 0.01  
12 -1.19 0.04  
13 1.99 0.0003  
14 (i) -1.77 0.009  
14 (ii) 1.46 0.006  
15 1.29 0.007  
16 1.23 0.01  
17 -1.72 0.0007  
18 -3.07 0.003  
20 3.55 0.0002  
23 (i) 4.04 3.4E-05 
23 (ii) 3.93 0.001  
 
 
Figure 3.24 
(A) 
(B) 
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Figure 3.24: Differential miR-224 expression in primary colorectal cancers and patient-
matched liver metastases. A) The expression of miR-224, relative to the control let-7a, was 
compared in 20 primary colorectal cancers and patient matched liver metastases as detailed in 
Section 2.2.9.2. Each sample was assessed in triplicate and the errors were determined by 
calculating 2 
(-δCt + sd δCt)
 and 2
(-δCt – sd δCt)
, as detailed in Section 2.2.9.5 B) Fold change represents 
the change of relative miR-224 expression from colorectal cancers to liver metastases. Statistical 
significance (p ≤ 0.05) was determined by performing independent T-tests. 
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3.4. Discussion 
 
A great wealth of research has described the many molecular events that occur 
during colorectal cancer progression. However we are still some way from 
identifying exactly how individuality in these molecular events leads to different 
clinical outcomes in colorectal cancer patients. The increasing understanding of 
the role of miRNAs in cancer progression may aid in this objective.  
The present study aimed to explore how individuality in miRNAs that regulate 
KRAS and its downstream pathways may mediate different clinical outcomes and 
further sub-classify colorectal cancers at a molecular level or serve as markers of 
disease progression.  
MiRNA profiling of colorectal cancers, normal mucosa and adenomas and 
HCT116 KRAS WT and mutant cell lines identified miR-224 as being 
overexpressed in colorectal cancer progression and potentially having an 
important role in the regulation of KRAS and its downstream pathways.  
The present study shows that miR-224 expression was increased in colorectal 
cancers compared to normal mucosa, an observation that is supported by a 
number of other studies (Monzo et al, 2008; Arndt et al, 2009; Sarver et al, 
2009; Wang et al, 2010c; Fu et al, 2012; Liao et al, 2012; Yuan et al, 2013; Zhang 
et al, 2014). Furthermore, our data is also supported by Bartley et al (2011) and 
Oberg et al (2011) who also reported that miR-224 expression was increased in 
both colorectal adenomas and cancers compared to normal mucosa. This 
suggests that the increased expression of miR-224 is an early and persistent 
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event in colorectal cancer development and progression. In addition to miR-224, 
miR-29c and miR-139-5p were found to be differentially expressed in HCT116 
KRAS WT and mutant cells and additionally differentially expressed in colorectal 
adenomas and cancers compared to normal mucosa.  
Given the increase in miR-29c in KRAS mutant cell lines compared to KRAS WT 
cells, one could speculate that the constitutive activation of the RAS/MAPK 
pathway activates the expression of miR-29c. Similar to miR-21 (Hatley et al, 
2010), miR-29c may possibly itself also potentiate the activation of the pathway, 
if there was no activating mutation present, through the silencing of negative 
regulators of the RAS/MAPK pathway. Considering that miR-29c is increased in 
colorectal cancer in the present study, miR-29c may have a role in KRAS-
mediated tumorigenesis through this proposed regulation of the RAS/MAPK 
pathway. 
On the other hand, as low expression of miR-139-5p is associated with a 
constitutively active RAS/MAPK pathway and is also decreased in colorectal 
cancer, it may suggest that miR-139-5p may influence KRAS-mediated 
tumorigenesis through the targeting and repression of a driver of the pathway, 
including KRAS itself.      
MiR-224 expression was increased in colorectal adenomas and cancers but also 
decreased in KRAS mutant cell lines. Interestingly, miR-224 has been 
experimentally validated to directly target and repress RAF kinase inhibitory 
protein (RKIP; Huang et al, 2012a). 
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RKIP has been shown to be cancer suppressive and protect against metastasis in 
a number of cancers by dissociating the interaction between RAF-1 and MEK and 
thus inhibiting the RAF/MAPK pathway. Al-Mulla et al (2006) were first to 
demonstrate that RKIP expression was directly correlated with patient survival in 
colorectal cancer and that it was an indicator of metastatic recurrence. Whilst 
low miR-224 expression is associated with a constitutively active RAS/MAPK 
pathway in KRAS mutant cell lines, the interaction between miR-224 and RKIP 
shows that increasing the expression of miR-224 could also, under the right 
selective pressures, increase the activity of the RAS/MAPK pathway downstream 
of RAF-1. This highlights the complexities of miRNA and target mRNA networks 
and show that miRNAs may have, in theory, opposing effects on a pathway. The 
eventual dominant phenotype may depend on outward selective pressures.  
Previous studies have investigated why and how miR-224 is up-regulated in 
hepatocellular carcinoma (HCC), which may shed light on how it is 
overexpressed in colorectal cancer. The miR-224 gene is located at chromosome 
Xq28, a chromosomal region (Xq) which has been reported to be duplicated in 
colorectal cancer (Reid et al, 2009). The Xq28 region consists of the pre-miR-224 
and pre-miR-452 genes which reside in intron 6 of GABRE, the gene that codes 
for the GABA-A receptor, and the testis antigen genes MAGEA4 and MAGEA5 
that reside either side of GABRE.   
Wang et al (2012) showed that the expression of miR-224 and other Xq28 genes 
were increased in HCC patients through epigenetic mechanisms. They showed in 
vitro that the Xq28 locus was regulated by the histone deacetylases HDAC1 and 
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HDAC3, which render the locus transcriptionally inactive and also by the histone 
acetylase protein, EP300 which allows for transcription. Cancer progression was 
therefore linked with an increase in EP300 and thus an increase in miR-224 
expression. Moreover, the pre-miR-224 gene has its own promoter which is 
predicted in silico to contain NF-kB sites (Scisciani et al, 2012). The increased 
transcription of miR-224 and cancer cell invasion was subsequently shown to be 
induced by inflammatory pathways in HCC (Scisciani et al, 2012). To date no 
work has explored in colorectal cancer whether the increase in miR-224 
expression could be due to the increased copy number of the Xq28 locus, to 
altered epigenetic mechanisms at the Xq28 locus or through inflammatory 
activation. 
An additional important finding in the present study was that the expression of 
miR-224 was 3.3-fold higher in KRAS WT HCT116 cells compared to KRAS mutant 
cells. We also demonstrated that the transient knockdown of miR-224 in KRAS 
WT cells by a specific miR-224 inhibitor increased the activation (and thus GTP 
binding) of KRAS. This was confirmed by showing that the phosphorylation of 
ERK and AKT in KRAS WT cells was increased following miR-224 knockdown, 
mimicking a KRAS-mutant like phenotype.  
The inherent low expression of miR-224 in HCT116 KRAS mutant cells could 
suggest a downstream repression of miR-224 transcription and thus expression 
by one of the many effectors that are activated. Using the 5 miRNA target 
prediction databases described earlier in the chapter, we produced a list of 1305 
predicted miR-224 targets that were common to at least two of the databases 
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(Appendix I). Although the overwhelming majority of the predicted targets have 
not been experimentally validated, the size of the list shows the many 
downstream effects miR-224 could potentially have. Noteworthy was the 
inclusion of the sons of sevenless (SOS-) 2 gene, which was predicted by 3 of the 
5 databases to be potentially targeted by miR-224.  
As discussed in Chapter 1, KRAS in its inactive form is bound to guanosine 
disphosphate (GDP) and is activated when bound to guanosine trisphosphate 
(GTP). The SOS genes code for guanine nucleotide exchange factors (GEFs) that 
function by binding to KRAS and causing the dissociation of KRAS and GDP. As 
cytosol contains much higher levels of GTP than GDP, KRAS is more likely to bind 
to GTP and thus become activated (illustrated in Figure 3.25).  
 
Figure 3.25: A schematic diagram of the downstream pathways affected by RAS (Schubbert 
et al, 2007). 
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The increase in SOS2 levels by the knockdown of miR-224 in HCT116 KRAS WT 
cells could cause KRAS activation by increased GTP binding. The subsequent 
repression of miR-224 as a result of the activation of the RAS/MAPK pathway (as 
seen in HCT116 KRAS mutant cells) could create a feed forward loop of KRAS 
activation. A priority experiment in future studies would therefore be to 
determine experimentally whether SOS2 is targeted by miR-224 and to 
determine exactly what causes a repression in miR-224 expression in HCT116 
cells when the RAS/MAPK pathway is activated. 
The human cancer data shows that there was no statistically significant 
difference in miR-224 expression in KRAS and BRAF WT cancers and KRAS 
mutant cancers. However, the significant decrease in BRAF mutant cancers 
compared to WT cancers suggest that a factor downstream of the RAF-1, MEK or 
ERK could play a role in repressing miR-224 expression in cancers. 
To date, miR-146b-3p and miR-486-5p (Ragusa et al, 2010; discussed above) and 
miR-92a, miR-127-3p and miR-378 (Mosakhani et al, 2012) are miRNAs that have 
been shown to differentiate between KRAS mutant and WT cancers. Mosakhani 
et al (2012) profiled the expression of 723 miRNAs in 15 KRAS mutant cancers, 
45 KRAS WT cancers as well as their patient-matched normal mucosa samples. 
They reported that miR-92a and miR-127-3p were increased and miR-378 was 
decreased in KRAS mutant cancers compared to WT cancers, suggesting that the 
RAS/MAPK pathway may control the expression of these miRNAs. Mosakhani et 
al (2012) did not look at how the three aforementioned miRNAs affected clinical 
outcomes. However, miR-92a, a member of the miR-17-92 cluster, has been 
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consistently reported to be increased in colorectal cancer (Table 3.1) and has 
been shown to predict lower patient survival (Tsuchida et al, 2011; Zhou et al, 
2013). The poor patient survival seen in KRAS mutant colorectal patients (Conlin 
et al, 2005) may therefore be, in part, attributed to the effects of miR-92 in 
colorectal cancer progression. 
Further investigation of the phenotypic effects of miR-224 in cell lines showed 
that the knockdown of miR-224 in HCT116 KRAS WT cells increased cell doubling 
time. This suggests that the net phenotypic function of miR-224 under normal 
physiological conditions is to favour proliferation and survival by inhibiting 
apoptosis. MiR-224 has been shown to increase proliferation in colorectal and 
liver cancers through the repression of the tumour suppressor gene SMAD4 
(Wang et al, 2013; Zhang et al, 2013b). In contrast, miR-224 has also been shown 
to be pro-apoptotic. In hepatocellular carcinoma (HCC), miR-224 was shown to 
directly target apoptosis inhibitor protein-5 (API-5), and thus promote apoptotic 
cell death (Wang et al, 2008).  
In the present study, based on the measured phosphorylation of key signalling 
molecules as determined by the PathScan signalling array, the knockdown of 
miR-224 could in theory have opposing phenotypic effects on cells if selective 
conditions were set in the favour of one pathway. The increased 
phosphorylation of ERK and AKT in KRAS WT cells, following miR-224 
knockdown, suggests an increase in pro-proliferation and pro-survival pathways. 
This is also reflected in the increased phosphorylation of Stat3, which has been 
shown to be constitutively active and overexpressed in colorectal cancers and 
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reported to induce angiogenesis (Kasuba et al, 2006). The knockdown of miR-
224, in contrast, also suggested the phosphorylation of Stat1 which is reported 
to affect cancer suppressive and anti-angiogenesis pathways (Battle et al, 2006). 
The chaperone protein HSP27, which has pro-apoptotic functions, was also 
activated. Interestingly, the phosphorylation of p38 MAPK which induces 
apoptosis following genotoxic stress was also increased. The α-isoform of p38 is 
coded by the MAPK14 gene, a predicted target of miR-224 (Appendix I). 
However, the nature of the PathScan signalling array as a screening method 
means that further validation work using Western blots is required to better 
understand the effect of miR-224 knockdown on a number of signalling 
pathways. 
Our data also shows that the knockdown of miR-224 did not have any marked 
effect on cell cycle kinetics in HCT116 KRAS WT cells, even in the presence of 5-
FU.  The percentage of cells that were in either G1 or S phase of the cell cycle as 
determined by flow cytometry suggests that miR-224 knockdown in HCT116 
KRAS WT cells had no impact on cell cycle regulation, even in response to 5-FU 
(Figure 3.19 and Figure 3.20). As mentioned previously, the higher proportion of 
cells in the G1 phase in KRAS mutant cells compared to KRAS WT cells is 
inconsistent with the cell proliferation data that shows that the two cell lines did 
not have significantly different doubling times.  
MiR-224 has been shown to directly target CDKN1A which codes for p21cip1 
(Olaru et al, 2013). Our bioinformatics data also suggests that miR-224 is 
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predicted to target CDKN1B, which codes for p27kip1, in 2 of the 5 databases 
used (Appendix I). 
Both p21 and p27 are cyclin dependent kinase (CDK) inhibitors which function as 
cell cycle regulators particularly in the transition from early to mid-phase G1 to 
late G1/S phase. They are able to cause cell cycle arrest in response to DNA 
damage or other types of stress if their levels are increased.  
A recent study by Liao et al (2013) reports that miR-224 increased the G1/S 
transition by down-regulating p21cip1 and p27kip1 and up-regulating cyclin-D. It 
also shows that miR-224 increased proliferation through AKT signalling and by 
the direct suppression of the tumour suppressor genes PHLPP1 and PHLPP2. The 
interaction between miR-224 and p21cip1 and p27kip1 may therefore contribute to 
why miR-224 knockdown slows cell proliferation in HCT116 KRAS WT cells. 
Another key and novel finding in the present study was that miR-224 knockdown 
could sensitise KRAS WT cells to 5-FU, possibly in part by increasing KRAS 
activation. The increased sensitivity of HCT116 KRAS WT cells to 5-FU could be 
due to a number of reasons. One theory proposed was that the increase in KRAS 
activation by miR-224 knockdown to resemble a mutant-KRAS-like phenotype 
increased cell proliferation. The cells would therefore be more sensitive to 5-FU 
as the active metabolite F-UTP would incorporate into the RNA, replacing uracil, 
at a higher rate. However, the present study shows that miR-224 knockdown in 
fact decreased cell proliferation. There was also no significant difference in the 
proliferation of the KRAS WT and mutant cells, which could be a limitation of the 
use of immortalised cell lines. 
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The present study did not explore whether miR-224 knockdown could have 
potentiated 5-FU induced apoptosis. Data from the PathScan signalling array 
suggests that miR-224 knockdown could potentially have pro-apoptotic effects. 
Therefore, in further work it would be important to determine what pro-
apoptotic pathways, if any, miR-224 may affect in response to 5-FU treatment.  
Consistent with the findings of the present study, Klampfer et al (2005) suggests 
a link between KRAS mutation status and 5-FU chemosensitivity. They found 
that HCT116 colorectal cells were protected from 5-FU induced apoptosis after 
targeted deletion of a mutant KRAS allele. Additionally, they showed that 
intestinal epithelial cells with inducible mutant KRAS (V12)  promoted cell death 
upon 5-FU treatment and that KRAS promoted the accumulation of p53 in 
response to 5-FU in colorectal cancer cells.  
Many studies including work from our own research group (Conlin et al, 2005) 
have published data on the lower survival of colorectal patients with KRAS 
mutant cancers. This therefore raises questions on whether we would want to 
hypothetically modulate KRAS WT cancers to phenotypically resemble those of 
KRAS mutants. Large scale clinical studies, however, have not seen any 
conclusive association between KRAS mutation status and response to 5-FU 
based therapy (Markowitz et al, 1995; Etienne-Grimaldi et al, 2008).  
The present study also shows that miR-224 knockdown in HCT116 KRAS WT cells 
increase the expression TYMP, TYMS and DPYD. In clinical studies however, the 
decreased expression of TYMS and DPYD and the increased expression of TYMP 
in colorectal cancers have been associated with better response to 5-FU based 
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therapy (Goto et al, 2012). TYMP, TYMS or DPYD have not been reported to have 
any association with miR-224 nor do they appear to be predicted targets of miR-
224 (Appendix I). However, our data suggests that miR-224 may have an impact 
on 5-FU response in patients through the indirect regulation of 5-FU drug 
metabolising enzymes. A large-scale study based on whether miR-224 can 
stratify patients based on KRAS mutation status and response to 5-FU-based 
therapy would be of interest, and we have begun to identify appropriate patient 
cohorts. 
With regards to oxaliplatin, our data suggests that there is no association with 
KRAS mutation status and oxaliplatin sensitivity. This is perhaps unsurprising 
given the nature of the drug in forming cross-links in DNA and having less 
involvement in the proliferative or apoptotic nature of KRAS in its active or 
inactive state. The data does show, however, that the expression of ERCC1 was 
significantly increased following miR-224 knockdown in KRAS WT cells. The 
increase of this DNA damage repair pathway is associated with resistance to 
oxaliplatin (Seetharam et al, 2010). Time constraints prevented an investigation 
into the effects of miR-224 on irinotecan sensitivity, which could be an 
interesting future direction.   
The drugs sorafenib and cetuximab both function, all be it at different targets, to 
block KRAS mediated cancer growth in KRAS and BRAF WT patients. The present 
study shows that various KRAS mutations and V600E BRAF mutation confer 
resistance to sorafenib by increasing KRAS activity in NIH3T3 cells, however this 
was not observed following miR-224 knockdown. This may suggest that miR-224 
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knockdown does not sufficiently activate KRAS to the level of when KRAS 
mutants have been stably transfected into NIH3T3 cells, where heterozygous 
KRAS expression is able to counteract the effects of sorafenib. However at 
higher concentrations sorafenib successfully kills cells regardless of miRNA 
modulation and KRAS activity.  
The present study has shown through bioinformatics analysis that miRNAs that 
are differentially expressed in KRAS WT and mutant cells, and thus may 
represent a miRNA signature of KRAS activation, are predicted to mediate a 
large number of cancer related pathways such as cell proliferation, cell cycle 
regulation, cytoskeleton remodelling and EMT. This is perhaps not surprising 
given the known variety of pathways affected by KRAS. This also shows that the 
phenotypic consequences of oncogenic changes can be regulated or mediated 
through miRNAs. 
The bioinformatics analysis showed a predicted link with miR-224 and EMT. 
Testing this association experimentally, it was shown that cell invasion was 
inherently decreased in HCT116 KRAS mutant cells compared to KRAS WT cells. 
We also showed that miR-224 knockdown cells were less invasive than 
untransfected KRAS WT cells. Therefore, miR-224 knockdown in WT cells again 
reflects a KRAS mutant-like phenotype. In contrast, stably transfecting a 
dominant mutant KRAS construct into NIH3T3 cells had a very marked effect on 
cell invasion. 
This suggests that in the HCT116 model the effect of miR-224 on cell invasion 
may not be directly due to activation of KRAS and the RAS/MAPK pathway. This 
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may be supported by the fact that, as discussed previously, miR-224 knockdown 
decreases cell proliferation in HCT116 KRAS WT cells.  
MiR-224 knockdown in KRAS WT cells was causal in the increased expression of 
E-cadherin and decrease in vimentin suggesting that miR-224 knockdown may 
have some impact on mediating a less mesenchymal cell phenotype. However, 
more detailed protein analysis is needed to fully elucidate if miR-224 drives cell 
invasion through EMT. Our bioinformatics data (Appendix I) suggests that miR-
224 is predicted to target claudins (CLDN11 and CLDN14) and desmogleins 
(DGS2) groups of proteins involved in cell adhesion and reported to be down-
regulated during EMT (Lamouille et al, 2014).  
Previous studies in hepatocellular carcinoma support the data in the present 
study that miR-224 promotes cell migration and invasion in colorectal cancer. 
Ma et al (2012) showed in HEPG2 cells that miR-224 promoted cell invasion and 
migration by activating the AKT signalling pathway and by directly targeting the 
tumour suppressor gene, PPP2R1B.  
Rho GTPases such as CDC42 are activated when they dissociate from GDP and 
bind to GTP, and contribute to migration and invasion by affecting a number of 
downstream pathways including cytoskeleton remodelling. MiR-224 was 
suggested to target the Rho GTPase-activating proteins ARHGAP9 and 
ARHGAP21 which deactivates CDC42 (Scisciani et al, 2012). Thus through the 
repression of ARHGAP9 and ARHGAP21, miR-224 was suggested to increased cell 
migration and invasion in HEPG2 cells. 
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MiR-224 may also play a role in invasion and metastasis through the indirect 
regulation of matrix metalloproteinases, enzymes that are usually secreted by 
cancer cells to degrade the extracellular matrix and aid cancer dissemination. Li 
et al (2010) showed that increased miR-224 expression correlated with 
increased expression of PAK4, an effector of CDC42 that plays a role in 
cytoskeleton remodelling, and one of the matrix metalloproteinases MMP9. A 
later study by the same group confirmed that miR-224 regulated PAK4 and 
MMP9 expression, and thus cell invasion, though directly targeting the 
transcription factor HOXD10 (Li et al, 2014). An earlier study by Illemann et al 
(2006) reports that MMP9 was differentially expressed in primary colorectal 
cancers and their matched liver and lymph node metastases. Further studies 
could explore the relationship with miR-224 and the aforementioned targets in 
colorectal cancer cells.  
To support my in vitro data linking miR-224 with cell invasion, the expression of 
miR-224 was assessed in metastasis samples and patient-matched primary 
colorectal cancers. My data shows that miR-224 expression was decreased in 
lymph node metastases compared to primary colorectal cancers in the majority 
of patients studied. It also shows that the majority of matched liver metastases-
primary colorectal cancers in which miR-224 was differentially expressed by 
more than 1.5-fold were over-expressed in liver metastases.   
Recent studies that explore the role of miR-224 in cell invasion and metastasis 
specifically in colorectal cancer contradict each other. Whilst Zhang et al (2013a) 
report miR-224 as pro-metastatic; Yuan et al (2013) suggest that miR-224 
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suppresses metastasis. This may suggest that miR-224 expression in metastases 
is affected by the anatomical site of metastases or that miR-224 has a dual role 
in promoting and suppressing cancer metastasis by affecting different pathways 
and thus impact patient survival. This may also suggest inter-patient differences 
in the mechanisms by which metastatic disease develops in colorectal cancer 
patients. There could be patients, for example, in which miR-224 is one of the 
dominant drivers of metastasis whereas in other patients miR-224 expression is 
suppressed in favour of other more dominant drivers.  
To date, only a small number of studies have investigated the differential 
expression of a small number of miRNAs in primary colorectal cancers and 
patient-matched metastases samples. Global miRNA profiling in primary 
colorectal cancers and patient-matched metastases samples could identify what 
miRNAs, and therefore the pathways they mediate, collectively drive metastasis 
in colorectal cancer patients.  
3.5. Conclusions and future work 
3.5.1. Conclusions 
 
The present study has shown that increased expression of miR-224 is an early 
and persistent feature of colorectal cancer development. The study also shows 
for the first time that miR-224 regulates KRAS activation in colorectal cancer. 
However, miR-224 affects a large variety of pathways and for this reason the 
regulation of KRAS-mediated tumorigenesis may not necessarily be the 
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dominant way by which miR-224 exerts its oncogenic effects as summarised in 
Figure 3.26.  
 
Figure 3.26: A schematic diagram showing the effect of miR-224 on the RAS/MAPK pathway 
and its wider implications. The data in the present study suggests that miR-224 promotes cell 
proliferation and invasion as the transient knockdown of miR-224 reduces proliferation and 
invasion. These phenotypes could be mediated, in part, through the repression of previously 
validated targets of miR-224 such as CDKN1A, SMAD4, HOXD10 and RKIP. The reduced 
expression of miR-224 in KRAS mutant cells and BRAF mutant colorectal cancers suggest that the 
RAS/MAPK pathway represses the transcription and expression of miR-224. The knockdown of 
miR-224 may also cause KRAS activation through the repression of the predicted miR-224 target, 
SOS2. The subsequent activation of the RAS/MAPK pathway leads to a repression of miR-224 
expression, creating a feed forward loop. The reduced expression of miR-224 may also, in theory, 
de-repress the RAS/MAPK pathway downstream of RAF-1 through its repression of RKIP. This 
highlights the many opposing roles of a single miRNA in one pathway.  
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Furthermore, miR-224 has been shown in vitro to modulate 5-FU 
chemosensitivity perhaps, in part, through the regulation of KRAS pathways and 
by indirectly affecting the expression of 5-FU metabolising enzymes.  
Finally, miR-224 has been shown to promote cell invasion in HCT116 KRAS WT 
cells. The variability of differential miR-224 expression in lymph node or liver 
metastases and primary colorectal cancers may reflect the variability in the 
mechanisms by which metastatic disease may develop.   
3.5.2. Future work 
 
Future cell line studies would be directed towards trying to establish exactly why 
and how miR-224 regulates KRAS activation. A possible link with SOS2 has been 
suggested above and therefore there is a need to validate whether miR-224 
directly targets the 3’UTR of SOS2. Furthermore, to support the data linking miR-
224 with KRAS activation, it would be of interest to use miR-224 mimics to 
increase miR-224 expression in KRAS mutant cells (low miR-224 expression) and 
repeat the above experiments to establish whether we see a reversal of the 
effects that have been described above in relation to KRAS activation, cell cycle 
and proliferation, cell invasion and 5-FU sensitivity. I did attempt to perform 
these experiments but had difficulty in restoring miR-224 expression at 
physiological levels. As shown in Figure 3.27, miR-224 expression in HCT116 
KRAS mutant cells was 414-fold higher following transfection with miR-224 
mimic at the very lowest concentration suggested by the manufacturer. The 
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expression of miR-224 was, in contrast, 3.3-fold higher in HCT116 KRAS WT cells 
compared to HCT116 KRAS mutant cells (Figure 3.2) 
 
 
Figure 3.27: MiR-224 mimic optimisation. HCT116 KRAS mutant cells were transiently 
transfected with 0.3 nM, 1 nM, 5 nM, 10 nM and 20 nM of miR-224 specific miRNA mimic and a 
negative control, as described in Section 2.2.5. The expression of miR-224, relative to the control 
miRNA let-7a, was assessed as described in Section 2.2.9.2. The fold change in miR-224 
expression in transfected KRAS mutant cells compared to untransfected KRAS mutant cells is 
represented. Experiment was performed once.  
Future human tissue based studies would be directed towards correlating miR-
224 expression with colorectal cancer patient survival and response to 5-FU 
based therapy. Furthermore, it would be important to relate the variability in 
differential miR-224 expression in lymph node or liver metastasis compared to 
primary colorectal cancers to patient relapse. 
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Chapter 4 
4. Identification of novel candidate 5-FU 
and oxaliplatin drug resistance 
mechanisms 
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4.1. Introduction 
4.1.1. Mechanisms of 5-FU and oxaliplatin resistance in colorectal cancer 
 
Colorectal cancer treatment, as discussed in Chapter 1, involves the 
administration of 5-FU based chemotherapy regimens with folinic acid. 
However, response to treatment is very poor in colorectal cancer patients, with 
only 10-15% of patients responding (Johnston & Kaye, 2001). Second line 
treatment may include the addition of oxaliplatin (FOLFOX) or irinotecan 
(FOLFIRI) which have been shown in clinical trials to improve response rate to up 
to 50% (de Gramont et al, 2000; Douillard et al, 2000) in advanced colorectal 
cancer. However, a large proportion of patients see little, if any, benefit from 
standard chemotherapeutic treatment. The limitations to drug treatment are 
due to the development of resistance to drugs such as 5-FU, oxaliplatin and 
irinotecan and inherent drug resistance.  
As discussed below, many studies have proposed and demonstrated that 
mechanisms of resistance to 5-FU may include the aberrant expression of 5-FU 
metabolising enzymes and alterations to drug efflux via drug transporters. 
Additionally, common mechanisms of resistance to 5-FU and oxaliplatin are 
reported to involve alterations to DNA damage repair mechanisms and the 
evasion of apoptosis (Longley et al, 2006). Most previous studies have also taken 
a candidate gene approach to investigating the mechanisms of drug resistance. 
Dihydropyrimidine dehydrogenase (DPD), which is coded by the gene DPYD, is 
the rate-limiting enzyme in the catabolism of 5-FU (Figure 4.1). DPD 
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overexpression has been shown to be associated with 5-FU resistance, as 5-FU 
resistant cells adapt by increasing the removal of 5-FU (Soong et al, 2008). 
Increased expression of TYMS and under-expression of TYMP have been 
associated with 5-FU resistance in colorectal cancer patients (Goto et al, 2012).  
 
Figure 4.1: 5-FU metabolism pathways. Many factors are involved in the cellular response, 
metabolism and efflux/reuptake of 5-FU. Abnormal changes in the expression of genes such as 
DPYD, TYMP, TYMS and ABCC5 are reported to have an impact on 5-FU resistance 
(https://www.pharmgkb.org/pathway/PA150653776). 
ATP-binding cassette transporter (ABC transporter) proteins are a family of 
transmembrane proteins that transport various substances across the cell 
membrane. The multi-drug resistance P-glycoprotein (coded by the ABCB1 gene) 
is reported to be involved in the efflux of a number of chemotherapeutic drugs 
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thus reducing the accumulation of drug within the cancer cell excluding 5-FU. 
Pratt et al (2005) showed that human kidney embryo (HEK-293) cells transfected 
with, and therefore expressing a higher protein level of, MRP5 (coded by ABCC5 
gene) were more resistant to 5-FU and oxaliplatin. They showed that there was a 
lower intracellular accumulation of 5-FU and that its metabolites were 
transported out of the cell via MRP5, as shown in Figure 4.1. A more recent 
study showed that MRP5-positive circulating cancer cells (CTCs) isolated from 
colorectal cancer patients correlated with a shorter progression-free survival in 
patients (Gazzaniga et al, 2010).  
An increase in repair mechanisms to the drugs that cause DNA damage is 
another way by which cancer cells resist the cytotoxic effects of 5-FU and 
oxaliplatin. Nuclear excision repair (NER) is one of the major DNA repair 
mechanisms (Shuck et al, 2008). Among the many protein involved in NER is the 
excision repair cross-complementing 1 (ERCC1) protein. The aim of NER is to 
target and remove damage such as DNA adducts, created by drugs like 
oxaliplatin, allowing for the normal replication of DNA (Shuck et al, 2008).  
ERCC1 expression has been shown to be increased in oxaliplatin resistant cells 
compared to drug sensitive cells (Arnould et al, 2003; Boyer et al, 2004) and was 
shown to be increased in colorectal cancer patients with lower survival (Shirota 
et al, 2001). 
The DNA mismatch repair (MMR) system is another mechanism of DNA damage 
repair. This system recognises and repairs the misincorporation of bases during 
DNA replication and the repair of double stranded breaks. One of the main 
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proteins involved in MMR is human MutL homolog 1 (hMLH1). Defects in hMLH1 
are associated with the microsatellite instability (MSI) phenotype and studies 
suggest that MSI correlates with adaptive resistance to 5-FU in colorectal cancer 
patients (Meyers et al, 2001; Arnold et al, 2003; Ribic et al, 2003). 
Studies have also shown that cells may develop resistance to 5-FU or oxaliplatin 
through a p53 dependent arrest of the cell cycle. This decrease in cell cycle 
progression with respect to 5-FU, may reduce the rate of the incorporation of 5-
FU metabolites into DNA and allow for more time for DNA repair to occur. 
Furthermore, Nita et al (1998) demonstrated that 5-FU was an apoptosis-
inducing agent which modulated members of the BCL-2 family of apoptosis-
related protein such as the pro-apoptotic factor Bax. Violette et al (2002) also 
suggest that the anti-apoptotic protein BCL-2 is increased in 5-FU resistant cells. 
Oxaliplatin resistance cells have also been shown to be associated with a loss of 
the pro-apoptotic factor, Bax (Gourdier et al, 2002).  
There is now evidence emerging that cells can evade the effect of 
chemotherapeutic drugs by undergoing an epithelial-to-mesenchymal transition 
(EMT) and as a consequence becoming more invasive. The exact reasons for why 
undergoing EMT may provide a survival advantage in the long term presence of 
a drug are poorly understood. Yang et al (2006) were the first to describe the 
concept of chemotherapy-induced EMT in oxaliplatin resistant colorectal cell 
lines. They speculated that oxaliplatin resistant cells may switch from a 
proliferative, epithelial phenotype to one of a more invasive and migratory but 
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less proliferative phenotype. This would in turn allow the resistant cells to 
escape the effects of oxaliplatin due to the decrease in proliferation. 
We are clearly a long way from knowing the full extent by which colorectal 
cancer cells develop resistance to 5-FU and oxaliplatin. However, the emergence 
of miRNAs as regulators of gene expression with key roles in many biological 
processes means that it is logical to investigate the role miRNAs may have in the 
development of drug resistance. 
4.1.2. The role of miRNAs in 5-FU and oxaliplatin resistance 
 
Blower et al (2007) introduces a panel of cell lines, NCI-60, which were used by 
the National Institute of Cancer (NCI) to screen thousands of chemical 
compounds and natural product extracts (including known chemotherapeutic 
drugs) for their pharmacological activities. The panel comprises a large variety of 
different human cell lines derived from cancers of the breast, central nervous 
system, colon and rectum, lungs, ovaries, prostate and renal tissue, as well as 
from leukaemia and melanomas. Prior to the study, the cell lines had been 
extensively profiled for their mRNA and protein expression, as well as for 
mutation status, chromosomal aberration and DNA copy number 
(http://discover.nci.nih.gov/cellminer/).  
Due to the emerging knowledge at the time of the role of miRNAs as additional 
regulators of gene expression and their role in cancer progression, the authors 
used microarray technology to profile for miRNA expression in the NCI-60 panel.  
The study used a number of algorithms and computational tools to ascertain 
172 
 
 
 
that miRNAs cluster based on tissue type, reaffirming the notion that miRNA 
expression profiles can classify cancers. Furthermore, Blower et al (2007) 
demonstrated significant correlations between miRNA expression profiles and 
compound potency (measured by growth inhibition), suggesting a role for 
miRNAs in chemoresistance, although paired drug sensitive and drug resistant 
cell lines were not directly compared. A later study predicted that miR-224 and 
miR-24-1* (the passenger strand of miR-24-1) were negatively correlated with, 
amongst others drugs, 5-FU and irinotecan sensitivity (Gmeiner et al, 2010). 
Climent et al (2007) initially implied a link between miRNA deregulation and 
chemoresistance by suggesting that the increased sensitivity of breast cancer 
patients to anthracycline-based chemotherapy may be related to the deletion of 
chromosome 11q, which contains the miR-125b gene. Prior to the beginning of 
the present study in October 2010, only a small number of studies had 
investigated the relationship between miRNAs and the drugs 5-FU and 
oxaliplatin. In colorectal cancer, Nakajima et al (2006) investigated the clinical 
significance of let-7g, miR-143, miR-145, miR-181b and miR-200c in cancer 
samples from a cohort of colon cancer patients (responders and non-
responders) treated with the 5-FU based antimetabolite, S-1. The study found 
that let-7g and miR-181b were strongly associated with patient response to S-1, 
although they were not significant prognostic factors for predicting survival.  
In colorectal cancer cell line studies, Rossi et al (2007) were the first to report 
that acute 5-FU treatment in colorectal cancer cell lines modulated miRNA 
expression. The study reported that clones of the colorectal cancer cell lines 
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HT29 and HCT116 were treated with 10 µM 5-FU for 6 days. MiRNA expression 
profiling showed that, compared to their respective non-drug treated parental 
cells, 18 miRNAs were differentially over-expressed in both cell lines whereas 3 
miRNAs were differentially under-expressed. Amongst the miRNAs that were 
overexpressed in response to 5-FU were miR-20a, miR-21 and miR-135b 
whereas miR-224 was amongst the miRNAs under-expressed in response to 5-FU 
treatment. These miRNAs have been shown to be some of the most consistently 
differentially expressed miRNAs in colorectal cancer (Section 3.1.2, Table 3.2). As 
previously discussed in Chapter 3, these miRNAs may have important impacts on 
colorectal cancer progression by affecting multiple pathways. This suggests that 
the pharmacodynamic action of 5-FU could partly be due to the alteration of 
miRNA expression leading to changes in apoptosis, cell cycle and cell 
proliferation.  
In a similar study, Zhou et al (2010) treated HCT-8 and HCT116 colorectal cancer 
cells with either 5-FU or oxaliplatin for 24 hours. They report that 56 and 50 
miRNAs were differentially over and under-expressed respectively in treated 
cells compared to untreated cells. 
Other studies reported on miRNAs that could modulate 5-FU sensitivity and 
resistance in colorectal cancer. The studies that were conducted prior to the 
beginning of the present study are listed in Table 4.1.  
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Table 4.1: Studies in colorectal cancer cell lines that report miRNA modulation of 
5-FU sensitivity 
Study Cell line Number of 
microRNAs 
examined 
miRNAs  
(↑or ↓expression 
associated with 5-FU 
resistance) 
mRNA 
targets  
Song et al, 
2009 
HCT116 1 miR-140 ↑ HDAC4 
Borralho et 
al, 2009 
HCT116 1 miR-143 ↓ ERK5, NF-kB, 
BCL-2* 
Boni et al, 
2010 
RKO, LoVo, 
DLD1, SW620 
2 miR-192 ↑ miR-215 ↑ TYMS** 
Wang et al, 
2010a 
HCT116 1 miR-31 ↑ None 
Valeri et al 
(2010) 
Colo-320 DM, 
SW620, 
HCT116, 
SW480, RKO 
1 miR-21 ↑ hMSH2 
 
*Determined by inverse protein expression 
** Direct target but phenotype but effect on 5-FU resistance through independent mechanism 
Borralho et al (2009) showed that miR-143 expression was inversely correlated 
with the expression of BCL2 and that miR-143 contributed to increased 
sensitivity to 5-FU by potentiating 5-FU-induced apoptosis. Boni et al (2010) 
show that miR-192/215 directly target TYMS. However, the miRNA mediated 
down regulation of TYMS did not sensitise cells to 5-FU. It was in fact due to the 
induction of p21cip1 and p27kip1 which slows down cell cycle progression by 
causing arrest in G1. This therefore showed that miR-192 and miR-215 mediated 
another mechanism of 5-FU resistance other than through TYMS 
overexpression. Furthermore, Valeri et al (2010) reported that miR-21 conferred 
resistance to 5-FU by directly targeting and down-regulating the mismatch repair 
175 
 
 
 
enzyme, hMSH2 thus promoting a MSI phenotype. This shows that miRNAs are 
able to affect adaptive resistance to 5-FU through regulating genes involved in 
apoptosis, DNA repair and cell cycle regulation.  
The above studies show what happens to miRNA expression in the immediate 
aftermath of acute 5-FU challenge. However, there were no studies looking at 
the role of miRNA in acquired 5-FU or oxaliplatin resistance in colorectal cancer. 
Although many groups had successfully generated 5-FU and oxaliplatin resistant 
colorectal cancer cell lines, none at the time had profiled for differential miRNA 
expression.  
4.2. Aims and objectives 
The aims of the present study were therefore twofold. Firstly to generate 5-FU 
and oxaliplatin resistant cell lines in two different colorectal cancer cell line 
backgrounds (HCT116 and DLD-1). Secondly, we aimed to use mRNA and miRNA 
expression profiling to predict novel mechanisms of acquired 5-FU and 
oxaliplatin resistance.  
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4.3. Results 
4.3.1. Generation of drug resistant cell lines 
To identify and investigate novel mechanisms of acquired drug resistance in 
colorectal cancer, two colorectal cancer cell lines, HCT116 and DLD-1, were each 
made resistant to either 5-FU or oxaliplatin by continuous selection, as described 
in Section 2.2.6, generating four novel drug resistant cell lines.  
The concentration of 5-FU or oxaliplatin in which HCT116 or DLD-1 cells were 
cultured was incrementally increased from 0.1 µM to the highest concentration 
at which the cells remained viable and able to grow in culture. As shown in 
Section 2.2.6 (Table 2.3), the highest 5-FU concentration at which HCT116 and 
DLD-1 cells were still viable was 2 µM and 10 µM respectively, and at oxaliplatin 
concentrations of 10 µM and 24 µM respectively. This suggests that HCT116 cells 
were inherently more sensitive to both drugs compared to DLD-1 cells. 
MTT cytotoxicity assays were performed to confirm that the drug resistant cells, 
compared to their respective drug-sensitive parental cells, were resistant to 
their selection drug, as described in Section 2.2.4. Cytotoxicity assays were also 
used to determine whether HCT116 and DLD-1 5-FU resistant cells were also 
cross-resistant to oxaliplatin and vice versa. Additionally, MTT cytotoxicity assays 
were used to ascertain whether 5-FU and oxaliplatin resistant DLD-1 cells were 
cross-resistant to irinotecan.   
HCT116 5-FU resistant cells were significantly more resistant to 5-FU (higher 
IC50) than the HCT116 parental cells (4.65-fold, p=0.01; Figure 4.2) but were not 
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cross-resistant to oxaliplatin (1.42-fold; p=0.75; Figure 4.2). In contrast, HCT116 
oxaliplatin resistant cells were 28.22-fold more resistant to oxaliplatin than 
HCT116 parental cells (p=0.01; Figure 4.3) and also cross-resistant to 5-FU (2.1-
fold; p=0.04; Figure 4.3). 
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Cell line 5-FU  Oxaliplatin  
  IC50 fold change  p value  IC50 fold change  p value  
HCT116 5-FU (2 µM)  4.65 ± 0.58  0.01 1.42 ± 0.66  0.75 
Figure 4.2 
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Figure 4.2: 5-FU and oxaliplatin sensitivity in HCT116 5-FU resistant cells. MTT assays were 
used to compare the sensitivities of A) 5-FU and B) oxaliplatin in HCT116 5-FU resistant cells 
compared to HCT116 parental cells as described in Section 2.2.4. MTT assays were performed 3 
times and a representative graph is presented here. C) The IC50 for each cell line was calculated 
on GraphPad Prism version 6 and presented as a fold change relative to the IC50 of the HCT116 
parental cell line. The errors represent the SEM of 3 separate experiments. Statistical significance 
(p≤0.05) was determined by performing independent T-tests.  
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Cell lines  5-FU  Oxaliplatin  
  IC50 fold change  p value  IC50 fold change  p value  
HCT116 oxaliplatin (10 µM)  2.1 ± 0.43  0.04 28.22 ± 16.67  0.01 
 
Figure 4.3: 5-FU and oxaliplatin sensitivity in HCT116 oxaliplatin resistant cells. MTT assays 
were used to compare the sensitivities of A) oxaliplatin and B) 5-FU in HCT116 oxaliplatin 
resistant cells compared to HCT116 parental cells as described in Section 2.2.4. MTT assays were 
performed 3 times and a representative graph is presented here. C) The IC50 for each cell line was 
calculated on GraphPad Prism version 6 and presented as a fold change relative to the IC50 of the 
HCT116 parental cell line. The errors represent the SEM of 3 separate experiments. Statistical 
significance (p≤0.05) was determined by performing independent T-tests. 
DLD-1 5-FU resistant cells were significantly more resistant to their selection 
drug 5-FU (21.49-fold; p=0.016) compared to DLD-1 parental cells. However, 
DLD-1 5-FU resistant cells did not confer cross resistance to oxaliplatin (1.39-
fold; p=0.12; Figure 4.4). 
Similarly, DLD-1 oxaliplatin resistance cells were significantly more resistant to 
oxaliplatin (8.87-fold; p=0.03). However, in contrast to HCT116 oxaliplatin 
resistant cells, they were not cross-resistant to 5-FU (1.13-fold; p=0.49; Figure 
4.5).  
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Cell lines  5-FU  Oxaliplatin  
  IC50 fold change  p value  IC50 fold change  p value  
DLD-1 5-FU (10 µM)  21.49 ± 2.45  0.016 1.39 ± 0.5  0.12 
 
Figure 4.4: 5-FU and oxaliplatin sensitivity in DLD-1 5-FU resistant cells. MTT assays were 
used to compare the sensitivities of A) 5-FU and B) oxaliplatin in DLD-1 5-FU resistant cells 
compared to DLD-1 parental cells as described in Section 2.2.4. MTT assays were performed 3 
times and a representative graph is presented here. C) The IC50 for each cell line was calculated 
on GraphPad Prism version 6 and presented as a fold change relative to the IC50 of the DLD-1 
parental cell line. The errors represent the SEM of 3 separate experiments. Statistical significance 
(p≤0.05) was determined by performing independent T-tests. 
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Cell lines  5-FU  Oxaliplatin  
  IC50 fold change  p value  IC50 fold change  p value  
DLD-1 oxaliplatin (24 µM)  1.13 ± 0.31  0.49 8.87 ± 1.55  0.03 
 
Figure 4.5: 5-FU and oxaliplatin sensitivity in DLD-1 oxaliplatin resistant cells. MTT assays 
were used to compare the sensitivities of A) oxaliplatin and B) 5-FU in DLD-1 oxaliplatin resistant 
cells compared to DLD-1 parental cells as described in Section 2.2.4. MTT assays were performed 
3 times and a representative graph is presented here. C) The IC50 for each cell line was calculated 
on GraphPad Prism version 6 and presented as a fold change relative to the IC50 of the DLD-1 
parental cell line. The errors represent the SEM of 3 separate experiments. Statistical significance 
(p≤0.05) was determined by performing independent T-tests. 
(A) 
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Additionally, MTT cytotoxicity assays showed that neither DLD-1 5-FU resistant 
cells nor DLD-1 oxaliplatin resistant cells were cross resistant to irinotecan (DLD-
1 5-FU resistant: 0.67 fold; p=0.27; DLD-1 oxaliplatin resistant: 1.19 fold; p=0.63; 
Figure 4.6). Therefore, if this represented a patient, it also suggests that 
irinotecan would be an effective course of treatment if the patient was resistant 
to 5-FU and/or oxaliplatin. Time constraints, however, meant that the effect of 
5-FU or oxaliplatin resistance on sensitivity to irinotecan could not be 
investigated in HCT116 cells. This would therefore be a priority future 
experiment.  
Previous studies show that 5-FU and oxaliplatin cross-resistance was observed in 
5-FU and oxaliplatin resistant HT-29 cells (Dallas et al, 2009) and cross-resistance 
to 5-FU in SW620 oxaliplatin resistant cells (Liu et al, 2010). Cross-resistance to 
irinotecan has also been observed in HCT116 oxaliplatin resistant cells (Gourdier 
et al, 2002) and 5-FU resistant HCT116 cells (Boyer et al, 2004).  
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 Cell Lines  Irinotecan  
 
IC
50
 fold change  p value  
DLD-1 5-FU (10 µM)  0.64 ± 0.08  0.27  
DLD-1 oxaliplatin (24 µM)  1.19 ± 0.07  0.63  
 
Figure 4.6: Irinotecan sensitivity in DLD-1 5-FU and oxaliplatin resistant cells. MTT assays 
were used to compare the sensitivity of irinotecan in A) DLD-1 5-FU resistant and B) DLD-1 
oxaliplatin resistant cells compared to DLD-1 parental cells as described in Section 2.2.4. MTT 
assays were performed 3 times and a representative graph is presented here.  C) The IC50 for each 
cell line was calculated on GraphPad Prism version 6 and presented as a fold change relative to 
the IC50 of the DLD-1 parental cell line. The errors represent the SEM of 3 separate experiments. 
Statistical significance (p≤0.05) was determined by performing independent T-tests. 
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4.3.2. Messenger RNA profiling and predicted drug resistance mechanisms  
 
The present study then took a bioinformatics approach in an attempt to identify, 
firstly, the common mechanisms by which cells may develop drug resistance to 
both 5-FU and oxaliplatin and, secondly, the unique mechanisms by which cells 
may develop resistance to either 5-FU or oxaliplatin. These objectives were 
addressed by using Illumina HT-12 BeadChip mRNA expression arrays, as 
described in Section 2.2.10, to identify differentially expressed genes in HCT116 
or DLD-1 drug resistant cells compared to their respective drug sensitive 
parental cells.  
In our analysis, only known genes that were differentially increased or decreased 
in 5-FU or oxaliplatin resistant cells by more than 2-fold (following correction for 
multiple testing) compared to their respective parental cells were included in 
further analysis. Therefore, 1998 and 392 genes were differentially expressed in 
HCT116 5-FU resistant and HCT116 oxaliplatin resistant cells respectively 
compared to HCT116 parental cells. In DLD-1 cells, 3617 and 4982 genes were 
differentially expressed in 5-FU and oxaliplatin resistant cells respectively 
(Appendix J).  
Tables 4.2 – 4.5 show the top 20 over and under-expressed genes in each drug 
resistant cell line compared to their respective drug sensitive parental cells. 
Among the most prominently differentially expressed genes in 5-FU or 
oxaliplatin resistance were genes coding for actin filaments. ACTG1 (actin, 
gamma 1) was the most differentially under-expressed gene in HCT116 5-FU 
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resistant cells and the 7th and 11th most decreased in DLD-1 5-FU and oxaliplatin 
resistant cells respectively. Additionally ACTB (actin, beta) expression was the 1st 
and 2nd most differentially decreased gene in DLD-1 5-FU and oxaliplatin 
resistant cells respectively.  
Similarly, genes coding for various tubulin proteins were also prominently 
represented within the top 20 under-expressed genes in 5-FU or oxaliplatin 
resistant cells. TUBA1C (tubulin, alpha 1C) was the 1st and 2nd most under-
expressed gene in DLD-1 oxaliplatin and 5-FU resistant cells respectively whereas 
TUBA1A (tubulin, alpha 1A) was the 4th and 9th most abundantly decreased gene 
in DLD-1 5-FU and oxaliplatin resistant cells respectively. Additionally, TUBB 
(tubulin, beta) was the 10th and 13th most under-expressed gene in DLD-1 
oxaliplatin and 5-FU resistant cells respectively. Actin and tubulin proteins are 
components of the cell cytoskeleton which aid in cell motility. The prominence 
of these genes in Tables 4.2 – 4.5 suggests that 5-FU and oxaliplatin resistance 
mechanisms involve cytoskeleton remodelling.  
Other gene families that were among the top 20 differentially increased or 
decreased in 5-FU and oxaliplatin resistant cells included the ATP-binding 
cassette transporter genes involved in multi-drug resistance (ABCC3) or 
cholesterol and lipid transport and homeostasis (ABCA1, ABCG1), aldo-ketose 
reductases (AKR1C3, AKR1B10) which are involved in Phase II detoxification of a 
large number of drugs and xenobiotics (Barski et al, 2008) and some poorly 
characterised cytochrome P450 enzymes (CYP4X1, CYP4F11, CYP4F12).  
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Table 4.2: Top 20 over and under-expressed genes in HCT116 5-FU resistant cells 
Gene  Fold change 
Adjusted 
p value 
 
Gene Fold Change 
Adjusted 
p value 
SUSD2 19.22 9.81E-32 
 
ACTG1 -25.66 3.44E-32 
APOBEC3G 16.86 2.45E-30 
 
ALDOA -21.25 1.83E-28 
TGM2 15.56 1.94E-32 
 
THOC4 -15.88 1.46E-30 
BMP4 11.29 4.26E-30 
 
PSMC4 -11.94 2.90E-32 
APOBEC3G 11.07 2.10E-28 
 
CLEC2D -11.61 2.65E-28 
ABCC3 10.34 7.27E-27 
 
PGAM1 -11.08 4.06E-29 
ABCA1 10.34 1.38E-26 
 
CCT7 -9.69 3.11E-28 
IDUA 9.93 6.07E-29 
 
RPL8 -9.03 2.75E-29 
GNE 9.57 1.50E-27 
 
MKX -8.24 3.32E-27 
GDF15 9.32 8.31E-29 
 
C20orf127 -7.78 4.06E-26 
TACSTD2 8.86 4.27E-26 
 
ID2 -7.70 4.89E-27 
ITGB4 8.84 6.18E-29 
 
CD151 -7.38 6.71E-27 
LAMB2 8.38 1.73E-23 
 
MAEA -7.25 2.26E-28 
PLAU 8.21 1.49E-20 
 
PSMC4 -7.17 5.63E-24 
FGF19 8.15 1.28E-26 
 
ID2 -7.16 1.48E-24 
KRT80 7.88 1.90E-24 
 
MT1E -7.14 1.12E-27 
GSN 7.86 3.44E-26 
 
RGS2 -7.01 4.75E-27 
GRB7 7.83 2.20E-27 
 
MAGEB6B -6.93 1.16E-23 
MEGF6 7.70 2.10E-26 
 
MCM4 -6.85 8.39E-26 
LCN2 7.31 6.27E-25 
 
RPL13 -6.53 1.34E-25 
 
Full gene names and full list of genes presented in Appendix J 
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Table 4.3: Top 20 over and under-expressed genes in HCT116 oxaliplatin 
resistant cells 
Gene  Fold change 
Adjusted     
p value 
 
Gene Fold Change 
Adjusted      
p value 
HIST1H2BD 7.15 2.70E-26 
 
PDE4B -8.93 2.35E-26 
KLK6 7.11 3.37E-23 
 
MKX -6.14 2.41E-24 
TP53I3 6.48 2.50E-26 
 
IRS1 -5.30 3.40E-24 
GDF15 6.10 3.23E-25 
 
FBLN1 -5.08 9.38E-23 
BST2 6.09 2.52E-23 
 
PRKACB -4.36 1.65E-22 
KLK5 5.82 3.23E-25 
 
RGS2 -4.10 3.89E-22 
VCAN 5.70 2.74E-24 
 
IFIT1 -4.07 8.50E-22 
HINT3 5.64 3.76E-24 
 
TMEM16A -3.57 1.35E-19 
HIST1H2BD 4.94 3.40E-24 
 
PCDH7 -3.48 1.61E-17 
HAS3 4.90 1.31E-21 
 
ARMC4 -3.44 1.49E-22 
ABCC3 4.89 4.12E-21 
 
PDE4B -3.44 4.34E-21 
AKAP12 4.51 3.62E-18 
 
IFI27 -3.43 1.11E-21 
CPA4 4.42 4.29E-20 
 
GPR126 -3.35 6.52E-22 
KLK8 4.36 3.53E-23 
 
INSIG1 -3.34 3.43E-18 
JUN 4.35 6.24E-23 
 
CAV1 -3.30 1.18E-15 
ANGPTL4 4.27 1.47E-21 
 
CAV1 -3.22 2.66E-20 
FERMT1 4.18 2.90E-20 
 
NMB -3.21 4.08E-19 
AKR1C3 4.08 1.71E-19 
 
SREBF1 -3.14 6.68E-20 
KRT15 4.07 3.40E-24 
 
EMP1 -3.14 5.49E-20 
EIF3CL 3.90 1.89E-21 
 
ANXA10 -3.04 7.88E-20 
 
Full gene names and full list of genes presented in Appendix J 
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Table 4.4: Top 20 over and under-expressed genes in DLD-1 5-FU resistant cells 
Gene  Fold change 
Adjusted 
p value 
 
Gene Fold Change 
Adjusted 
p value 
ANGPTL4 31.46 2.38E-34 
 
ACTB -99.09 4.45E-37 
FBXO32 26.74 4.59E-34 
 
TUBA1C -71.37 1.19E-34 
ALDH1A3 18.58 1.34E-34 
 
RPLP0 -52.57 5.94E-38 
C15orf48 17.86 3.05E-35 
 
TUBA1A -43.65 4.54E-35 
TRIM31 16.65 1.65E-33 
 
EEF1G -39.80 5.35E-34 
LAMB2 12.45 2.29E-26 
 
FKSG30 -37.48 3.27E-34 
TPM2 12.37 4.62E-31 
 
ACTG1 -36.32 2.02E-34 
YPEL3 12.02 2.58E-29 
 
RPS2 -33.07 4.59E-34 
CYP4F12 11.92 2.88E-32 
 
PGAM1 -31.64 3.05E-35 
GCNT3 11.53 5.09E-31 
 
ALDOA -31.60 4.80E-31 
AKR1C3 11.50 3.31E-28 
 
CYBA -30.96 4.05E-34 
TPM2 11.48 5.34E-31 
 
HNRNPK -30.37 8.25E-36 
RARRES3 11.32 3.57E-31 
 
TUBB -30.07 4.13E-33 
CYBRD1 11.31 8.54E-28 
 
PRDX2 -29.31 3.05E-35 
HIST1H2BD 11.09 9.49E-31 
 
AP1S1 -28.64 6.18E-35 
C20orf54 10.79 6.86E-32 
 
RPLP0 -28.35 1.24E-32 
LCN2 10.64 6.18E-28 
 
CCT7 -28.13 3.85E-34 
CLIP2 10.60 1.32E-31 
 
CXCL5 -24.67 9.41E-34 
LINCR 10.59 2.88E-32 
 
TPI1 -23.99 3.30E-31 
ARL14 10.38 2.22E-31 
 
AP1S1 -23.33 6.10E-35 
 
Full gene names and full list of genes presented in Appendix J 
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Table 4.5: Top 20 over and under-expressed genes in DLD-1 oxaliplatin resistant 
cells 
Gene  Fold change 
Adjusted   
p value 
 
Gene Fold Change 
Adjusted 
p value 
AKR1C3 20.04 3.50E-31 
 
TUBA1C -128.21 1.42E-36 
M160 17.28 4.08E-35 
 
ACTB -101.62 2.10E-37 
AKR1B10 17.09 1.50E-35 
 
RPLP0 -60.78 4.26E-38 
CYP4X1 14.17 4.57E-33 
 
EEF1G -53.54 2.85E-35 
SCG5 13.18 6.14E-33 
 
RPS2 -51.34 7.79E-36 
LAMB2 12.50 1.31E-26 
 
FTL -47.07 7.99E-37 
ABCG1 12.06 2.73E-31 
 
FTL -44.34 3.22E-36 
CD163L1 11.36 3.50E-31 
 
HNRNPK -41.01 3.02E-37 
CYP4F11 10.45 5.38E-31 
 
TUBA1A -39.84 3.52E-35 
CYP4F12 10.32 9.27E-32 
 
TUBB -39.67 1.89E-34 
EPOR 10.05 2.09E-32 
 
ACTG1 -38.42 4.90E-35 
PVRL3 9.81 1.12E-29 
 
PGAM1 -37.84 3.13E-36 
SERPINA1 9.57 2.64E-29 
 
FKSG30 -36.94 1.51E-34 
ACOX2 9.17 2.01E-29 
 
CYBA -35.73 5.62E-35 
CYTH2 9.00 3.34E-29 
 
RPS3 -35.68 5.71E-37 
KLHL24 8.88 1.95E-25 
 
RPLP0 -33.54 1.44E-33 
LCN2 8.60 6.93E-27 
 
RPL10A -33.48 1.41E-35 
WDR72 8.41 1.31E-27 
 
AP1S1 -33.13 7.80E-36 
CD44 8.20 1.18E-24 
 
PRDX2 -32.52 5.11E-36 
DHRS3 8.19 4.19E-29 
 
AHCY -31.98 1.60E-31 
 
Full gene names and full list of genes presented in Appendix J 
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Using the bioinformatics tool Metacore, as described in Section 2.2.17, we 
identified pathways and processes that were enriched and significantly 
associated with the differentially increased and decreased genes in each drug 
resistant cell line compared to their respective parental cells.  
Tables 4.6 – 4.9 show the top ten most enriched pathways and processes 
associated with all significantly under-expressed genes in HCT116 5-FU resistant, 
HCT116 oxaliplatin resistant, DLD-1-5-FU resistant and DLD-1 oxaliplatin 
resistant cells compared to their respective parental cells. The tables show that 
there was an overwhelming enrichment of cell cycle regulation and progression. 
This suggests that decreased cell cycle progression is a major mechanism of drug 
resistance irrespective of the cell line or selection drug. There was also 
enrichment in ATP and ITP metabolism in both HCT116 and DLD-1 5-FU resistant 
cells (Tables 4.6 and 4.8).  
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Table 4.6: Pathways and processes associated with the genes differentially 
under-expressed in HCT116 5-FU resistant cells compared to HCT116 parental 
cells 
 
Pathway name p value Ratio 
1 Cell cycle_The metaphase checkpoint 2.29E-11 29/36 
2 Cell cycle_Start of DNA replication in early S phase 4.58E-11 26/31 
3 dATP/dITP metabolism 1.55E-10 37/54 
4 Cell cycle_Role of APC in cell cycle regulation 1.92E-09 25/32 
5 Oxidative phosphorylation 2.37E-09 42/69 
6 Cell cycle_Chromosome condensation in prometaphase 5.12E-09 18/20 
7 ATP/ITP metabolism 1.26E-08 47/84 
8 dCTP/dUTP metabolism 5.10E-08 30/46 
9 GTP-XTP metabolism 7.20E-08 35/58 
10 Cell cycle_Transition and termination of DNA replication 1.37E-07 20/26 
 
 
Process name p value Ratio 
1 Cell cycle_Mitosis 1.30E-29 118/177 
2 Translation_Translation in mitochondria 1.39E-29 82/103 
3 Cell cycle_G2-M 7.67E-21 117/205 
4 Cell cycle_S phase 1.11E-20 92/146 
5 Transcription_mRNA processing 5.51E-19 95/159 
6 Cell cycle_Core 1.16E-18 75/114 
7 Translation_Translation initiation 1.91E-13 87/163 
8 Cell cycle_G1-S 1.99E-12 85/163 
9 DNA damage_DBS repair 2.47E-12 63/108 
10 DNA damage_Checkpoint 4.86E-12 69/124 
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Table 4.7: Pathways and processes associated with the genes differentially 
under-expressed in HCT116 oxaliplatin resistant cells compared to HCT116 
parental cells 
 Pathway name p value Ratio 
1 Cell cycle_The metaphase checkpoint 1.17E-15 32/36 
2 Cell cycle_Role of APC in cell cycle regulation 4.42E-11 26/32 
3 Cell cycle_Start of DNA replication in early S phase 1.45E-10 25/31 
4 Cell cycle_Spindle assembly and chromosome separation 5.03E-10 25/32 
5 Cell cycle_Chromosome condensation in prometaphase 3.39E-08 17/20 
6 Cell cycle_Transition and termination of DNA replication 3.01E-06 18/26 
7 dCTP/dUTP metabolism 6.00E-06 26/46 
8 
Development_MAG-dependent inhibition of neurite 
outgrowth 9.15E-06 20/32 
9 Cholesterol Biosynthesis 1.16E-05 15/21 
10 Cell cycle_Sister chromatid cohesion 1.16E-05 15/21 
 
 
Process name p value Ratio 
1 Cell cycle_Mitosis 3.00E-29 114/177 
2 Cell cycle_S phase 2.23E-27 98/146 
3 Cell cycle_Core 1.68E-24 80/114 
4 Cytoskeleton_Spindle microtubules 2.59E-14 64/108 
5 Cell cycle_G2-M 1.99E-13 99/205 
6 DNA damage_DBS repair 1.40E-09 56/108 
7 Transcription_mRNA processing 2.00E-09 74/159 
8 Proteolysis_Ubiquitin-proteasomal proteolysis 4.13E-09 75/164 
9 Transcription_Chromatin modification 5.66E-09 61/125 
10 DNA damage_Checkpoint 2.48E-07 57/124 
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Table 4.8: Pathways and processes associated with the genes differentially 
under-expressed in DLD-1 5-FU resistant cells compared to DLD-1 parental cells 
 
Pathway name p value Ratio 
1 Cell cycle_The metaphase checkpoint 4.54E-12 32/36 
2 Cell cycle_Role of APC in cell cycle regulation 2.87E-09 27/32 
3 Cell cycle_Start of DNA replication in early S phase 6.74E-08 25/31 
4 Cholesterol Biosynthesis 7.05E-08 19/21 
5 Cell cycle_Chromosome condensation in prometaphase 1.94E-07 18/20 
6 Cell cycle_Spindle assembly and chromosome separation 2.12E-07 25/32 
7 Cell cycle_Transition and termination of DNA replication 7.71E-07 21/26 
8 Apoptosis and survival_BAD phosphorylation 1.68E-06 26/36 
9 dATP/dITP metabolism 6.05E-06 34/54 
10 Cell cycle_Role of Nek in cell cycle regulation 6.57E-06 21/28 
 
 
Process name p value Ratio 
1 Cell cycle_Mitosis 9.25E-29 127/177 
2 Cytoskeleton_Spindle microtubules 6.67E-20 80/108 
3 Cell cycle_S phase 4.63E-19 98/146 
4 Cell cycle_Core 4.96E-19 82/114 
5 Translation_Translation in mitochondria 8.50E-19 76/103 
6 Transcription_mRNA processing 4.76E-17 101/159 
7 Cell cycle_G2-M 1.55E-16 121/205 
8 DNA damage_DBS repair 8.13E-13 70/108 
9 Translation_Translation initiation 2.84E-12 94/163 
10 DNA damage_Checkpoint 6.72E-11 74/124 
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Table 4.9: Pathways and processes associated with the genes differentially 
under-expressed in DLD-1 oxaliplatin resistant cells compared to DLD-1 parental 
cells 
 
Pathway name p value Ratio 
1 Cell cycle_The metaphase checkpoint 7.77E-09 30/36 
2 Cell cycle_Role of APC in cell cycle regulation 2.68E-08 27/32 
3 Apoptosis and survival_Granzyme B signalling 3.45E-07 24/29 
4 Apoptosis and survival_BAD phosphorylation 4.05E-07 28/36 
5 Cell cycle_Chromosome condensation in prometaphase 9.15E-07 18/20 
6 DNA damage_ATM/ATR regulation of G1/S checkpoint 1.51E-06 25/32 
7 Cell cycle_Spindle assembly and chromosome separation 1.51E-06 25/32 
8 Apoptosis and survival_FAS signaling cascades 1.51E-06 30/41 
9 Development_IGF-1 receptor signalling 1.90E-06 32/45 
10 DNA damage_ATM / ATR regulation of G2 / M checkpoint 4.17E-06 21/26 
 
 
Process name p value Ratio 
1 Cell cycle_Mitosis 2.92E-21 122/177 
2 Cell cycle_S phase 5.77E-20 104/146 
3 Cell cycle_G2-M 2.51E-18 131/205 
4 Cytoskeleton_Spindle microtubules 1.92E-14 76/108 
5 Cell cycle_Core 2.26E-14 79/114 
6 DNA damage_Checkpoint 2.01E-11 79/124 
7 Cell cycle_G1-S 3.45E-11 97/163 
8 Translation_Translation in mitochondria 1.82E-10 67/103 
9 DNA damage_DBS repair 3.21E-10 69/108 
10 Transcription_mRNA processing 9.05E-10 92/159 
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In contrast, Tables 4.10 – 4.13 show that the pathways and processes enriched 
by genes over-expressed in 5-FU or oxaliplatin resistant cells were less definitive 
than those enriched by under-expressed genes. In general, pathways and 
processes involved in inflammatory or immune responses, cytoskeleton 
remodelling and cell adhesion were enriched, consistent with work published by 
de Angelis et al (2006). Cytoskeleton remodelling, in particular, has been 
suggested to occur in EMT and cancer invasion (Yilmaz & Christofori, 2009). In 
DLD-1 oxaliplatin cells (Table 4.13) there was also a strong predicted association 
with lipid metabolism.  
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Table 4.10: Pathways and processes associated with the genes differentially 
over-expressed in HCT116 5-FU resistant cells compared to HCT116 parental 
cells  
 
Pathway name p value Ratio 
1 Cytoskeleton remodeling_TGF, WNT and cytoskeletal remodelling 3.27E-07 61/107 
2 G-protein signaling_Proinsulin C-peptide signalling 8.92E-07 27/37 
3 Development_A3 receptor signalling 9.78E-06 25/36 
4 Immune response _IFN gamma signaling pathway 1.81E-05 29/45 
5 
Immune response_Neurotensin-induced activation of IL-8 in 
colonocytes 2.07E-05 24/35 
6 Development_c-Kit ligand signaling pathway during hemopoiesis 2.69E-05 32/52 
7 Immune response_IL-15 signaling 3.85E-05 34/57 
8 Apoptosis and survival_NGF activation of NF-kB 3.88E-05 19/26 
9 
Cell adhesion_Histamine H1 receptor signaling in the interruption of 
cell barrier integrity 4.26E-05 24/36 
10 G-protein signaling_RhoA regulation pathway 4.34E-05 23/34 
 
 
Process name p value Ratio 
1 Cell adhesion_Integrin-mediated cell-matrix adhesion 2.77E-10 110/210 
2 Development_Neurogenesis_Axonal guidance 2.35E-08 108/218 
3 Cell adhesion_Attractive and repulsive receptors 6.12E-08 87/169 
4 Inflammation_Neutrophil activation 1.52E-07 92/184 
5 Signal transduction_NOTCH signalling 5.84E-07 108/229 
6 Development_Regulation of angiogenesis 5.84E-07 99/206 
7 
Cytoskeleton_Regulation of cytoskeleton 
rearrangement 1.34E-06 88/181 
8 Reproduction_Feeding and Neurohormone signaling  4.27E-06 95/203 
9 Development_Blood vessel morphogenesis 5.86E-06 98/212 
10 Cell adhesion_Integrin priming 6.25E-06 52/97 
 
 
 
 
197 
 
 
 
Table 4.11: Pathways and processes associated with the genes differentially 
over-expressed in HCT116 oxaliplatin resistant cells compared to HCT116 
parental cells 
 
Pathway name p value Ratio 
1 
Immune response_HSP60 and HSP70/ TLR signaling 
pathway 8.55E-05 24/54 
2 Cytoskeleton remodeling_Cytoskeleton remodeling 1.36E-04 36/96 
3 Development_GDNF signaling 1.63E-04 12/20 
4 
Cytoskeleton remodeling_TGF, WNT and cytoskeletal 
remodelling 3.31E-04 38/107 
5 Glutathione metabolism / Rodent version 5.75E-04 17/37 
6 Immune response_HMGB1/RAGE signaling pathway 6.03E-04 21/50 
7 Apoptosis and survival_Role of IAP-proteins in apoptosis 6.13E-04 14/28 
8 
Development_VEGF signaling via VEGFR2 - generic 
cascades 6.21E-04 26/67 
9 Glutathione metabolism 1.30E-03 16/36 
10 Reproduction_GnRH signaling 1.53E-03 23/60 
 
 
Process name p value Ratio 
1 Response to hypoxia and oxidative stress 2.73E-05 41/109 
2 Cell adhesion_Integrin-mediated cell-matrix adhesion 3.02E-05 68/210 
3 Inflammation_Amphoterin signaling 4.94E-05 42/115 
4 Cell adhesion_Attractive and repulsive receptors 7.44E-05 56/169 
5 Cytoskeleton_Actin filaments 9.20E-05 57/174 
6 
Cytoskeleton_Regulation of cytoskeleton 
rearrangement 3.00E-04 57/181 
7 Inflammation_TREM1 signaling 4.13E-04 42/125 
8 Inflammation_Neutrophil activation 4.79E-04 57/184 
9 Inflammation_Protein C signaling 5.66E-04 33/93 
10 Cell adhesion_Cell junctions 8.07E-04 47/148 
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Table 4.12: Pathways and processes associated with the genes differentially 
over-expressed in DLD-1 5-FU resistant cells compared to DLD-1 parental cells 
 
Pathway name p value Ratio 
1 Development_VEGF signaling via VEGFR2 - generic cascades 2.20E-06 45/67 
2 Immune response _IFN gamma signaling pathway 1.07E-05 32/45 
3 Development_c-Kit ligand signaling pathway during hemopoiesis 2.81E-05 35/52 
4 Cytoskeleton remodeling_TGF, WNT and cytoskeletal remodeling 4.12E-05 62/107 
5 Regulation of CFTR activity (norm and CF) 6.13E-05 28/40 
6 PGE2 pathways in cancer 1.22E-04 28/41 
7 ENaC regulation in airways (normal and CF) 1.50E-04 23/32 
8 Translation _Regulation of EIF4F activity 1.50E-04 32/49 
9 Immune response_Gastrin in inflammatory response 1.64E-04 37/59 
10 Cell adhesion_Cadherin-mediated cell adhesion 1.74E-04 19/25 
 
 
Process name p value Ratio 
1 Inflammation_Interferon signaling 5.03E-06 64/109 
2 Inflammation_IFN-gamma signaling 1.46E-05 59/101 
3 Cell adhesion_Amyloid proteins 3.69E-05 93/178 
4 Signal transduction_NOTCH signaling 4.71E-05 115/229 
5 Cell adhesion_Cell junctions 5.41E-05 79/148 
6 Autophagy_Autophagy 1.27E-04 32/50 
7 Cytoskeleton_Actin filaments 1.47E-04 89/174 
8 Reproduction_FSH-beta signaling pathway 2.31E-04 79/153 
9 
Immune response_Innate immune response to RNA viral 
infection  2.80E-04 40/68 
10 
Apoptosis_Anti-Apoptosis mediated by external signals via 
MAPK and JAK/STAT 3.66E-04 80/157 
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Table 4.13: Pathways and processes associated with the genes differentially 
over-expressed in DLD-1 oxaliplatin resistant cells compared to DLD-1 parental 
cells 
 
Pathway name p value Ratio 
1 Immune response_Antiviral actions of Interferons 8.37E-04 23/33 
2 Immune response _IFN gamma signaling pathway 1.31E-03 29/45 
3 
Regulation of lipid metabolism_Regulation of acetyl-CoA 
carboxylase 1 activity in lipogenic tissue 2.00E-03 7/7 
4 
Regulation of lipid metabolism_Regulation of acetyl-CoA 
carboxylase 1 activity in keratinocytes 2.00E-03 7/7 
5 Immune response_CD40 signaling 2.33E-03 33/54 
6 PGE2 pathways in cancer 3.23E-03 26/41 
7 Cortisone biosynthesis and metabolism 3.59E-03 10/12 
8 Phosphatidylinositol metabolism 3.85E-03 19/28 
9 
Development_WNT signaling pathway. Part 1. Degradation of 
beta-catenin in the absence WNT signaling 4.15E-03 14/19 
10 Development_Role of IL-8 in angiogenesis 5.34E-03 31/52 
 
 
Process name p value Ratio 
1 Signal transduction_NOTCH signaling 1.83E-04 119/229 
2 Development_Regulation of angiogenesis 6.46E-04 106/206 
3 
Immune response_Innate immune response to RNA viral 
infection  1.47E-03 40/68 
4 Apoptosis_Apoptotic nucleus 2.12E-03 79/152 
5 Inflammation_Interferon signaling 2.24E-03 59/109 
6 Reproduction_FSH-beta signaling pathway 2.68E-03 79/153 
7 Apoptosis_Death Domain receptors & caspases in apoptosis 4.06E-03 64/122 
8 Cell adhesion_Leucocyte chemotaxis 6.08E-03 93/188 
9 Development_ERK5 in cell proliferation and neuronal survival 8.07E-03 16/24 
10 Inflammation_TREM1 signaling 8.26E-03 64/125 
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To support the predicted pathways and processes analysis generated in Tables 
4.6 - 4.13 and to further investigate mechanisms of resistance common to both 
5-FU and oxaliplatin, we identified genes that were common to both HCT116 5-
FU and oxaliplatin resistant cell lines and both DLD-1 5-FU and oxaliplatin 
resistant cell lines compared to their respective parental cell lines. We identified 
that 135 genes were differentially expressed (90 up, 45 down) in both 5-FU and 
oxaliplatin resistant HCT116 cells (Appendix K, Table K1). In addition, 2357 genes 
were differentially expressed (980 up, 1377 down) in both 5-FU and oxaliplatin 
resistant DLD-1 cells (Appendix K, Table K2). Ultimately, we identified 48 genes 
that were differentially expressed (31 up, 17 down) in all four drug resistant cells 
compared to their respective parental cells, representing a possible general drug 
resistance mRNA signature (Appendix K, Table K3).  
Consistent with the bioinformatics data presented above, the 1377 genes under-
expressed in DLD-1 drug resistant cells were associated with pathways and 
processes involving cell cycle regulation and ATP/ITP metabolism when analysed 
using Metacore (Appendix L, Table L1). This approach, however, yielded few 
cancer-related processes and pathways significantly associated with genes over-
expressed in DLD-1 drug resistant cells or genes over or under-expressed in 
HCT116 drug resistant cells due to the small number of genes in each group 
(Appendix L, Tables L2 – L4). 
Metacore was further used to identify pathways and processes associated with 
genes (213 in total; Appendix K, Table K4) that were uniquely differentially 
expressed in 5-FU resistant HCT116 and DLD-1 cells but not in oxaliplatin 
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resistant cells in an attempt to identify the unique mechanisms by which cells 
may develop resistance to 5-FU. Table 4.14 shows that pathways involved in 
glucocorticoid receptor signalling, ERBB family signalling, evasion of apoptosis 
and immune responses were prominent. Additionally, enriched processes 
involved in regulation of the cytoskeleton were also identified.  
Conversely, genes (21 in total, Appendix K, Table K5) that were uniquely 
differentially expressed in oxaliplatin resistant HCT116 and DLD-1 cells but not 5-
FU resistant cells were not significantly associated with any enriched pathways 
or processes, most likely because of the very small number of genes (data not 
shown). However, genes differentially expressed in oxaliplatin resistant DLD-1 
cells but not HCT116 (5-FU or oxaliplatin resistant) or DLD-1 5-FU resistant cells 
were significantly associated with pathways and processes involved in cell cycle 
regulation, cell adhesion and cytoskeleton remodelling (Table 4.15).  
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Table 4.14: Pathways and processes associated with the 5-FU resistance specific 
genes common to HCT116 and DLD-1 cells 
 
Pathway name p value  Ratio  
1 Development_Glucocorticoid receptor signaling  1.35E-02 4/24  
2 Development_ERBB-family signaling  3.18E-02 4/39  
3 Apoptosis and survival_Anti-apoptotic TNFs/NF-kB/Bcl-2 pathway 3.18E-02 4/42  
4 Apoptosis and survival_Lymphotoxin-beta receptor signaling  3.18E-02 4/42  
5 Immune response_TNF-R2 signaling pathways 3.32E-02 4/45  
6 Immune response_MIF-mediated glucocorticoid regulation 3.83E-02 3/22  
7 Transcription_NF-kB activation pathways 3.83E-02 4/51  
8 Apoptosis and survival_Role of PKR in stress-induced apoptosis 3.88E-02 4/53  
9 Immune response_Role of PKR in stress-induced antiviral cell response 4.22E-02 4/57  
10 HCV-dependent regulation of membrane receptors signaling in HCC 4.22E-02 3/27  
11 
Neurophysiological process_Constitutive and activity-dependent synaptic 
AMPA receptor delivery 4.222E-02  4/59 
12 Immune response_Innate immune response to RNA viral infection 4.24E-02 3/28  
13 Immune response_CD137 signaling in immune cell 4.34E-02 3/29  
14 Immune response_IL-4 - antiapoptotic action 4.45E-02 3/30  
 
 
Process name p value  Ratio  
1 Cytoskeleton_Actin filaments  4.34E-03 11/176  
2 Cytoskeleton_Regulation of cytoskeleton rearrangement 4.34E-03 11/183  
3 Cytoskeleton_Intermediate filaments 7.07E-03 7/81  
4 Immune response_Phagocytosis  1.19E-02 11/222  
5 Inflammation_Protein C signaling  2.46E-02 7/108  
6 Cell cycle_G1-S Growth factor regulation 4.13E-02 9/195  
7 Reproduction_FSH-beta signaling pathway 4.13E-02 8/160  
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Table 4.15: Pathways and processes associated with the oxaliplatin resistance 
specific genes in DLD-1 cells 
 
Pathway name  p value  Ratio  
1 Cell cycle_Role of Nek in cell cycle regulation 3.82E-03 10/32  
2 Transport_Clathrin-coated vesicle cycle 3.82E-03 15/71  
3 G-protein signaling_RhoA regulation pathway 3.82E-03 10/34  
4 Colorectal cancer (general schema) 6.47E-03 9/30  
5 Cell cycle_Role of APC in cell cycle regulation 9.14E-03 9/32  
6 Cell cycle_Spindle assembly and chromosome separation 9.94E-03 9/33  
7 Immune response_Function of MEF2 in T lymphocytes 1.30E-02 11/51  
8 Development_Notch Signaling Pathway 1.30E-02 10/43  
9 Cell adhesion_Ephrin signalling 1.74E-02 10/45  
10 Transcription_Transcription factor Tubby signaling pathways 1.88E-02 6/17  
11 Glutathione metabolism / Human version 2.00E-02 12/65  
12 Cell cycle_Initiation of mitosis 2.44E-02 7/25  
13 Signal transduction_Calcium signaling  4.89E-02 9/45  
 
 
Process name p value  Ratio  
1 Cytoskeleton_Spindle microtubules 7.94E-04 26/109  
2 Cell cycle_Mitosis  3.08E-02 31/179  
3 
Cardiac development_Wnt_beta-catenin, Notch, 
VEGF, IP3 and integrin signalling 3.08E-02 27/150  
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4.3.3. MicroRNA profiling and predicted drug resistance mechanisms 
Section 4.3.2 used mRNA profiling and bioinformatics analysis to predict 
mechanisms by which HCT116 and DLD-1 cells may develop 5-FU and oxaliplatin 
resistance, some of which have been previously reported. We show that 
hundreds of genes are differentially expressed in 5-FU or oxaliplatin resistant 
cells and contribute to a complex network of pathways involved in acquired 
resistance. 
To support the above data, TLDA miRNA cards were used to profile each drug 
resistant cell line compared to their respective parental cell line, as detailed in 
Section 2.2.9.8. Due to the nature of miRNAs as key regulators of gene 
expression, we aimed to identify differentially expressed miRNA 5-FU and/or 
oxaliplatin resistance signatures and determine whether they predicted 
mechanisms of resistance.  
In HCT116 5-FU resistant cells, 19 miRNAs were differentially expressed (5 up, 14 
down) compared to HCT116 parental cells, with miR-99a and miR-483-5p the 
most abundantly over and under-expressed miRNAs respectively (Table 4.16). 
Only 5 miRNAs were differentially expressed (2 up, 3 down) in HCT116 
oxaliplatin resistant cells compared to HCT116 parental cells with miR-19b and 
miR-328 the most abundantly over and under-expressed miRNAs respectively 
(Table 4.17).  
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Table 4.16: miRNAs differentially expressed in HCT116 5-FU resistant cells 
compared to HCT116 parental cells 
microRNA Fold change 
Adjusted   
p value 
miR-99a 6.26 0.025 
miR-19b 5.18 0.010 
miR-15b 3.94 0.015 
miR-17 3.24 0.024 
miR-494 3.04 0.048 
let-7c -3.75 0.040 
miR-886-5p -3.89 0.014 
miR-223 -4.04 0.015 
miR-193b -4.63 0.003 
miR-196b -4.81 0.015 
miR-197 -4.86 0.014 
miR-181a -5.16 0.036 
miR-574-3p -8.66 0.011 
miR-210 -9.28 0.036 
miR-320 -9.41 0.003 
let-7b -10.96 0.001 
miR-328 -16.59 0.003 
miR-886-3p -26.13 0.003 
miR-483-5p -40.97 0.001 
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Table 4.17: miRNAs differentially expressed in HCT116 oxaliplatin resistant cells 
compared to HCT116 parental cells 
microRNA Fold change 
Adjusted          
p value 
miR-19b 7.21 0.027 
miR-25 3.46 0.033 
let-7b -3.46 0.034 
miR-320 -6.85 0.033 
miR-328 -6.96 0.033 
 
In DLD-1 5-FU resistant cells, 36 miRNAs were differentially expressed (29 up, 7 
down) when compared to DLD-1 parental cells with miR-20a the most 
abundantly and miR-146a the least abundantly expressed miRNAs (Table 4.18). 
In addition,  27 miRNAs were differentially expressed (23 up, 4 down) in DLD-1 
oxaliplatin resistant cells relative to DLD-1 parental cells with miR-17 and miR-
886-3p the most abundantly over and under-expressed miRNAs respectively 
(Table 4.19).   
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Table 4.18: Differentially expressed miRNAs in DLD-1 5-FU resistant cells  
microRNA Fold Change 
Adjusted  
p value 
miR-20a 16.84 0.005 
miR-10a 13.82 0.007 
miR-186 11.21 0.006 
let-7a 10.70 0.013 
miR-19b 9.07 0.008 
miR-200a 8.72 0.003 
miR-200b 8.56 0.003 
miR-106a 7.74 0.006 
miR-494 7.38 0.031 
miR-16 7.15 0.003 
miR-17 7.10 0.003 
miR-221 5.83 0.016 
miR-26b 5.15 0.015 
miR-203 5.12 0.015 
let-7e 4.56 0.013 
miR-29a 4.52 0.006 
miR-93 4.48 0.003 
miR-30c 4.45 0.015 
miR-149 4.39 0.010 
miR-26a 4.20 0.003 
miR-375 3.90 0.015 
let-7d 3.79 0.009 
miR-744 3.76 0.021 
miR-15b 3.38 0.037 
miR-532-3p 3.25 0.006 
miR-92a 2.98 0.015 
miR-484 2.89 0.003 
miR-24 2.53 0.023 
miR-196b 1.95 0.034 
miR-320 -1.70 0.042 
miR-574-3p -2.64 0.015 
miR-192 -2.68 0.015 
miR-328 -2.77 0.023 
miR-483-5p -2.83 0.013 
miR-886-3p -7.17 0.006 
miR-146a -9.96 0.015 
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Table 4.19: Differentially expressed miRNAs in DLD-1 oxaliplatin resistant cells  
microRNA Fold change 
Adjusted     
p value 
miR-17  21.97  0.001 
miR-16 18.02 0.002 
miR-106a 18.01 0.002 
let-7a 16.78 0.014 
miR-93 14.10 0.003 
let-7e 10.45 0.002 
miR-200b 8.95 0.002 
miR-149 8.44 0.006 
miR-186 7.40 0.006 
miR-29a 7.09 0.002 
miR-200a 5.69 0.005 
miR-92a 4.56 0.005 
miR-24 4.40 0.002 
miR-331-3p 4.08 0.014 
miR-345 3.81 0.004 
miR-222 3.49 0.002 
miR-26a 3.45 0.005 
miR-196b 3.20 0.002 
miR-223 2.70 0.017 
miR-31 2.39 0.019 
miR-200c 2.07 0.017 
miR-191 2.00 0.002 
miR-484 1.45 0.026 
miR-320 -2.02 0.004 
miR-574-3p -3.37 0.002 
miR-146a -6.71 0.015 
miR-886-3p -16.35 0.002 
 
During the development of the drug resistant cell lines in the present study, two 
studies were published reporting the generation of DLD-1 5-FU resistant cells 
and describing miRNAs differentially expressed in resistant cells relative to DLD-
1 parental cells (Akao et al, 2011; Kurokawa et al, 2012). Akao et al (2011) and 
Kurokawa et al (2012) used miRNA microarray to profile 180 and 723 miRNAs 
respectively.  
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Consistent with the present study, microarray data from Akao et al (2011) 
suggests that miR-92 was differentially over-expressed in 5-FU resistant cells. 
Our TLDA data show that miR-92 was overexpressed in both 5-FU and oxaliplatin 
resistant cells compared to parental cells. Moreover, Kurokawa et al (2012) 
showed that miR-19b was overexpressed in DLD-1 5-FU resistant cells, which we 
also show to be overexpressed in our DLD-1 5-FU resistant cells and HCT116 5-
FU and oxaliplatin resistant cells. In a recent study, Zhou et al (2014) generated 
HT29, RKO and HCT116 oxaliplatin resistant cell lines. The study also used miRNA 
microarrays to profile 389 miRNAs in paired drug resistant and sensitive cells. 
There were no similarities, however, in differentially expressed miRNAs in the 
HCT116 oxaliplatin resistant cells generated in the present study and those 
generated in the study by Zhou et al (2014).  
In the present study, we identified miRNAs that were, for example, differentially 
expressed in both HCT116 5-FU and oxaliplatin resistant cells (e.g. let-7b) or in 
both DLD-1 5-FU and oxaliplatin resistant cells (e.g. 200a, miR-200b) compared 
to their respective parental cells. Additionally, miRNAs that were commonly 
differentially expressed in both HCT116 and DLD-1 5-FU resistant cells compared 
to their parental cells (miR-15b, miR-494, miR-483-5p) or uniquely differentially 
expressed in only  DLD-1 5-FU resistant cells (e.g. miR-20a) or DLD-1 oxaliplatin 
resistant cells (e.g. miR-31) compared to DLD-1 parental cells were identified 
(Figure 4.7). Our analysis therefore identified potential miRNA signatures of 5-FU 
or oxaliplatin resistance in colorectal cancer.  
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Figure 4.7:  MiRNAs uniquely or commonly differentially expressed in 5-FU and oxaliplatin 
resistant cells. TLDA miRNA cards were used, as described in Section 2.2.9.8, to identify miRNAs 
that were differentially expressed in HCT116 5-FU and oxaliplatin resistant cells compared to 
HCT116 parental cells and in DLD-1 5-FU and oxaliplatin resistant cells compared to DLD-1 
parental cells. The Venn diagram shows miRNAs that were uniquely differentially expressed in 
one particular cell line or that were commonly differentially expressed in at least 2 of the drug 
resistant cell lines. ↑ and ↓represent over and under-expressed miRNAs respectively. 
The bioinformatics tool Metacore, as previously described, was used to identify 
pathways and processes that were enriched and associated with the predicted 
targets (identified from 5 miRNA target prediction databases, Section 2.2.17) of 
differentially expressed miRNAs in each drug resistant cell line compared to their 
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respective parental cells. In this analysis, the most prominently represented 
cancer-related pathways and processes that were enriched were those involved 
in cytoskeleton remodelling and cell adhesion (Tables 4.20 – 4.23), consistent 
with the pathways and processes analysis generated from the differentially 
expressed mRNA data.  The next step was therefore to experimentally validate 
the phenotypes predicted by bioinformatics analysis.  
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Table 4.20: Pathways and processes associated with the predicted targets of 
miRNAs differentially expressed in HCT116 5-FU resistant cells compared to 
HCT116 parental cells 
 
Pathway name 
Adjusted  
p value  Ratio 
1 Cytoskeleton remodeling_TGF, WNT and cytoskeletal remodeling  1.93E-26 94/111  
2 Cytoskeleton remodeling_Cytoskeleton remodeling  2.62E-20 82/102  
3 Development_Regulation of epithelial-to-mesenchymal transition (EMT) 9.81E-19 57/64  
4 Cell adhesion_Chemokines and adhesion 2.32E-16 76/100  
5 Development_WNT signaling pathway. Part 2 2.16E-14 46/53  
6 Cell adhesion_ECM remodeling  5.44E-13 44/52  
7 Cell adhesion_Ephrin signaling  2.44E-12 39/45  
8 Development_GM-CSF signaling  3.08E-12 42/50  
9 Normal and pathological TGF-beta-mediated regulation of cell proliferation 3.34E-12 31/33  
10 Development_TGF-beta-dependent induction of EMT via SMADs  9.67E-12 32/35  
 
 
Process name 
Adjusted       
p value  Ratio 
1 Cytoskeleton_Regulation of cytoskeleton rearrangement 5.45E-12 155/183  
2 Signal transduction_WNT signaling  1.11E-11 150/177  
3 Signal transduction_NOTCH signaling  1.17E-11 193/236  
4 Development_Neurogenesis_Synaptogenesis  1.59E-10 150/180  
5 Cytoskeleton_Actin filaments 1.73E-10 147/176  
6 
Development_EMT_Regulation of epithelial-to-mesenchymal 
transition 9.23E-09 179/226  
7 Development_Hedgehog signaling  3.67E-08 197/254  
8 Reproduction_FSH-beta signaling pathway 6.28E-08 130/160  
9 Development_Neurogenesis_Axonal guidance 1.01E-07 179/230  
10 Reproduction_Feeding and Neurohormone signaling  4.07E-07 164/211  
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Table 4.21: Pathways and processes associated with the predicted targets of 
miRNAs differentially expressed in HCT116 oxaliplatin resistant cells compared 
to HCT116 parental cells 
 
Pathway name 
Adjusted 
p value  Ratio 
1 Cytoskeleton remodeling_TGF, WNT and cytoskeletal remodeling  3.36E-25 73/111  
2 Cytoskeleton remodeling_Cytoskeleton remodeling  8.68E-20 63/102  
3 Cell adhesion_Chemokines and adhesion 9.12E-16 57/100  
4 Cardiac Hypertrophy_NF-AT signaling in Cardiac Hypertrophy 3.58E-12 39/65  
5 Development_WNT signaling pathway. Part 2 4.01E-11 33/53  
6 Development_VEGF signaling via VEGFR2 - generic cascades 8.39E-11 44/84  
7 Transport_Macropinocytosis regulation by growth factors 1.72E-10 36/63  
8 Cell adhesion_Ephrin signaling  1.85E-10 29/45  
9 Cell adhesion_Histamine H1 receptor signaling in the interruption of 
cell barrier integrity 1.85E-10 29/45  
 10 Cytoskeleton remodeling_Fibronectin-binding integrins in cell motility 1.87E-10 23/31  
 
 
Process name 
Adjusted        
p value  Ratio 
1 Development_Neurogenesis_Synaptogenesis  3.66E-11 107/180  
2 Cytoskeleton_Regulation of cytoskeleton rearrangement 1.47E-10 107/183  
3 Cytoskeleton_Actin filaments 3.04E-10 103/176  
4 Signal transduction_WNT signaling  1.23E-09 102/177  
5 Cardiac development_BMP_TGF_beta_signaling  7.74E-09 72/117  
6 Reproduction_FSH-beta signaling pathway 9.38E-09 92/160  
7 Cell adhesion_Synaptic contact 2.12E-08 102/184  
8 Cardiac development_Wnt_beta-catenin, Notch, VEGF, 
IP3 and integrin signaling  3.45E-08 86/150  
 9 Cell adhesion_Attractive and repulsive receptors 1.10E-07 96/175  
10 Signal transduction_ESR1-nuclear pathway 2.49E-07 113/216  
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Table 4.22: Pathways and processes associated with the predicted targets of 
miRNAs differentially expressed in DLD-1 5-FU resistant cells compared to DLD-1 
parental cells 
 
Pathway name 
Adjusted 
p value  Ratio 
1 Cytoskeleton remodeling_TGF, WNT and cytoskeletal remodeling  4.01E-26 101/111  
2 Cytoskeleton remodeling_Cytoskeleton remodeling  3.66E-22 91/102  
3 Development_Regulation of epithelial-to-mesenchymal transition (EMT) 2.37E-20 62/64  
4 Cell adhesion_Chemokines and adhesion 1.16E-18 86/100  
5 Immune response_HSP60 and HSP70/ TLR signaling pathway 2.08E-18 53/54  
6 Transport_Clathrin-coated vesicle cycle 1.95E-15 63/71  
7 Development_WNT signaling pathway. Part 2 3.68E-15 50/53  
8 Development_TGF-beta-dependent induction of EMT via MAPK  1.94E-14 45/47  
9 Neurophysiological process_Receptor-mediated axon growth repulsion 9.45E-14 43/45  
10 Cell adhesion_ECM remodeling 1.31E-13 48/52  
  
 
Process name 
Adjusted      
p value  Ratio 
1 Development_Neurogenesis_Synaptogenesis  5.43E-13 170/180  
2 Signal transduction_WNT signaling  3.25E-11 165/177  
3 Cell adhesion_Cadherins  7.54E-11 167/180  
4 Cytoskeleton_Actin filaments 1.91E-10 163/176  
5 Cytoskeleton_Regulation of cytoskeleton rearrangement 6.87E-10 168/183  
6 Signal transduction_NOTCH signaling  2.36E-09 211/236  
7 Cell adhesion_Integrin-mediated cell-matrix adhesion 6.38E-09 192/214  
8 Cell cycle_G1-S Growth factor regulation 2.92E-08 175/195  
9 Proliferation_Positive regulation cell proliferation 4.30E-08 196/221  
10 Cell adhesion_Attractive and repulsive receptors 5.06E-08 158/175  
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Table 4.23: Pathways and processes associated with the predicted targets of 
miRNAs differentially expressed in DLD-1 oxaliplatin resistant cells compared to 
DLD-1 parental cells 
 
Pathway name 
Adjusted    
p value  Ratio 
1 Cytoskeleton remodeling_TGF, WNT and cytoskeletal remodeling  6.43E-23 98/111  
2 Immune response_HSP60 and HSP70/ TLR signaling pathway 3.17E-20 54/54  
3 Cytoskeleton remodeling_Cytoskeleton remodeling  3.89E-20 89/102  
4 Cell adhesion_Chemokines and adhesion 1.31E-18 86/100  
5 
Development_Regulation of epithelial-to-mesenchymal transition 
(EMT) 1.45E-17 60/64  
6 Cell adhesion_ECM remodeling  3.92E-16 50/52  
7 Immune response_IL-1 signaling pathway 7.80E-15 43/44  
8 Transport_Clathrin-coated vesicle cycle 1.99E-14 62/71  
9 Development_WNT signaling pathway. Part 2 6.60E-14 49/53  
10 Immune response_HMGB1/RAGE signaling pathway 6.60E-14 49/53  
 
 
Process name 
Adjusted     
p value  Ratio 
1 Development_Neurogenesis_Synaptogenesis  4.53E-14 171/180  
2 Signal transduction_WNT signaling  1.81E-11 165/177  
3 Transcription_mRNA processing 1.04E-09 148/160  
4 Cytoskeleton_Regulation of cytoskeleton rearrangement 1.53E-09 167/183  
5 Cell adhesion_Cadherins  2.97E-09 164/180  
6 Signal transduction_NOTCH signaling  1.10E-08 209/236  
7 Proliferation_Positive regulation cell proliferation 6.85E-08 195/221  
8 Cytoskeleton_Actin filaments 8.23E-08 158/176  
9 Cell cycle_G1-S Interleukin regulation 9.45E-08 118/128  
10 Cytoskeleton_Cytoplasmic microtubules 1.01E-07 107/115  
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4.3.4. The relationship between acquired drug resistance, EMT and cell 
invasion 
 
To investigate the predicted association between acquired 5-FU or oxaliplatin 
resistance in HCT116 and DLD-1 cells and EMT, the expression of a panel of well-
known EMT genes, CDH1, CDH2, TWIST1 and VIM was compared in drug 
resistant cells and their respective drug sensitive parental cells, by Taqman qRT-
PCR analysis as described in Section 2.2.9.4.  
CDH1 (E-cadherin) expression was significantly increased in HCT116 5-FU (2.4-
fold; p=0.003) and oxaliplatin resistant cells (2.1-fold, p=0.008) compared to 
HCT116 parental cells (Figure 4.8 A), and in DLD-1 5-FU (3.7-fold, p=0.007) and 
oxaliplatin resistant cells (3.9-fold, p=0.04) compared to DLD-1 parental cells 
(Figure 4.8 B). As a decrease in E-cadherin is a hallmark of EMT, this was a 
surprising result. However, pathways and processes associated with cell 
adhesion are significantly associated with genes over-expressed in drug resistant 
cell lines compared to their respective parental cells. Moreover, it was observed 
whilst culturing the drug resistant cell lines that the cells were more clumped 
together and more resistant to the effects of trypsin.  
The expression of CDH2 (N-cadherin) was not significantly changed in DLD-1 5-
FU (1.4-fold; p=0.17) and oxaliplatin (0.66-fold; fold; p=0.16) resistant cells 
(Figure 4.8 C), and was not expressed at all in HCT116 cells (data not shown). 
The expression of vimentin was significantly decreased (1.4-fold; p=0.03) in 
oxaliplatin resistant HCT116 cells. VIM expression was also decreased in 5-FU 
resistant HCT116 cells but not to a statistically significant level (1.3-fold; p=0.08; 
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Figure 4.8 D). The expression of TWIST1 was significantly increased (2.5-fold; 
p=0.02; Figure 4.8 E) in 5-FU resistant HCT116 cells but not in oxaliplatin 
resistant cells (1.6-fold; p=0.1). The data suggests that an EMT phenotype may 
not be consistently displayed. However, the change in expression of many other 
genes also defines EMT. DSG2 (desmoglein 2), for example, is decreased in DLD-
1 5-FU and oxaliplatin resistant cells (Appendix J, Table J3 and J4). Therefore 
further studies may be needed to assess the expression of other EMT genes and 
to also assess protein expression.  
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Figure 4.8 
(A) 
(B) 
(C) 
(D) 
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Figure 4.8: The expression of EMT genes in 5-FU and oxaliplatin resistant cells. The mRNA 
expression of A) CDH1 in HCT116 5-FU resistant, oxaliplatin resistant and parental cells, B) CDH1 
in DLD-1 5-FU resistant, oxaliplatin resistant and parental cells, C) CDH2 in DLD-1 5-FU resistant, 
oxaliplatin resistant and parental cells, D) VIM in HCT116 5-FU resistant, oxaliplatin resistant and 
parental cells and E) TWIST1 in HCT116 5-FU resistant, oxaliplatin resistant and parental cells. 
Gene expression was relative to the control gene 18S ribosomal RNA and assessed as detailed in 
Section 2.2.9.4. Each sample was assessed in triplicate and the errors were determined by 
calculating 2 
(-δCt + sd δCt)
 and 2
(-δCt – sd δCt)
, as detailed in section 2.2.9.5. Statistical significance 
(p≤0.05) was determined by performing independent T-tests. 
To investigate possible changes in cell invasion as a result of acquired drug 
resistance, a Calbiochem InnoCyte invasion assay was used to model and 
quantify cancer cell invasion in vitro, as described in Section 2.2.7. In both 
HCT116 and DLD-1 cell line backgrounds, oxaliplatin resistant cells were more 
invasive than their respective parental cells (HCT116: 2.5-fold; p=0.008; DLD-1: 
7.5-fold; p=0.01; Figure 4.9). This is consistent with a study by Yang et al (2006) 
which showed that in oxaliplatin resistant KM12L4 and HT29 colorectal cancer 
cells showed more migration and invasion compared to their respective parental 
cells. Surprisingly, however, there were no significant differences in cell invasion 
(E) 
(A) 
(B) 
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in both 5-FU resistant cells compared to their respective parental cells (HCT116: 
0.9-fold; p=0.45; DLD-1: 1.5-fold; p=0.07) , in spite of the predicted phenotypes 
(Figure 4.9). 
 
Figure 4.9: The invasiveness of 5-FU and oxaliplatin resistant cells. The Calbiochem InnoCyte 
invasion assay was used to model and quantify cancer cell invasion in vitro, as detailed in Section 
2.2.7. The invasiveness of 5-FU and oxaliplatin resistant HCT116 and DLD-1 cells was compared to 
the parental cells. Each sample was analysed in triplicate and errors represent the SEM of three 
separate experiments. Statistical significance (p≤0.05) was determined by performing 
independent T-tests. 
4.3.5. The effect of drug resistance on cell proliferation and the cell cycle 
 
We next investigated the effect of 5-FU and oxaliplatin resistance on cell 
proliferation by flow cytometry using the CellTrace Violet Cell Proliferation Kit as 
detailed in Section 2.2.14.3. In HCT116 cells, cell doubling time was significantly 
increased in oxaliplatin resistant cells compared to parental cells (from 25.2 
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hours to 26.3 hours, p=0.04) over a 96 hour period (Table 4.24). In contrast, the 
doubling time of 5-FU resistant cells was significantly decreased (from 25.2 
hours to 20.9 hours, p=0.0007). Similarly, DLD-1 oxaliplatin resistant cells did not 
have a significantly different doubling time compared to their parental line (24.2 
hours to 25.6 hours, p=0.12; Table 4.24). DLD-1 5-FU resistant cells however 
doubled at a slower rate compared to parental cells (24.2 hours to 29.8 hours, 
p=0.008).  
Table 4.24: Doubling times of HCT116 and DLD-1 parental cells compared to 
their respective 5-FU and oxaliplatin resistant cells as determined by the 
CellTrace Violet Cell Proliferation Kit 
Cell line Doubling time (hours) 
p value (compared to 
respective parental) 
HCT116 Parental 25.2 ± 0.11 - 
HCT116 oxaliplatin resistant 26.3 ± 0.15 0.004 
HCT116 5-FU resistant 20.9 ± 0.44 0.0007 
DLD-1 Parental 24.2 ± 0.13 - 
DLD-1 oxaliplatin resistant  25.6 ± 0.54 0.12 
DLD-1 5-FU resistant 29.8 ± 0.48 0.008 
 
The effect of drug resistance on cell cycle kinetics was then investigated by 
staining cells with Propidium iodide and analysing DNA content using a flow 
cytometer, as described in Section 2.2.14.1. Figure 4.10 shows that over 96 
hours the HCT116 5-FU resistant cells were arrested in the G0/G1 phase 
compared to HCT116 parental cells. HCT116 oxaliplatin resistant cells spent less 
time in the G0/G1 phase compared to parental cells (with the exception of the 
72 hour time point) and also compared to the 5-FU resistant cells. These results 
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suggest, firstly, that HCT116 5-FU resistant cells progress through the cell cycle 
slower than its drug sensitive parental cells. Secondly, the data presented in 
Figure 4.10 suggests that oxaliplatin resistant HCT116 cells proliferate at similar 
or slightly faster rate to HCT116 parental cells and also at a faster rate than 5-FU 
resistant cells. These observations were not reflected by the proliferation data 
presented in Table 4.24 and suggest that there is not a direct association 
between doubling time and cell cycle progression.  However, due to time 
constraints this analysis was only performed once and further studies may shed 
better light on this relationship.  
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Figure 4.10 
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Figure 4.10: The cell cycle kinetics of 5-FU and oxaliplatin resistant HCT116 cells.  Cells were 
seeded at a density of 1x10
6 
 cells per 10 cm diameter plate, harvested at 4 time points over 96 
hours and labelled with Propidium iodide. DNA content was then analysed by flow cytometry to 
determine the percentage of cells in the defined phases of the cell cycle, as described in Section 
2.2.14.1. Experiment was performed once. 
Similarly, Figure 4.11 shows that in DLD-1 cells there was an evident arrest in 
G0/G1 phase in 5-FU resistant cells at 48 and 72 hours. This is reflected in the 
much slower proliferation of DLD-1 5-FU resistant cells (Table 4.24). There was 
also a slight arrest at G1 in oxaliplatin resistant cells.  
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Figure 4.11 
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Figure 4.11: The cell cycle kinetics of 5-FU and oxaliplatin resistant DLD-1 cells.  Cells were 
seeded at a density of 1x10
6
 cells per 10 cm diameter plate, harvested at 4 time points over 96 
hours and labelled with Propidium iodide. DNA content was then analysed by flow cytometry to 
determine the percentage of cells in the defined phases of the cell cycle, as described in Section 
2.2.14.1. Experiment was performed once. 
In collaboration with Professor Julian Blow and colleagues (University of 
Dundee), we next sought to distinguish between cells that were in G0 and 
therefore quiescent and cells that were in G1. This was determined by using flow 
cytometry to determine DNA content and plotting these results against levels of 
chromatin-bound MCM2. MCM2 is a minichromosome maintenance protein 
which plays an essential role in the initiation of eukaryotic DNA replication and 
binds with chromatin (Kearsey & Labib, 1998). MCM proteins are licensing 
factors that allows for DNA replication to be initiated and ensures that DNA is 
replicated only once during the cell cycle (Kearsey & Labib, 1998). Therefore in 
this assay, cells that were in the G1 phase, as determined by analysing DNA 
content, and also had low levels of chromatin-bound MCM2 were considered to 
be in G0 whereas cells showing intermediate or high levels of MCM2 where 
considered to be in G1.  
Figure 4.12 independently suggested that there was a greater proportion of 
HCT116 5-FU resistant cells in G1 (51.3%) compared to HCT116 parental cells 
(48.5%) and HCT116 oxaliplatin resistant cells (47.7%; Figure 4.11). In DLD-1 
cells, there was a marked increase in G1 arrest in 5-FU resistant cells (61%) 
compared to parental (44.5%) and oxaliplatin resistant cells (43.6%), consistent 
with the data presented in Figure 4.11. 
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Figure 4.12: The cell cycle kinetics and MCM2 loading profile of 5-FU and oxaliplatin 
resistant HCT116 and DLD-1 cells. Cells were labelled with Propidium iodide and fluorescently 
tagged MCM2 antibody. DNA content and MCM2 was then analysed by flow cytometry to 
determine the percentage of cells in the defined phases of the cell cycle, as described in Section 
2.2.14.1. Experiment was performed once.  
Figure 4.13 shows that when cells in phase G1 were gated and plotted against 
MCM2 levels, the proportion of MCM2-positive cells in G1 did not significantly 
change between HCT116 parental cells (93.8%) and 5-FU (94.4%) and oxaliplatin 
resistant cells (93.8%; Figure 4.13 A).  The same observation was noted in DLD-1 
parental cells (96.6%) compared to 5-FU (97.9%) and oxaliplatin resistant cells 
(96.6%; Figure 4.13 B). This suggests that the G0/G1 arrest highlighted in HCT116 
and DLD-1 5-FU resistant cells are unlikely to be due to a tendency for the cells 
to enter G0.  
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Figure 4.13: The cell cycle kinetics and MCM2 loading profile of 5-FU and oxaliplatin 
resistant HCT116 and DLD-1 cells. A) HCT116 and B) DLD-1 cells were labelled with Propidium 
iodide and fluorescently tagged MCM2 antibody and then analysed by flow cytometry to 
determine the percentage of cells in the defined phases of the cell cycle, as described in Section 
2.2.14.1. The DNA content of cells in G0/G1 phase was then plotted against MCM2 levels to 
determine the proportion of cells in G0 in comparison to cells in G1.  Experiment was performed 
once. 
It was speculated that the increase in G1 arrest in 5-FU resistant HCT116 and 
DLD-1 cells may therefore be due to a delay in the commitment of cells entering 
late G1. The p21cip21 protein is a cyclin dependent kinase (CDK) inhibitor which 
functions as a cell cycle regulator particularly in the transition from early to mid-
phase G1 to late G1/S phase. It is able to cause cell cycle arrest in response to 
DNA damage or other types of stress if their levels are increased.  
(A) 
(B) 
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Taqman qRT-PCR analysis was performed to assess the expression of CDKN1A, 
the gene that codes p21cip21, in the drug resistant cells compared to their 
respective parental cells. CDKN1A expression was significantly increased (1.68 
fold; p=0.001) in HCT116 5-FU resistant cells compared to HCT116 parental cells. 
There was no significant difference in CDKN1A expression between HCT116 
parental cells and HCT116 oxaliplatin resistant cells (p=0.1; Figure 4.14 A).  This 
increase in p21 is consistent with the cell cycle kinetics showing that HCT116 5-
FU resistant cells spend longer in G1. CDNK1A expression was significantly 
increased in DLD-1 5-FU resistant cells (6.3 fold; p=0.03) compared to parental 
cells and also significantly increased in DLD-1 oxaliplatin resistant cells (28.8 fold; 
p=0.04). Whilst the cell cycle kinetics and CDNK1A expression is consistent in 
DLD-5-FU resistant cells, this is not the case in DLD-1 oxaliplatin resistant cells. 
However, this could be a reflection of DLD-1 harbouring mutant p53 and thus 
not reflecting a normal p53 response to cellular stress whereas HCT116 has WT 
p53.    
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Figure 4.14: The expression of CDKN1A in 5-FU and oxaliplatin resistant cells.  The expression 
of CDKN1A was assessed, relative to the control gene 18S ribosomal RNA, in A) HCT116 5-FU 
resistant, oxaliplatin resistant and parental cells and B) DLD-1 5-FU resistant, oxaliplatin resistant 
and parental cells, as detailed in section 2.2.9.4. Each sample was assessed in triplicate and the 
errors were determined by calculating 2 
(-δCt + sd δCt)
 and 2
(-δCt – sd δCt)
, as detailed in section 2.2.9.5. 
Statistical significance (p ≤ 0.05) was determined by performing independent T-tests. 
4.3.6. The relationship between cancer cell glycolysis and drug resistance  
 
Tables 4.2 - 4.5 show that genes coding for enzymes involved in glycolysis are 
amongst the top 20 differentially over and under-expressed genes in HCT116 
and DLD-1 drug resistant cells. In particular, we show that PGAM1 
(phosphoglycerate mutase) was under-expressed in HCT116 5-FU resistant cells 
(A) 
(B) 
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(11.05-fold), DLD-1 5-FU resistant cells (31.64-fold) and DLD-1 oxaliplatin 
resistant cells (37.84-fold). ALDOA (Aldolase A), another enzyme involved in 
glycolysis, was under-expressed in HCT116 5-FU resistant cells (21.25-fold) and 
DLD-1 5-FU resistant cells (31.6-fold).   
Therefore to explore the effect of acquired drug resistance on cell glycolysis, the 
Seahorse Bioanalyser and XF glycolysis stress test kit was used to investigate the 
extracellular acidification rate (ECAR) in response to glucose in DLD-1 parental 
and drug resistant cells as described Section 2.2.15.  
Following the injection of glucose, the ECAR was increased 5-fold from baseline 
(100%) to 500% in DLD-1 parental cells at the first measurement (44 minutes; 
Figure 4.15). The fold change in ECAR was lower in 5-FU resistant cells (4-fold) 
and oxaliplatin resistant cells (3.5-fold). This suggests that 5-FU and oxaliplatin 
resistant cells lower their glycolytic activity which is consistent with the marked 
under-expression of glycolytic enzymes such as PGAM1 and ALDOA. However 
this is very preliminary data and further studies would be required to better 
understand this relationship.  
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Figure 4.15: The ECAR of DLD-1 parental and drug resistant cells in response to glucose. The 
Seahorse Bioanalyser and XF glycolysis stress test kit was used to compare the ECAR of DLD-1 
parental, 5-FU resistant and oxaliplatin resistant cells in response to 20 µM glucose, as described 
in Section 2.2.15. The blue horizontal line indicates the point at which glucose was injected. 
Experiment was performed once. 
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4.3.7. Signalling pathways affected by 5-FU and oxaliplatin resistance 
 
To investigate the effect of 5-FU and oxaliplatin resistance in HCT116 and DLD-1 
cells on downstream signalling pathways, a PathScan intracellular signalling 
array which detects the phosphorylation or cleavage of 18 well characterised 
signalling molecules was used as described in Section 2.2.13. 
In the HCT116 cell line background, the acquisition of 5-FU and oxaliplatin 
resistance led to a decrease in the phosphorylation of ERK 1/2, p70 S6 kinase, 
and PRAS40 and a decreased cleavage of PARP (Figure 4.16; Figure 4.17). 
HCT116 5-FU resistant cells showed a decrease in the phosphorylation of Stat3 
and S6 (Figure 4.16) whereas in HCT116 oxaliplatin resistant cells, there was a 
decreased phosphorylation of the pro-apoptotic protein Bad and an increased 
phosphorylation of p53 at serine 15 (Figure 4.17).  
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Figure 4.16: Signalling pathways affected by 5-FU resistance in HCT116 cells.  A) The 
PathScan intracellular signalling array and LiCor Odyssey fluorescence imaging system was used 
to assess the effect of 5-FU resistance in HCT116 cells on the phosphorylation or cleavage of 18 
signalling molecules compared to HCT116 parental cells as detailed in Section 2.2.13. Each 
signalling molecule is represented in duplicate. B) The fluorescent signals at wavelength 680/700 
nm as determined by LiCor Image Studio are represented graphically. Experiment was performed 
once and error bars represent the technical replictates.   
(A) 
(B) 
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Figure 4.17 
(A) 
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Figure 4.17: Signalling pathways affected by oxaliplatin resistance in HCT116 cells.  A) The 
PathScan intracellular signalling array and LiCor Odyssey fluorescence imaging system was used 
to assess the effect of oxaliplatin resistance in HCT116 cells on the phosphorylation or cleavage of 
18 signalling molecules compared to HCT116 parental cells as detailed in Section 2.2.13. Each 
signalling molecule is represented in duplicate. B) The fluorescent signals at wavelength 680/700 
nm as determined by LiCor Image Studio are represented graphically. Experiment was performed 
once and error bars represent the technical replictates.  
Interestingly, in the DLD-1 cell line background, 5-FU and oxaliplatin resistance 
affected distinctly different pathways. In response to DLD-1 5-FU resistance 
there was a decrease in the phosphorylation of Stat1 but an increase in the 
phosphorylation of S6 ribosomal protein and PRAS40 (Figure 4.18). In contrast, 
in DLD-1 oxaliplatin resistant cells, there was a decrease in the phosphorylation 
of AMPK, mTOR, HSP27, Bad, PRAS40, p38 and SAPK/JNK and a decreased 
cleavage of caspase 3 (Figure 4.19). 
This suggests that HCT116 and DLD-1 cells develop resistance to 5-FU and 
oxaliplatin by affecting different signalling pathways. Intriguingly, the data 
suggests that in HCT116 cells the development of 5-FU and oxaliplatin may be 
mediated by similar pathways whereas 5-FU and oxaliplatin resistance in DLD-1 
cells may be mediated by very different pathways. This could be part of the 
reason why there was no cross-resistance to 5-FU and oxaliplatin in DLD-1 
oxaliplatin and DLD-1 5-FU resistant cells and vice versa, and why there was 
cross-resistance to 5-FU in HCT116 oxaliplatin resistant cells (Section 4.3.1). Thus 
this analysis identifies potential signalling molecules and pathways that could be 
investigated further using Western blots. 
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Figure 4.18: Signalling pathways affected by 5-FU resistance in DLD-1 cells.  A) The PathScan 
intracellular signalling array and LiCor Odyssey fluorescence imaging system was used to assess 
the effect of 5-FU resistance in DLD-1 cells on the phosphorylation or cleavage of 18 signalling 
molecules compared to DLD-1 parental cells as detailed in Section 2.2.13. Each signalling 
molecule is represented in duplicate. B) The fluorescent signals at wavelength 680/700 nm as 
determined by LiCor Image Studio are represented graphically. Experiment was performed once 
and error bars represent the technical replictates.  
(A) 
(B) 
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Figure 4.19: Signalling pathways affected by oxaliplatin resistance in DLD-1 cells.  A) The 
PathScan intracellular signalling array and LiCor Odyssey fluorescence imaging system was used 
to assess the effect of oxaliplatin resistance in DLD-1 cells on the phosphorylation or cleavage of 
18 signalling molecules compared to DLD-1 parental cells as detailed in Section 2.2.13. Each 
signalling molecule is represented in duplicate. B) The fluorescent signals at wavelength 680/700 
nm as determined by LiCor Image Studio are represented graphically. Experiment was performed 
once and error bars represent the technical replictates.  
(A) 
(B) 
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4.3.8. The effect of drug resistance on drug metabolism genes 
 
Having explored the drug resistance phenotypes predicted from our 
bioinformatics data, we next investigated whether HCT116 and DLD-1 cells 
developed resistance to 5-FU or oxaliplatin by affecting the gene expression of 
5-FU metabolising enzymes and DNA repair proteins.  
The expression of TYMS, TYMP and DPYD was assessed in HCT116 and DLD-1 5-
FU and oxaliplatin resistant cells compared to their respective drug sensitive 
parental cells using Taqman qRT-PCR analysis as described in Section 2.2.9.4. The 
expression of TYMP was significantly increased in HCT116 5-FU resistant (1.4 
fold, p=0.013) and oxaliplatin resistant (2.5 fold, p=0.001) compared to HCT116 
parental cells (Figure 4.20 A). TYMP was not expressed in DLD-1 cells (data not 
shown).  
In HCT116 cells, TYMS expression levels were decreased in 5-FU resistant cells 
(3.4 fold; p=6.4x10-5) and to a lesser extent also decreased in oxaliplatin 
resistant cells (1.5 fold, p=0.0003; Figure 4.20 B). Similarly, TYMS expression was 
significantly decreased in both DLD-1 5FU resistant (5.4 fold; p=1.6x10-5) and 
oxaliplatin resistant (4.2 fold; p=2.6x10-6) cells (Figure 4.20 C). These results 
were unexpected as the overexpression of TYMS and under-expression of TYMP 
has been associated with a 5-FU resistant phenotype in patients (Goto et al, 
2012). DPYD expression was as expected increased in 5-FU resistant HCT116 
cells (1.9 fold, p=0.0027) and in oxaliplatin resistant cells (1.3 fold, p=0.03; Figure 
240 
 
 
 
4.20 D). DPYD was not expressed in DLD-1 cells (data not shown). Further 
protein expression experiments would help to confirm these results.  
 
 
 
 
Figure 4.20 
(B) 
(C) 
(A) 
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Figure 4.20: The expression of 5-FU drug metabolising enzymes in 5-FU and oxaliplatin 
resistant cells. The mRNA expression of A) TYMP in HCT116 5-FU resistant, oxaliplatin resistant 
and parental cells, TYMS in B) HCT116 5-FU resistant, oxaliplatin resistant and parental cells and 
in C) DLD-1 5-FU resistant, oxaliplatin resistant and parental cells and D) DPYD in HCT116 5-FU 
resistant, oxaliplatin resistant and parental cells was assessed, relative to the control gene 18S 
ribosomal RNA, as detailed in Section 2.2.9.4. Each sample was assessed in triplicate and the 
errors were determined by calculating 2 
(-δCt + sd δCt)
 and 2
(-δCt – sd δCt)
, as detailed in Section 2.2.9.5. 
Statistical significance (p≤0.05) was determined by performing independent T-tests. 
The expression of ERCC1 and TOPO1 was also assessed in HCT116 and DLD-1 
drug resistant and parental cells by Taqman qRT-PCR analysis. ERCC1 expression 
was unchanged in HCT116 5-FU resistant cells and increased in oxaliplatin 
resistant cells (2.3 fold; p=0.02; Figure 4.21 A). Similarly, in DLD-1 cells the 
expression of ERCC1 was increased in 5-FU resistant cells (1.4 fold; p=0.002) and 
oxaliplatin resistant cells (2.1 fold. p=0.0006; Figure 4.21 B), consistent with the 
findings of Seetharam et al (2010).  
TOPO1 expression was increased in both HCT116 5-FU and oxaliplatin resistant 
cells compared to their drug sensitive parental cells (Figure 4.21 C). Conversely, 
consistent with our Illumina microarray data analysis (Appendix J, Table J3 and 
(D) 
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J4), TOPO1 expression was decreased in both DLD-1 5-FU and oxaliplatin 
resistant cells compared to their parental cells (Figure 4.21 D). Future work 
would, once again, be directed towards performing Western blots to assess 
relative protein expression of ERCC1 and TOPO1 in the drug resistant cell lines 
compared to their parental cells. 
 
 
  
 
Figure 4.21 
 
(A) 
(B) 
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Figure 4.21: The expression of ERCC1 and TOPO1 in 5-FU and oxaliplatin resistant cells. The 
mRNA expression of in ERCC1 A) HCT116 5-FU resistant, oxaliplatin resistant and parental cells 
and B) DLD-1 5-FU resistant, oxaliplatin resistant and parental cells and TOPO1 in C) HCT116 5-
FU resistant, oxaliplatin resistant and parental cells and D) DLD-1 5-FU resistant, oxaliplatin 
resistant and parental cells was assessed, relative to the control gene 18S ribosomal RNA, as 
detailed in Section 2.2.9.4. Each sample was assessed in triplicate and the errors were 
determined by calculating 2 
(-δCt + sd δCt)
 and 2
(-δCt – sd δCt)
, as detailed in Section 2.2.9.5. Statistical 
significance (p≤0.05) was determined by performing independent T-tests. 
4.3.9. The expression of miR-224 in 5-FU and oxaliplatin resistant cells  
 
Chapter 3 discussed the role of miR-224 in promoting tumorigenesis and 
metastasis in colorectal cancer. I also discussed how miR-224 modulates 5-FU 
(C) 
(D) 
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sensitivity possibly through the regulation of KRAS pathways or by affecting the 
expression of 5-FU metabolising enzymes.  
The present study therefore investigated how acquired 5-FU or oxaliplatin 
resistance would affect miR-224 expression. The expression of miR-224 was 
compared in 5-FU and oxaliplatin resistant HCT116 and DLD-1 cells and their 
respective drug sensitive parental cells.  
MiR-224 was initially eliminated from the analysis presented in Tables 4.16 – 
4.19 as TLDA analysis suggested that the miR-224 had a CT value greater than 35 
in 5-FU and oxaliplatin resistant cell lines whereas miR-224 expression was 
marked as ‘undetermined’ or unexpressed in DLD-1 5-FU and oxaliplatin 
resistant cells.  
Single-probe qRT-PCR Taqman analysis showed that miR-224 expression was 
significantly decreased in HCT116 5-FU resistant (2.9-fold, p=0.001), HCT116 
oxaliplatin resistant cells (2.7-fold, p=0.002) compared to HCT116 parental cells. 
The expression of miR-224 was also significantly decreased in DLD-1 5-FU 
resistant (5.9-fold, p=0.0002) and oxaliplatin resistant cells (6.1-fold, p=0.0002 
Figure 4.22). 
Rossi et al (2007) have previously reported decreased expression of miR-224 in 
HCT116 and HT29 colorectal cancer cells following treatment with 10 µM 5-FU 
for 6 days. MiR-224 expression has also been shown to be decreased in 
methotrexate resistant HT29 cells (Mencia et al, 2011). This suggests that under-
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expression of miR-224 may be involved in stress-response and resistance 
mechanisms to a number of chemotherapeutic drugs.  
 
Figure 4.22: The expression of miR-224 in 5-FU and oxaliplatin resistant cells. The expression 
of miR-224, relative to the control U6, was assessed in HCT116 5-FU and oxaliplatin resistant cells 
compared to HCT116 parental cells and in DLD-1 5-FU and oxaliplatin resistant cells compared to 
DLD-1 parental cells as detailed in Section 2.2.9.2. Each sample was assessed in triplicate and the 
errors were determined by calculating 2 
(-δCt + sd δCt)
 and 2
(-δCt – sd δCt)
, as detailed in Section 2.2.9.5. 
Statistical significance (p≤0.05) was determined by performing independent T-tests. 
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4.4. Discussion 
 
The aim of the present study was to generate 5-FU and oxaliplatin resistant 
colorectal cancer cell lines and to use miRNA and mRNA expression profiling to 
identify 5-FU, oxaliplatin or common drug resistant signatures and predict 
mechanisms of drug resistance.  
In the present study, we have established using MTT cytotoxicity assays that all 
drug resistant cells were resistant to their selection drug. Additionally, we have 
shown that HCT116 oxaliplatin resistant cells were also cross-resistant to 5-FU 
whereas neither DLD-1 drug resistant cell line showed cross-resistance. We also 
show that both 5-FU and oxaliplatin resistant DLD-1 cells were not cross-
resistant to irinotecan. Chemosensitivity to irinotecan in 5-FU and oxaliplatin 
resistant HCT116 cells was not assessed in the present study. However, it is 
interesting that previous studies have shown cross-resistance to irinotecan in 
HCT116 oxaliplatin resistant cells (Gourdier et al, 2002) and HCT116 5-FU 
resistant cells (Boyer et al, 2004).  
HCT116 cells were also more sensitive to 5-FU and oxaliplatin (2 µM 5-FU and 10 
µM oxaliplatin) than DLD-1 cells (10 µM 5-FU and 24 µM oxaliplatin). The two 
cell lines, amongst other factors, differ in their p53 mutation status with DLD-1 
cells harbouring a mutation p53 Ser241Phe mutation compared to WT in HCT116. 
Loss of functional p53 is associated with resistance to both 5-FU and oxaliplatin 
(Violette et al, 2002, Boyer et al, 2004) which could partly explain the higher 
resistance of DLD-1 cells to 5-FU and oxaliplatin.  
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The present study also used mRNA and miRNA profiling to independently predict 
mechanisms of 5-FU and/or oxaliplatin resistance which were then 
experimentally validated in the drug resistant cell lines.  
We firstly identified genes that were specifically differentially expressed in 5-FU 
resistant cells, oxaliplatin resistant cells or that were commonly differentially 
expressed in both 5-FU and oxaliplatin resistant cells and therefore may 
represent a general drug resistance expression signature. Bioinformatics analysis 
of genes differentially under-expressed in each drug resistant cell line compared 
to their respective parental cell line, showed an enrichment of cell cycle 
regulation pathways. Bioinformatics analysis also showed an enrichment of 
pathways involved in cytoskeleton remodelling and immune or inflammatory 
response with differentially over-expressed genes. This was irrespective of 
whether the cells were resistant to 5-FU and oxaliplatin suggesting similar 
resistance mechanisms.  
Previous studies have described a link between chronic inflammation and cancer 
development (Chen et al, 2007). The activation of the transcription factor NF-kB, 
a key event in the inflammatory response, has been reported to lead to the 
production of pro-inflammatory cytokines, chemokines, growth factors, and the 
expression of anti-apoptotic genes, thus giving a survival advantage to cells and 
aiding in their resistance to chemotherapy (Chen et al, 2007). NF-kB has been 
reported to contribute to resistance to 5-FU in gastric and colorectal cancer 
(Camp et al, 2003; Voboril et al, 2006). 
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In the present study, amongst the most abundantly differentially expressed 
genes in all four drug resistant cells compared to their respective parental cells 
were genes that were commonly differentially expressed in both 5-FU and 
oxaliplatin resistant cells. Included were genes coding for cytoskeletal actin and 
tubulin proteins (TUBA1A, TUBA1C, TUBB, ACTB, ACTG1) as well as genes 
involved in glycolysis (PGAM1, ALDOA, TPI1), cell cycle progression (MCM4), 
multidrug resistance (ABCC3), metastasis (ANGPTL4) and steroidogenesis 
(AKR1C3).  
Beta-actin (ACTB) is a highly conserved cytoskeleton structural protein that is 
widely distributed in all eukaryotic cells and plays critical roles in cell migration, 
cell division, embryonic development, wound healing, immune response and 
gene expression (Guo et al, 2013). In colorectal cancer, ACTB expression has 
been shown to be increased in colorectal cancers compared to matched normal 
mucosa and a role for ACTB in promoting cell motility, invasiveness and 
metastasis has been suggested (Guo et al, 2013). Tubulin beta chain protein 
(TUBB), which is one of the tubulin proteins that make up microtubules, has also 
been shown to be differentially over-expressed in colorectal cancers compared 
to normal mucosa (Yang et al, 2012a). The cytoskeleton proteins, though 
prominently decreased in 5-FU and oxaliplatin resistant cells in the present 
study, have not been previously associated with a role in conferring drug 
resistance.  
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Assessing the expression of EMT genes did not show what would have been 
expected if the cells were actively undergoing EMT. Furthermore, a decrease in 
the expression of actin and tubulin proteins also indicates less cell motility. 
Therefore, the invasive phenotype that was observed in oxaliplatin resistant cells 
could occur through another mechanism such as the overexpression of 
Angiopoetin-like protein 4 (ANGPTL4).  
 
ANGPTL4 is a glycosylated, secreted protein that functions as a serum hormone 
that regulates glucose homeostasis, lipid metabolism, and insulin sensitivity. It 
has also been shown to be involved with promoting an invasive phenotype in 
colorectal cancer cells (Nakayama et al, 2011; Huang et al, 2012b). This could 
possibly be through the disruption of adhesion molecules in the vasculature, as 
suggested earlier by Huang et al (2011) who showed that ANGPTL4 contributed 
to metastasis in lung cancer by disrupting VE-cadherin and claudin-5. However, 
it has not been previously linked to having a role in 5-FU or oxaliplatin resistance 
in cancer. 
 
MCM4 is a licensing factor protein that is involved in the initiation and 
regulation of the cell cycle. An increased expression of MCM4 is shown to 
increase cell proliferation (Kikuchi et al, 2010) and MCM4 has also been found to 
be increased in a number of cancers including colorectal cancer (Fijneman et al, 
2012). We show that MCM4 is prominently decreased in 5-FU and oxaliplatin 
resistant cells. This decrease is consistent with the cell cycle arrest and lower 
proliferation observed in the cells, particularly in the DLD-1 5-FU resistant cells.  
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The glycolytic enzyme Aldolase A (ALDOA), catalyses the breakdown of fructose 
1,6-bisphosphate to glyceraldehyde 3-phosphate in one of the many steps of 
glycolysis. Increased ALDOA expression has previously been associated with an 
aggressive phenotype in hepatocellular carcinoma (Hamaguchi et al, 2008) and 
breast cancer (Migneco et al, 2010). ALDOA has not been previously suggested 
to be linked with 5-FU or oxaliplatin resistance. 
Phosphoglycerate mutase 1 (PGAM1) is also a glycolytic enzyme and catalyses 
the conversion of 3-phosphoglycerate (3PG) to 2-phosphoglycerate (2PG), 
downstream in the glycolytic pathway to ALDOA. Similarly to ALDOA, PGAM1 
expression is increased in a number of cancers including hepatocellular 
carcinoma (Ren et al, 2010) and glioma (Gao et al, 2013). Moreover, Chen et al 
(2014) recently reported PGAM1 to be decreased in methotrexate resistant 
breast cancer cells.  
The decrease in ALDOA and PGAM1 expression is therefore consistent with our 
preliminary data suggesting that DLD-1 5-FU and oxaliplatin resistant cells had 
lower glycolytic activity than DLD-1 parental cells. An increase in glycolysis is 
commonly seen in cancer, as they try to support their rapid growth, sometimes 
in hypoxic conditions, by switching from aerobic to anaerobic glycolysis in a 
phenomenon known as the Warburg effect (Vander Heiden et al, 2009). 
However, decreased expression of these genes in drug resistance cell lines could 
be a consequence of the decrease in proliferation.     
We also showed that AKR1C3, an enzyme involved in steroidogenesis and the 
control of growth and differentiation, is increased 5-FU and oxaliplatin 
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resistance. It has previously been found to be enhanced in cisplatin resistance in 
colorectal cancer cells (Matsunga et al, 2013). Additionally, the ATP-cassette 
drug transporter, ABCC3 is reported to be involved in multi-drug resistance. It 
has been shown to be increased in doxorubicin-resistant breast cancer cells (Liu 
et al, 2005), 5-FU resistant pancreatic cancer cells and adriamycin resistant HCC 
cells (Wang et al, 2010b).  
The PathScan signalling array suggested that in HCT116 5-FU and oxaliplatin 
resistant lines there was a reduction in ERK 1/2  phosphorylation which may 
indicate a less active RAS/MAPK pathway and reduced proliferation as has been 
demonstrated in HCT116 oxaliplatin resistant cells. Future experiments 
measuring GTP-bound activated KRAS in drug resistant cells compared to 
parental cells, as described in Section 2.2.12, could test this hypothesis. There 
was also a significant decrease in the activation of p70 S6 kinase. P70 S6 kinase is 
one of the downstream targets of the MAPK pathway and causes the 
phosphorylation of the ribosomal protein S6 allowing for protein synthesis to 
occur at this site and promotes cell growth (Harada et al, 2001). This also 
suggests that a major mechanism in the resistance 5-FU and oxaliplatin is 
through slowing cell cycle progression.  
The present study also identified a miRNA signature of acquired drug resistance 
in colorectal cancer cell lines. Previous studies had investigated the acute effect 
of 5-FU and oxaliplatin treatment on miRNA expression (Rossi et al, 2007; Zhou 
et al, 2010) creating a possible acute drug response signature that may 
contribute to the pharmacodynamics of the drug.  
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To date, only three other studies have performed miRNA profiling in 5-FU or 
oxaliplatin resistant colorectal cancer cells. Consistent with the present study, 
Akao et al (2011) and Kurokawa et al (2012) associate 5-FU resistance with the 
increased differential expression of miR-92 and miR-19b respectively. 
Furthermore miR-20a, the most abundantly overexpressed miRNA in 5-FU 
resistant DLD-1 cells in the present study, has previously been shown to 
contribute to 5-FU resistance by targeting BCL2/adenovirus E1B 19 kDa protein-
interacting protein 2 (BNIP2) in SW480 and SW620 colorectal cancer cells (Chai 
et al, 2011).  
In a recent study, Zhou et al (2014) generated oxaliplatin resistant cells in 
HCT116, RKO and HT29 colorectal cancer cell backgrounds. The differentially 
expressed miRNAs in their HCT116 oxaliplatin resistant cells did not match 
miRNAs differentially expressed in the HCT116 oxaliplatin resistant cells 
generated in the present study. However, Zhou et al (2014) show that 
differential expression of miRNAs such as miR-31, miR-200a and miR-93 was 
associated with an oxaliplatin resistance phenotype, consistent with some of the 
differentially expressed miRNAs expressed in our DLD-1 oxaliplatin resistant 
cells. 
Having identified potential mRNA and miRNA expression signatures of drug 
resistance, it is important to understand how miRNAs may mediate the drug 
resistant phenotypes that have been predicted from bioinformatics analysis and 
experimentally validated.  
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The miR-200 family and miR-31, which were differently expressed in the present 
study, have recently been shown to regulate cytoskeleton remodelling and cell 
invasion through the targeting of WAVE3, an actin remodelling protein, in a 
number of cancers (Sossey-Alaoui et al, 2009; Sossey-Alaoui et al, 2011). 
Moreover, miR-93, which was over-expressed in DLD-1 5-FU and oxaliplatin 
resistant cells in the present study, has been reported to target p21 and cause 
G2 arrest in colorectal cancer cells (Yang et al, 2012b).  
Using the online bioinformatics tool TargetScan                             
(http://www.targetscan.org/vert_61/) to predict which of our differentially 
expressed miRNAs may target the 3’UTR of some of genes mentioned above, 
may allow us to understand the role of miRNAs in mediating drug resistance 
mechanisms. Table 4.25 show examples of possible inverse relationships 
between drug resistance genes and miRNAs.  
Table 4.25: The inverse relationship between candidate drug resistance genes 
and miRNAs as predicted by TargetScan 
Differentially expressed gene  Differentially expressed miRNAs predicted to target 
gene 
ABCC3   ↓ miR-197 
MCM4  ↑ miR-24, miR-17, miR-20a, miR-93, miR-106a,  
     miR-186 
ACTG1 ↑ miR-186, miR-10a 
ACTB ↑ miR-31, miR-19b 
TUBA1A ↑ miR-221, miR-222, miR-15b, miR-16 
PGAM1 ↑ miR-92, miR-200a, miR-494 
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The overexpression of miR-20a in DLD-1 5-FU resistant cells may contribute to 
resistance, in part, through the down-regulation of the cell cycle regulator, 
MCM4.  In another example, the over-expression of miR-494 in HCT116 and 
DLD-1 5-FU resistant cells may also contribute to resistance through the down-
regulation of the glycolytic enzyme PGAM1. However, as discussed previously 
miRNAs have many targets due to imperfect complementarity that could in 
theory have opposing effects on a particular pathway or process. Therefore the 
prominent over or under-expression of mRNA genes may be more informative in 
how they would mediate drug resistance. However, miRNAs have the potential 
to be very useful as markers of drug resistance in colorectal cancer. A recent 
study by Kjersem et al (2014), for example, shows that the increased expression 
of miR-106a, miR-484 and 130b in the plasma of colorectal cancer patients, is 
associated with patients described as non-responders to 5-FU and oxaliplatin-
based therapy.  
The present study also showed that miR-224 expression was decreased in 5-FU 
and oxaliplatin resistant cells in both cell line backgrounds compared to their 
respective parental cells. As discussed in Chapter 3, we show that the increased 
expression of miR-224 is an early and persistent feature of colorectal cancer 
development. MiR-224 may also modulate 5-FU chemosensitivity through the 
regulation of KRAS pathways and by indirectly affecting the expression of 5-FU 
metabolising enzymes. 
In the drug resistant cell model, the cells have adapted and developed resistance 
to 5-FU and oxaliplatin partly through decreased expression of miR-224. MiR-
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224 has been experimentally validated to target the genes coding for p21 and 
p27, therefore, in theory, the decrease in miR-224 expression would lead to an 
increase in p21cip1 and p27kip1 and thus cell cycle arrest. However, there are 
many other factors that affect the expression of p21cip1 and p27kip1 and this 
relationship would need to be experimentally validated.  
4.5. Conclusions and future work 
4.5.1. Conclusions 
We have successfully created 5-FU and oxaliplatin resistant cells in HCT116 and 
DLD-1 colorectal backgrounds. We have also identified 5-FU and oxaliplatin 
mRNA and miRNA expression signatures that independently predict resistance 
mechanisms involving cell cycle progression, glycolysis, cytoskeleton remodelling 
and invasion. We also suggest, from a miRNA target prediction database, that 
miRNAs differentially expressed in the present study may mediate the 
aforementioned resistance mechanisms through targeting key genes highlighted 
in our study as having key roles in the development of drug resistance.  
4.5.2. Future work 
 
In further studies, it will be important to validate the expression of our 
candidate genes and miRNAs in paired drug sensitive and drug resistant cell 
lines. Our work would also progress through experimentally validating which of 
our candidate miRNAs, if any, may directly target the 3’UTR of one or more of 
our proposed candidate genes.  
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Ultimately, our aim is to investigate whether differential expression of our 
candidate mRNAs or miRNAs is associated with drug resistance in colorectal 
cancer patients. Professor Alastair Munro and colleagues have identified a 
cohort of over 200 colorectal cancer patients who have received 5-FU-based 
therapy. Future work would also be directed towards correlating some 
candidate drug resistance miRNAs (including miR-224) and genes with prognosis 
and treatment response in colorectal cancer patient samples.   
 
 
 
 
 
 
 
 
 
 
 
 
 
257 
 
 
 
 
 
 
 
Chapter 5 
5. The role of microRNAs in radiation 
response 
 
 
 
 
 
 
 
258 
 
 
 
5.1. Introduction 
5.1.1. Cellular response to radiation treatment 
 
The aim of radiation treatment is to eradicate or to reduce the size of cancers. 
Ionising radiation damages cancer cells through the production of free radicals, 
in particular the hydroxyl radical (OH∙), which causes injury to cellular 
components including DNA (Hu & Gatti, 2010). DNA damage, and in particular 
double-stranded breaks (DSB), are considered to be the most detrimental to cell 
survival. Cells respond to this kind of injury by activating the ATM pathway, 
eventually causing cell cycle arrest and allowing for DSB repair though non-
homologous end joining (NHEJ) during the G0/G1 phase of the cell cycle or by 
homologous recombination during the S/G2 phase (Hu & Gatti, 2010). However, 
should radiation dose and cellular damage be too high, cancer cells undergo cell 
death by apoptosis or mitotic catastrophe hence the reduction of cancer mass 
(Figure 5.1; Hu & Gatti, 2010).  
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Figure 5.1:  The cellular response to radiation. Radiation targets and causes injury to a 
number of cellular components including DNA. This leads to cell cycle arrest and DNA damage 
repair. However it may also lead it cell death through a number of mechanisms (Sanders, 2011). 
Radiation resistance remains a challenge to radiation treatment in many 
cancers, including rectal cancer. Factors including intrinsic radiation resistance, 
increased cancer cell proliferation, hypoxia and enhanced DNA damage repair 
have been suggested to contribute to radiation resistance (Pajonk et al, 2010).  A 
number of pathways that regulate the cell cycle, proliferation and apoptosis 
have also been shown to be induced in response to radiation and to also have a 
role in radiation resistance (Dent et al, 2003).   
Studies have shown that radiation exposure can lead to the activation of the ERK 
pathway through the activation of EGFR (Schmidt-Ullrich et al, 1997; Kavanagh 
et al, 1998). It was reported that radiation doses of 1-2 Gy led to the same level 
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of activation as with physiological growth factors such as EGF at a concentration 
of approximately 0.1 nM (Dent et al, 1999). The activation of the ERK pathway 
and the subsequent activation of PI3K/Akt pathways following radiation have 
thus been linked to the ability of cells to proliferate and survive despite 
irradiation.   
The present study has previously highlighted the importance of KRAS mutation 
status in colorectal cancer patients. KRAS mutant patients have significantly 
reduced survival and higher resistance to cetuximab than KRAS WT patients 
(Andreyev et al, 1998; Andreyev et al, 2001; Conlin et al, 2005; Lievre et al, 2006; 
Bokemeyer et al, 2008; Amado et al, 2008). Many studies have also shown a role 
for activated or mutant KRAS signalling in radiation resistance.  
5.1.2. KRAS-mediated radiation resistance  
 
The observation that activated RAS mediates radiation resistance is well 
established and was first described in NIH3T3 mouse fibroblast cells (Fitzgerald, 
1985; Sklar, 1988). McKenna et al (1990) subsequently showed in primary rat 
cells that activated HRAS transformation induced radiation resistance. However, 
they also showed that the v-myc oncogene, which had no effect on radiation 
resistance itself, was required for a synergistic induction of radiation resistance 
by HRAS. 
The blockage of post-translational farnesylation of HRAS, and thus HRAS 
processing, by the farnesylation inhibitor FTI-277 resulted in increased apoptosis 
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following irradiation and increased radio-sensitivity in HRAS-transformed rat 
embryos (Bernhard et al, 1996).  
In human cancer cell lines, both the presence of an activated NRAS allele and re-
introduction of an activated NRAS allele after loss were shown to increase 
clonogenic survival and radiation resistance in HT1080 fibrosarcoma cells 
(Bernhard et al, 2000). Bernhard et al (2000) also showed that the presence of a 
KRAS mutant allele contributed to radiation resistance in DLD-1 colorectal 
cancer cells.  
Gupta et al (2001) reported that the inhibition of the PI3K pathway by the 
inhibitor LY294002 selectively sensitised RAS-mutant cells, whilst having no 
effect on WT cells. Furthermore the induction of the PI3K pathway in RAS-WT 
cells increased radio-resistance which was subsequently reversed following 
treatment with LY294002. Additionally, Grana et al (2002) suggested that RAS-
mediated radio-resistance in rat intestinal epithelial cells was PI3K/Akt and RAF-
1 dependent but MEK independent, as the blockage of MEK using the inhibitor 
UO126 resulted in no change in survival, as determined by clonogenic survival 
assays, following irradiation.  
Despite these advances in knowledge, the molecular mechanisms governing 
response to radiation is poorly understood and there remains a great need to 
identify ways to manipulate these pathways for greater irradiation efficacy. 
MiRNAs, as described previously, are additional regulators of gene expression. 
Several miRNAs, with roles in controlling cell proliferation, cell cycle, apoptosis 
and DNA damage repair pathways, have been shown to be differentially 
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expressed in a number of cancer cell lines following irradiation (Metheetrairut & 
Slack, 2013). In particular, members of the let-7 family, which target KRAS, have 
been shown to be differentially over-expressed in response to radiation in 
glioblastomas (Chaudhry et al, 2010) but under-expressed in lung cancer 
(Weidhass et al, 2007). Saleh et al (2011) also showed that the expression of let-
7a and let-7b was decreased in HCT116 colorectal cancer cells after irradiation, 
and suggested that this was p53-dependent, as determined using HCT116 
p53(+/+) and p53-null cells. This shows that differential let-7 expression after 
radiation could be cancer cell-type and genotype dependent.  
Increased expression of let-7g was reported to be associated with a radio-
sensitive phenotype in non-small cell lung carcinoma cells (Jeong et al, 2009). 
The study also showed that LIN28, a posttranscriptional repressor of let-7 
biogenesis, increased KRAS expression through the repression of let-7g. The 
findings from Jeong et al (2009) suggest that post-transcriptional activation of 
KRAS may also regulate response to radiotherapy. Similarly, Oh et al (2010) 
found that the silencing of LIN28 led to the up-regulation of let-7a, a decrease in 
KRAS expression and thus KRAS signalling. This lead to radio-sensitisation in lung 
and pancreatic cancer cells, an effect that was not seen in KRAS WT SQ20B head 
and neck carcinoma cells or normal fibroblast cells.  
A recent study by Luu et al (2013) also showed in HCT116 cells that functional 
p53 was required for let-7-dependent repression of KRAS activity and 
sensitisation to chemo-radiotherapy (3 µM 5-FU and 2 Gy radiation). The cells 
subsequently became resistant to therapy when let-7 expression was inhibited.  
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The studies by Jeong et al (2009), Oh et al (2010) and Luu et al (2013) thus 
strengthen the notion that increased KRAS signalling through increased KRAS 
expression or the presence of mutant KRAS increases radiation resistance. They 
also suggest that manipulating the expression of miRNAs that target KRAS and 
its downstream targets provides an additional method of overcoming KRAS-
mediated radiation resistance. To date however, miRNA expression profiling has 
not been performed on isogenic KRAS WT and mutant colorectal cancer cells 
following irradiation. This would aid in the understanding of the role of miRNAs 
in KRAS-mediated radiation resistance.  
5.1.3. Aims and objectives 
 
The aims of the present study were firstly to identify miRNAs that were 
differentially expressed in colorectal cancer cell lines in response to radiation, 
and predict pathways and processes that they may regulate. Secondly, the study 
aimed to explore how the radiation response miRNA signature changed with 
KRAS mutation status. Thirdly, the present study aimed to identify miRNAs that 
may modulate radiation response in a KRAS-dependent manner.  
 
 
 
 
 
264 
 
 
 
5.3. Results 
5.3.1. Laboratory cell irradiator 
 
The present study used a laboratory irradiator to investigate the role of miRNAs 
in modulating response to radiotherapy in colorectal cancer cell lines, as 
described in Section 2.2.16. The laboratory irradiator was previously used by Dr 
Ian Sanders and Professor Alastair Munro (University of Dundee) as an in vitro 
simulation of rectal intraoperative radiotherapy (IORT) to identify biological 
markers of IORT response. 
Sanders (2011) showed that the expression of 3 proteins involved in the DNA 
double-strand break repair pathway, phosphorylated H2AX, ATM and p53 (serine 
15), were induced and detected by Western blotting 5 minutes after 5 Gy of 
radiation in a number of colorectal cancer cell lines. Sanders (2011) cites a study 
by Vaidya et al (2010) as being representative of the breast cancer IORT protocol 
used in the Targit trial and therefore was the basis of why 5 Gy of irradiation was 
used throughout his study. Based on this, the present study therefore irradiated 
HCT116 colorectal cancer cells at a dose of 5 Gy of radiation and confirmed that 
γH2AX was induced, after 5 minutes incubation, in treated cells compared to 
non-treated control cells (Figure 5.2). 
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Figure 5.2: The induction of gamma (γ-) H2AX in response to 5 Gy of radiation in HCT116 
colorectal cancer cells. HCT116 cells were irradiated in duplicate with 5 Gy of radiation using a 
laboratory in vitro cell irradiator, as described in Section 2.2.16. A Western blot was performed to 
quantify the protein expression of γH2AX in irradiated treated cells in comparison to untreated 
control cells. Actin was used as the loading control. 
5.3.2. Optimisation of maximum microRNA induction or inhibition time 
following radiation treatment  
 
To understand the role of miRNAs in the biological response to radiation in 
colorectal cancer, TLDA miRNA cards were used to identify miRNAs that were 
differentially expressed in response to 5 Gy of radiation as described in Section 
2.2.16.1. Whereas only 5 minutes was required for the induction of proteins 
such as γH2AX, it was speculated that the time required for optimum miRNA 
induction or inhibition may be considerably longer.   
Taqman qRT-PCR analysis was therefore used to assess the expression of miR-
24, miR-100 and miR-125b, which have previously been shown to be induced or 
decreased in response to radiation (Hu & Gatti, 2011), at 10, 30, 60 and 180 
minutes after treatment. From 10 minutes to 60 minutes, miR-24, miR-100 and 
miR-125 showed a time dependent decrease in expression followed by an 
increase in expression after 180 minutes. Expression levels for all three miRNAs 
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were at their lowest at 60 minutes. MiR-24 expression was significantly 
decreased 2.1-fold (p=0.0007) 60 minutes after irradiation. The expression of 
miR-100 and miR-125b were also decreased 5.4-fold (p=5.8x10-7) and 2.8-fold 
(p=1.6x10-5) respectively 60 minutes after irradiation (Figure 5.3). Thus for the 
following experiments with TLDA miRNA cards, cells were placed in an incubator 
for 60 minutes after radiation treatment before RNA was extracted for further 
analysis.   
 
 
 
Figure 5.3 
 
(A) 
(B) 
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Figure 5.3: The expression of miR-24, miR-100 and miR-125b at different time points 
following irradiation. The expression of A) miR-24, B) miR-100 and C) miR-125b, relative to the 
control U6, was assessed, as described in Section 2.2.9.2, 10, 30, 60 and 180 minutes after 
treatment of HCT116 cells with 5 Gy of radiation as described in Section 2.2.16. Data is 
represented as the fold change in relative expression in treated cells compared to non-treated 
control cells. Each sample was assessed in triplicate and the errors represent the SEM. Statistical 
significance (p≤0.05) was determined by performing Independent T-tests. 
5.3.3. MicroRNA profiling of irradiated isogenic KRAS mutant and WT cells  
 
Next, TLDA miRNA profiling was used to explore how differential miRNA 
expression following irradiation changed depending on KRAS mutation status. 
Following irradiation, 16 miRNAs were differentially expressed (14 up, 2 down) 
in treated cells compared to untreated HCT116 KRAS mutant cells. MiR-15b and 
let-7a were the most abundantly over and under-expressed miRNAs respectively 
in HCT116 KRAS mutant cells following treatment (Table 5.1).   
 
(C) 
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Table 5.1: MicroRNAs differentially expressed in irradiated HCT116 KRAS mutant 
cells compared to non-treated control cells 
microRNA Fold Change 
Adjusted 
value 
miR-15b 3.45 0.021 
miR-454 2.69 0.043 
let-7d 2.67 0.009 
miR-29a 2.62 0.006 
miR-886-3p 2.52 0.006 
miR-100 2.15 0.014 
miR-93 2.14 0.017 
miR-221 2.01 0.008 
miR-886-5p 1.99 0.022 
miR-30b 1.94 0.033 
miR-30c 1.87 0.009 
miR-17 1.84 0.004 
miR-16 1.80 0.026 
miR-200b 1.72 0.046 
miR-197 -1.82 0.008 
let-7a -3.06 0.008 
 
The miRNAs in bold were induced in both KRAS mutant and KRAS WT HCT116 cells in response to 
radiation 
As previously described in Section 2.2.17, the bioinformatic tool, Metacore was 
used to identify pathways and processes predicted to be enriched and 
significantly associated with the predicted targets of the miRNAs listed in Table 
5.1.  
Cancer related pathways and processes involved in cytoskeleton remodelling, 
development of EMT, cell adhesion and the immune response were prominently 
enriched (Table 5.2).  
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Table 5.2: Pathways and processes associated with the predicted targets of 
miRNAs differentially expressed in HCT116 KRAS mutant cells after irradiation 
 
Pathway name p value Ratio 
1 Cytoskeleton remodeling_TGF, WNT and cytoskeletal remodeling 2.00E-24 90/111 
2 Cytoskeleton remodeling_Cytoskeleton remodelling 2.67E-19 79/102 
3 
Development_Regulation of epithelial-to-mesenchymal transition 
(EMT) 1.13E-17 55/64 
4 Cell adhesion_Chemokines and adhesion 3.16E-16 74/100 
5 Cardiac Hypertrophy_NF-AT signaling in Cardiac Hypertrophy 4.90E-16 54/65 
6 
Normal and pathological TGF-beta-mediated regulation of cell 
proliferation 2.31E-14 32/33 
7 Development_TGF-beta receptor signalling 4.22E-14 43/50 
8 Development_TGF-beta-dependent induction of EMT via MAPK  5.93E-14 41/47 
9 Cell cycle_Regulation of G1/S transition (part 1) 1.03E-13 35/38 
10 Immune response_HSP60 and HSP70/ TLR signaling pathway 1.15E-13 45/54 
 
 
Process name p value Ratio 
1 Development_Neurogenesis_Synaptogenesis 2.26E-13 150/180 
2 Signal transduction_WNT signalling 2.45E-12 146/177 
3 Signal transduction_NOTCH signalling 2.38E-11 185/236 
4 Cytoskeleton_Regulation of cytoskeleton rearrangement 3.49E-11 148/183 
5 Cell adhesion_Synaptic contact 1.86E-09 145/184 
6 Development_Ossification and bone remodelling 2.66E-09 126/157 
7 
Development_EMT_Regulation of epithelial-to-
mesenchymal transition 4.27E-09 172/225 
8 Cytoskeleton_Actin filaments 8.48E-09 138/176 
9 Development_Hedgehog signalling 1.37E-08 190/254 
10 Cell adhesion_Cadherins 1.73E-08 140/180 
 
Similarly, HCT116 KRAS WT cells were treated with 5 Gy of radiation. Following 
treatment, 11 miRNAs were differentially expressed in treated cells compared to 
untreated HCT116 KRAS WT cells. All 11 miRNAs were significantly 
overexpressed in response to treatment, with miR-20a the most abundantly 
over-expressed miRNA (Table 5.3).  
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Table 5.3: MicroRNAs differentially expressed in irradiated HCT116 KRAS WT 
cells compared to its non-treated control 
microRNA Fold Change 
Adjusted 
p value 
miR-20a 4.43 0.010 
miR-19b 3.08 0.029 
miR-29a 2.38 0.019 
miR-126 2.35 0.008 
miR-200b 2.11 0.008 
miR-16 2.03 0.020 
miR-100 1.99 0.047 
miR-17 1.81 0.037 
miR-221 1.80 0.016 
miR-886-3p 1.76 0.038 
miR-125b 1.72 0.033 
 
The miRNAs in bold were induced in both KRAS mutant and KRAS WT HCT116 cells in response to 
radiation 
Metacore bioinformatics analysis also suggested that pathways and processes 
predicted to be enriched by the predicted targets of the miRNAs listed in Table 
5.3 included those involved in cytoskeleton remodelling, cell adhesion, EMT and 
an immune response. This suggests that HCT116 KRAS WT and KRAS mutant cells 
respond to the stress induced by radiation by activating similar pathways and by 
mediating similar phenotypes.  
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Table 5.4: Pathways and processes associated with the predicted targets of 
miRNAs differentially expressed in HCT116 KRAS WT cells after irradiation 
 
Pathway name p value Ratio 
1 Cytoskeleton remodeling_TGF, WNT and cytoskeletal remodeling 2.69E-25 98/111 
2 Cytoskeleton remodeling_Cytoskeleton remodelling 2.86E-22 89/102 
3 Development_TGF-beta-dependent induction of EMT via MAPK  4.25E-17 46/47 
4 Transport_Clathrin-coated vesicle cycle 6.32E-17 63/71 
5 Development_TGF-beta receptor signaling 2.61E-15 47/50 
6 
Development_Regulation of epithelial-to-mesenchymal transition 
(EMT) 1.42E-14 56/64 
7 Immune response_HSP60 and HSP70/ TLR signaling pathway 2.53E-14 49/54 
8 Cell adhesion_Chemokines and adhesion 4.57E-14 78/100 
9 Cardiac Hypertrophy_NF-AT signaling in Cardiac Hypertrophy 6.17E-14 56/65 
10 Immune response_IL-2 activation and signaling pathway 1.02E-13 45/49 
 
 
Process name p value Ratio 
1 Development_Neurogenesis_Synaptogenesis 1.26E-14 167/180 
2 Signal transduction_NOTCH signaling 7.08E-11 206/236 
3 Development_Neurogenesis_Axonal guidance 9.53E-11 201/230 
4 Cell adhesion_Cadherins 1.52E-09 159/180 
5 Cytoskeleton_Regulation of cytoskeleton rearrangement 2.37E-08 159/183 
6 Signal transduction_WNT signalling 3.20E-08 154/177 
7 Transcription_mRNA processing 6.15E-08 140/160 
8 Cytoskeleton_Actin filaments 1.18E-07 152/176 
9 Cell adhesion_Attractive and repulsive receptors 1.48E-07 151/175 
10 Cytoskeleton_Cytoplasmic microtubules 2.49E-07 103/115 
 
Despite the similarities, the bioinformatics analysis does not indicate the extent 
to which the two cell lines respond to ionising radiation. Seven miRNAs, miR-16, 
miR-17, miR-29a, miR-100, miR-200b, miR-221 and miR-886-3p, were similarly 
overexpressed in both cell lines in response to radiation, suggesting that they 
may represent a common stress response signature to radiation. Although not in 
colorectal cancer cells, the expression of miR-100 (Simone et al, 2009; Mueller et 
al, 2013), miR-17 (Weidhass et al, 2007; Chaudrey et al, 2010; John-Aryankalayil 
272 
 
 
 
et al, 2012) and miR-16 (Wagner-Ecker et al, 2010; Chaudrey et al, 2010) have 
previously been reported to be altered in response to radiation. MiR-221 was 
also shown to affect radiation resistance in gastric cancer (Chun-Zhi et al, 2010). 
The differential expression of miR-29a, miR-200b and miR-886-3p in response to 
irradiation has not been previously reported.  
We then compared irradiated HCT116 KRAS mutant cells to irradiated HCT116 
KRAS WT cells. This analysis allowed for identification of miRNAs that may 
mediate a KRAS pathway-dependent response to radiation. All 22 miRNAs were 
significantly over-expressed in KRAS mutant cells compared to KRAS WT HCT116 
cells, with miR-328 the most abundantly overexpressed miRNA (Table 5.5). The 
list includes 3 of the miRNAs (miR-17, miR-29a and miR-100) that were 
commonly differentially expressed in KRAS WT and mutant cells compared to 
their respective non-treated controls. Interestingly, the list also includes two 
members of the let-7 family (let-7e and let-7g). However, in contrast to 
previously discussed studies in lung cancer cells (Jeong et al, 2009; Oh et al, 
2010), increased expression of let-7e and let-7g appear to be associated with a 
mutant KRAS signalling and therefore possibly KRAS-dependent radiation 
resistance. The list also comprises miR-30c which has been experimentally 
validated to target KRAS in breast cancer (Tanic et al, 2012).  
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Table 5.5: MicroRNAs differentially expressed in irradiated HCT116 KRAS mutant 
cells compared to irradiated KRAS WT wells.  
microRNA Fold Change 
Adjusted         
p value 
miR-328 5.58 0.004 
miR-197 3.32 0.005 
miR-20a 3.21 0.014 
miR-186 3.15 0.003 
miR-126 2.90 0.001 
miR-574-3p 2.87 0.005 
miR-532-3p 2.74 0.009 
let-7e 2.66 0.003 
miR-29a 2.43 0.013 
miR-92a 2.34 0.008 
miR-320 2.29 0.001 
miR-191 2.17 0.001 
miR-149 2.13 0.010 
let-7g 2.10 0.018 
miR-145 1.85 0.008 
miR-100 1.78 0.041 
miR-19b 1.73 0.048 
miR-106a 1.70 0.035 
miR-30c 1.64 0.022 
miR-17 1.60 0.011 
miR-342-3p 1.42 0.049 
miR-200c 1.38 0.025 
 
Increased miRNA expression in irradiated KRAS mutant cells compared to 
irradiated KRAS WT cells therefore leads to the question of whether reducing 
the expression of miR-328 or any of the miRNAs listed in Table 5.5 would have a 
role in sensitising HCT116 KRAS mutant cells to radiation through regulating 
KRAS expression and signalling. 
Once again, bioinformatics analysis of the predicted targets of the miRNAs listed 
in Table 5.5 suggested associations with pathways and processes involved with 
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cytoskeleton remodelling, the immune response, cell adhesion, EMT and cell 
cycle regulation (Table 5.6).  
Table 5.6: Pathways and processes associated with the predicted targets of 
miRNAs differentially expressed in irradiated HCT116 KRAS mutant cells 
compared to irradiated KRAS WT cells 
 
Pathway name p value Ratio 
1 Cytoskeleton remodeling_TGF, WNT and cytoskeletal remodeling 1.46E-21 93/111 
2 
Development_Regulation of epithelial-to-mesenchymal 
transition (EMT) 1.55E-18 59/64 
3 Immune response_HSP60 and HSP70/ TLR signaling pathway 2.24E-17 51/54 
4 Cytoskeleton remodeling_Cytoskeleton remodelling 3.26E-16 81/102 
5 
Neurophysiological process_Receptor-mediated axon growth 
repulsion 2.40E-15 43/45 
6 Immune response_IL-1 signaling pathway 5.77E-15 42/44 
7 Cell adhesion_Chemokines and adhesion 7.34E-15 78/100 
8 Transport_Clathrin-coated vesicle cycle 1.07E-14 60/71 
9 Cardiac Hypertrophy_NF-AT signaling in Cardiac Hypertrophy 1.27E-13 55/65 
10 Development_WNT signaling pathway. Part 2 2.00E-12 46/53 
 
 
Process name p value Ratio 
1 Signal transduction_WNT signalling 5.95E-10 155/177 
2 Signal transduction_NOTCH signalling 1.26E-09 200/236 
3 Development_Neurogenesis_Synaptogenesis 2.96E-09 156/180 
4 Cell adhesion_Cadherins 9.17E-09 155/180 
5 Cell cycle_G1-S Interleukin regulation 1.29E-08 114/128 
6 Cell cycle_G1-S Growth factor regulation 1.69E-08 166/195 
7 Cell adhesion_Attractive and repulsive receptors 3.17E-08 150/175 
8 
Development_EMT_Regulation of epithelial-to-
mesenchymal transition 4.05E-08 188/225 
9 Transcription_mRNA processing 4.89E-08 138/160 
10 Cell adhesion_Synaptic contact 2.21E-07 155/184 
 
Additionally, we found that 6 miRNAs (miR-203, miR-224, miR-422a, miR-455-3p, 
miR-494 and miR-636) were expressed in irradiated HCT116 KRAS WT cells but 
expression was completely abolished in irradiated HCT116 KRAS mutant cells. 
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The expression of 5 of the above miRNAs (all but miR-636) were also completely 
abolished in irradiated KRAS mutant cells but expressed in non-radiated KRAS 
mutant cells.  
MiR-224 has been previously shown in Chapter 3 to be 3.3 times more highly 
expressed in HCT116 KRAS WT cells compared to KRAS mutant cells. TLDA 
profiling data suggests that the expression of the six miRNAs, including miR-224, 
was reduced in response to radiation in both KRAS WT and mutant cells. 
However, as the miRNA expression levels were so low in mutant cells, they were 
effectively abolished in response to radiation.  
These observations would need to be validated using single probe qRT-PCR 
Taqman analysis. However, it raises the question of whether reducing the 
expression of miR-203, miR-224, miR-422a, miR-455-3p, miR-494 or miR-636 in 
HCT116 KRAS WT cells would lead to a more mutant-KRAS radiation response 
phenotype. If this was the case then the increased expression of these miRNAs 
may be indicative of a radiation sensitive phenotype and the over-expression of 
the specific miRNA (e.g. by transfection of a specific miRNA mimic) in mutant 
cells would also sensitise KRAS mutant cells to radiation.  
Bioinformatics analysis also showed that pathways and processes involved in 
cytoskeleton remodelling, EMT, cell adhesion as well as TGF-β signalling were 
enriched and predicted to be significantly associated with the predicted targets 
of the six aforementioned miRNAs (Table 5.7).  
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Table 5.7: Pathways and processed associated with the predicted targets of the 
six miRNAs abolished in HCT116 KRAS mutant cells in response to radiation 
 
Pathway name p value Ratio 
1 Cytoskeleton remodeling_TGF, WNT and cytoskeletal remodeling 1.09E-12 62/111 
2 Cytoskeleton remodeling_Cytoskeleton remodeling 3.55E-11 56/102 
3 Development_Regulation of epithelial-to-mesenchymal transition (EMT) 4.39E-11 41/64 
4 IGF family signaling in colorectal cancer 4.30E-10 38/60 
5 Cell adhesion_Chemokines and adhesion 4.30E-10 53/100 
6 Development_Thrombopoietin-regulated cell processes 1.19E-09 31/45 
7 Development_TGF-beta-dependent induction of EMT via SMADs 3.29E-09 26/35 
8 Development_BMP signalling 3.37E-09 25/33 
9 Development_TGF-beta receptor signaling 7.27E-09 32/50 
10 Stimulation of TGF-beta signaling in lung cancer 9.20E-09 31/48 
 
 
Process name p value Ratio 
1 Development_Hedgehog signaling 1.28E-08 139/254 
2 Reproduction_FSH-beta signaling pathway 1.31E-07 93/160 
3 Signal Transduction_TGF-beta, GDF and Activin signaling 1.31E-07 90/154 
4 Signal Transduction_BMP and GDF signaling 2.80E-07 59/91 
5 Development_EMT_Regulation of epithelial-to-mesenchymal transition 4.03E-07 120/225 
6 Development_Blood vessel morphogenesis 4.28E-07 121/228 
7 Signal transduction_NOTCH signaling 1.11E-06 123/236 
8 Development_Neurogenesis_Synaptogenesis 3.32E-06 97/180 
9 Cell cycle_G1-S Growth factor regulation 4.59E-06 103/195 
10 Cardiac development_FGF_ErbB signaling 5.84E-06 71/124 
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5.3.4. The role of miR-224 in the modulation of radiation response 
 
The knockdown of miR-224 in HCT116 KRAS WT cells has previously been shown, 
in Chapter 3, to increase KRAS activation and ERK 1/2 phosphorylation and 
switch the phenotype of KRAS WT cells to a more mutant-like phenotype. We 
therefore hypothesised that the knockdown of miR-224 in KRAS WT cells would 
increase radiation resistance.  
Flow cytometry was used to determine the proportion of cells with reduced 
viability in response to 5 Gy of radiation, as determined by the SYTOX 
AADvanced Dead Cell Stain kit and described in Section 2.2.16.3.  
The percentage of non-viable cells in irradiated samples compared to non-
treated controls was increased by 1.75-fold (p=0.09) in HCT116 KRAS WT cells 
compared to KRAS mutant cells (Figure 5.4). An increased fold-change indicates 
higher sensitivity to radiation as a higher proportion of cells have lost viability. 
The knockdown of miR-224 in KRAS WT cells did not significantly change cell 
viability compared to untransfected KRAS WT cells in response to radiation 
(Figure 5.4). This suggests that miR-224 may not have a role in regulating 
radiation response in colorectal cancer. Future studies would be directed 
towards testing this relationship using γH2AX Western blots and clonogenic 
survival assays.  
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Figure 5.4: The effect of miR-224 knockdown on radiation response. HCT116 KRAS WT miR-
224 knockdown cells, HCT116 KRAS WT negative control miRNA knockdown cells and 
untransfected HCT116 KRAS WT and mutant cells were seeded at a density of 2.5 x 10
4
 cells per 
3.5 cm diameter plate and irradiated in triplicate at 5 Gy, as described in Section 2.2.16.3. The 
SYTOX AADvanced Dead Cell Stain kit was used to assess changes in cell viability in treated cells 
compared to non-treated controls using a flow cytometer. Graph represents the fold change in 
percentage of non-viable cells from untreated to treated cells and the errors represent the SEM of 
three separate experiments. Significance (p≤0.05) was determined using independent T tests.  
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5.4. Discussion  
 
In colorectal cancer, a small number of studies have explored the role of miRNAs 
in radiation response and resistance. Svoboda et al (2008) analysed miRNA 
expression in cancer biopsies from rectal cancer patients before and 2 weeks 
after capecitabine-based chemo-radiotherapy. The study reports the consistent 
over-expression of miR-125b and miR-137 in cancer biopsies after therapy. A 
later clinical study profiled miRNAs in good and poor responders to 5-FU or 
capecitabine-based chemo-radiotherapy (Svoboda et al, 2012). Svoboda et al 
(2012) showed that the expression of miR-215, miR-190b and miR-29b were 
increased in non-responders whereas let-7e, miR-196b, miR-450a, miR-450b-5p 
and miR-99a were decreased.  
Recent studies have reported that miR-21 increased resistance to both 5-FU and 
radiation (Deng et al, 2014) and that miR-124 sensitised colorectal cells to 
radiation through targeting PPRX1, a new EMT inducer and stemness regulator 
(Zhang et al, 2014). The work by Saleh et al (2011) and Luu et al (2013) showing 
the role of let-7 in modulating radiation response in HCT116 colorectal cancer 
cells have been previously discussed.  
The aim of the present study was firstly to identify miRNAs that were 
differentially expressed in HCT116 KRAS WT and mutant cell lines following 
radiation, and the predicted pathways and processes that they may mediate. 
There were 16 and 11 miRNAs that were differentially expressed in response to 
radiation in KRAS mutant and KRAS WT cells compared to their non-treated 
controls. Bioinformatics analysis showed that, despite differences in KRAS 
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mutation status, very similar pathways and processes were predicted to be 
associated with response to radiation in both cell lines.  
The predicted role of cytoskeleton remodelling, EMT and increased cell adhesion 
is consistent with previous studies showing cell phenotypes mediated in 
response to radiation. Radiation has been shown to enhance migration and 
invasiveness in colorectal cancer, alongside the up-regulation of MMPs (Kumar 
et al, 2000; Speake et al, 2005) and the molecular and morphological changes 
associated with EMT, including the remodelling of the cytoskeleton 
(Andarawewa et al, 2007; Kawamoto et al, 2012).  
The bioinformatics data predicted an involvement of TGF-β signalling in EMT, 
especially with the miRNAs involved in radiation response in KRAS mutant cells 
and the six miRNAs that were abolished in KRAS mutant cells following 
irradiation. This is consistent with the findings of Andarawewa et al (2007), who 
specifically showed that both TGF-β and irradiation was required to induce EMT 
in human mammary epithelial cells (HMEC). It is well established that TGF-β is a 
tumour suppressor during the early stages of carcinogenesis, but has the ability 
to switch to a cancer promoter in the latter stages (Bierie & Moses, 2006). Gene 
profiling data from Andarawewa et al (2007) suggested that ERK/MAPK 
activation may be important in inducing TGF-β and radiation induced EMT. They 
confirmed that the phosphorylation of ERK 1/2 and MEK 1/2 was markedly 
increased in response to TGF-β and radiation and that the blockage of MEK by 
UO126 decreased ERK activation, reversed EMT and decreased cell migration 
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(Andarawewa et al, 2007). This indicates the cross-talk between two different 
pathways that may occur during KRAS-mediated radiation resistance. 
The bioinformatics data also suggested a role for the immune response in 
radiation response. As discussed in Chapter 4, previous studies have described a 
link between the activation of immune and inflammatory mediators and cancer 
development (Chen et al, 2007). The activation of transcription factors such as 
NF-kB, Stat3 and HIF1α are known to play key roles in radiation-induced 
inflammatory responses (Multhoff & Radons, 2012). The activation of these 
transcription factors causes the recruitment of immune cells to the cancer 
microenvironment and leads to the production of pro-inflammatory cytokines, 
chemokines, growth factors, and the expression of anti-apoptotic genes, 
allowing cancer cells to gain a survival advantage (Multhoff & Radons, 2012). 
The induction of EMT and immune responses shows that through the normal 
mechanisms of cell survival, radiation treatment can also induce increased cell 
proliferation and cancer growth as well as cancer metastasis, thus contributing 
to radiation resistance.  
The present study also identified a possible common radiation response miRNA 
expression signature. In both HCT116 KRAS mutant and WT cells, 7 miRNAs (miR-
16, miR-17, miR-29a, miR-100, miR-200b, miR-221, miR-886-3p) were commonly 
over-expressed in response to radiation. The increased expression of miR-29a, 
miR-221 and miR-17 has already been shown to promote colorectal cancer 
progression. The present study has previously shown in Chapter 3 (Section 3.1.2, 
Table 3.2) that miR-29a is one of the most consistently reported over-expressed 
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miRNA in colorectal cancer. MiR-29a has been reported as a novel serum marker 
for early detection of liver metastasis (Wang & Gu, 2012) and has recently been 
shown to promote cell invasion in colorectal cancer cells (Tang et al, 2014). 
Additionally miR-17, a member of the miR-17-92 cluster, is reported to be over-
expressed in colorectal cancer and to contribute to colorectal cancer cell 
invasion (Zhang et al, 2014). Qin et al (2014) also recently report the 
involvement of miR-221 in promoting colorectal cancer cell invasion and 
metastasis by directly targeting and repressing the metastasis suppressor, RECK. 
Thus, there are many ways by which miRNAs that are induced by radiation can 
mediate the aforementioned predicted radiation-response phenotypes. The 
transcription and expression of miRNAs is known to be caused by the action of 
transcription factors (Chang et al, 2007; Chang et al, 2008). Further work could 
therefore be directed towards exploring whether the increased transcription 
and expression of the miRNA highlighted in the present study in response to 
radiation is, for example, p53 or Nf-kB dependent.  
The present study also aimed to identify miRNAs that may, in addition to the let-
7 family as previously reported, have important roles in modulating KRAS-
mediated radiation resistance. We have identified a group of 22 miRNAs that 
were induced in irradiated KRAS mutant cells compared to irradiated KRAS WT 
cells and may possibly be associated with a radiation resistant phenotype. We 
have also identified a group of 6 miRNAs, which included miR-224, that were 
abolished in irradiated KRAS mutant cells. The knockdown of miR-224 in HCT116 
KRAS WT cells however did not mediate a KRAS-mediated resistant phenotype in 
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KRAS WT cells. However, miR-224 has been shown to be associated with a 
radiation sensitive phenotype in medulloblastomas (Gokhake et al, 2010) and 
glioblastomas (Upraity et al, 2014). The data in the present study does provide a 
starting point from which candidate miRNAs can be explored further for their 
role in radiation response in future studies.    
5.5. Conclusions and Future work 
5.5.1. Conclusions 
 
The present study has identified a common miRNA radiation response 
expression signature, where the miRNAs may have roles in mediating radiation-
induced inflammation and cancer invasion.  The study has also suggested 
miRNAs that may play a role in regulating KRAS-mediated radiation resistance.  
5.5.2. Future work 
 
Future work would be directed towards exploring the role of some of the other 
listed miRNAs in radiation response in colorectal cancer in vitro and determining 
any association with regulating KRAS expression and signalling. There is also a 
need for more detailed time course experiments to determine the extent of 
miRNA induction or inhibition at different radiation doses.  
Radiotherapy is usually administered in a regimen involving 5-FU-based 
chemotherapy. A major priority will be to conduct detailed chemo-radiation 
experiments in isogenic KRAS WT and mutant cells colorectal cancer cells to 
investigate the links between miRNAs and KRAS signalling in response to both 5-
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FU and radiation. Moreover, using the drug resistant cell lines generated and 
described in Chapter 4, future work would also be directed towards investigating 
the miRNAs and pathways involved in cross-resistance to radiation treatment.  
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Chapter 6 
6. Conclusions and future perspectives 
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The present study set out to add to ongoing research into the molecular and 
genetic basis of colorectal cancer development and the mechanisms of 
resistance to commonly administered chemotherapeutic drugs and 
radiotherapy. Colorectal cancer remains a major cause of cancer-related death 
in the UK and is partly attributed to a failure to detect the disease at its early 
stages and also to inherent and acquired resistance to current drug and 
radiation treatment.  
Previous studies have shown at a molecular level variability amongst colorectal 
cancer patients in disease progression and prognosis as well as in response to 
treatment. Inter-patient differences in KRAS mutation status in colorectal 
cancers have been shown to impact patient survival (Andreyev et al, 1998; 
Andreyev et al, 2001; Conlin et al, 2005) and response to therapy such as the 
anti-EGFR monoclonal antibody drug cetuximab (Lievre et al, 2006; Bokemeyer 
et al, 2008; Amado et al, 2008). Mutant KRAS has also been shown in colorectal 
cancer cell lines to affect resistance to radiation (Jeong et al, 2009; Oh et al, 
2010; Luu et al, 2013). Moreover, inter-patient differences in p53 status or the 
expression of genes encoding drug transporters, for example, have been shown 
to impact both inherent and acquired drug resistance (Boyer et al, 2004; 
Gazzaniga et al, 2010). 
MiRNAs, which were first discovered in the early nineties (Lee et al, 1993), have 
emerged as additional regulators of gene expression. Calin et al (2002) first 
reported a role for miRNAs in the development of cancer and subsequent 
studies have also reported on the integral role miRNAs play in modulating 
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cellular drug and radiation response and resistance in a number of cancers 
(Hummel et al, 2010). The general aims of the present study were therefore to 
explore the potential of miRNAs as biomarkers of disease progression and 
treatment response in colorectal cancer.  
Given the importance of KRAS mutation status in patient survival as reported 
previously in our research group (Conlin et al, 2005), the present study aimed to 
firstly explore how inter-patient variability in miRNAs regulating KRAS and its 
signalling pathways affected disease progression and their potential to further 
sub-classify colorectal cancers. My data showed the over-expression of miR-224 
in colorectal cancer to be an early and persistent event in colorectal cancer as it 
was one of 7 miRNAs found to be increased in colorectal adenomas and cancers 
compared to patient-matched normal tissue. My study also showed that miR-
224 was the most abundantly differentially expressed miRNA in isogenic KRAS 
WT and mutant HCT116 colorectal cancer cell lines, with a higher expression of 
miR-224 in KRAS WT cells. The knockdown of miR-224 in KRAS WT cells 
increased the amount of GTP-bound activated KRAS and also increased ERK 1/2 
phosphorylation, thus increasing KRAS signalling and mimicking a KRAS mutant 
phenotype. Furthermore, miR-224 expression was found to be under-expressed 
in BRAF mutant colorectal cancers compared to KRAS and BRAF WT cancers. This 
suggests that the expression of miR-224 was suppressed by a currently unknown 
factor downstream of RAF-1 in both the KRAS mutant cell lines and BRAF mutant 
colorectal cancers.  
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Additionally, miR-224 regulated 5-FU sensitivity by indirectly affecting 
expression of 5-FU metabolising enzymes and perhaps through the regulation of 
KRAS signalling, although more work is required to further explore and verify 
this relationship.  
MiR-224 knockdown also reduced cell invasion in vitro and miR-224 expression 
was shown to be decreased in lymph node metastases but increased in liver 
metastases assessed in comparison to patient-matched primary colorectal 
cancers. Inter-patient differences in miR-224 expression in liver metastases 
suggest that miR-224 may have an important role in driving metastasis in some 
patients whereas in other patients, other mechanisms may dominate.  
In the wider context, the present study has for the first time showed that miR-
224 regulates KRAS signalling. It also suggests that miR-224 may have an 
important role in driving disease progression in colorectal cancer, although it is 
too early to state whether this is likely to be directly through KRAS-mediated 
tumorigenesis. Taken together, miR-224 could be a useful disease progression 
biomarker in conjunction with other markers to aid in determining patient 
prognosis. MiRNAs in blood serum have been shown to be stable biomarkers of 
disease progression in colorectal cancer (Chen et al, 2008; Mitchell et al, 2008), 
and thus exploring the potential of miR-224 as a non-invasive serum biomarker 
would be a future objective. Our close links with the Scottish National Bowel 
Screening Programme, directed by Professor Steele, will greatly facilitate these 
studies. 
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I have highlighted that a single miRNA can target a multitude of genes due to 
imperfect complementarity. Therefore miRNAs can in theory target and repress 
the translation of genes that have opposing effects on a particular pathway. 
Previous studies have, for example, shown an oncogenic role for miR-224 
through its repression of the tumour suppressor SMAD4 (Wang et al, 2013; 
Zhang et al, 2013a) and a pro-apoptotic role through the repression of the 
apoptosis inhibitor API5 (Wang et al, 2008). This shows that the miRNA-mRNA 
network within a given pathway is tightly controlled and that the net effect of 
modulating the expression of a miRNA can be tipped in favour of proliferation or 
apoptosis depending on certain external selective pressures. It also 
demonstrates the complexities of trying to elucidate how miRNAs regulate 
particular cellular phenotypes. MiRNAs are, however, better placed than protein 
coding genes to aid as biomarkers. The differential expression of a single miRNA 
may occur as a result of many upstream molecular events and represents an 
easier marker to exploit and detect. 
My second aim was to generate 5-FU and oxaliplatin resistant cell lines by 
incremental drug selection and to further investigate the role of miRNAs in the 
mechanism of acquired resistance. My findings show that miRNA and mRNA 
profiling and bioinformatics analysis predicted cancer-related pathways and 
processes involved with cell invasion, cell cycle regulation and glycolysis as drug 
resistance mechanisms, which were then experimentally validated in paired 5-
FU and oxaliplatin resistant and sensitive cell lines. The study also identified 
candidate drug resistance genes that were some of the most abundantly over or 
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under-expressed genes in drug resistant cell lines and were reported to be 
involved in the aforementioned cancer-related pathways and processes (ACTB, 
TUBB, ANGPTL4, MCM4, ALDOA, PGAM1, and AKR1C3). A miRNA target 
prediction database was then used to predict how my proposed candidate drug 
resistance miRNAs could regulate the expression of my proposed candidate 
genes and thus modulate drug resistance mechanisms. The expression of the 
DNA replication licensing factor, MCM4 which was under-expressed in my drug 
resistant cell lines could, for example, be regulated by candidate drug resistance 
miRNAs such as miR-24 or miR-93 which were overexpressed in drug resistant 
cells. The under-expression of miR-224 was also shown to be associated with a 
drug resistance phenotype.    
This work was one of four studies conducted concurrently in colorectal cancer 
where miRNAs had been profiled in paired 5-FU or oxaliplatin resistant and 
sensitive cell lines (Akao et al, 2011; Kurokawa et al, 2012; Zhou et al, 2014). This 
work benefits from the use of controlled, cell line backgrounds to identify novel 
miRNA and mRNA markers of 5-FU and/or oxaliplatin drug resistance in 
colorectal cancer that could then be tested in patients to determine whether 
they discriminate between good and poor responders to drug treatment.  
Thirdly, the present study aimed to further investigate the molecular basis of 
radiation response and KRAS-mediated radiation resistance using miRNA 
expression profiling in isogenic KRAS WT and mutant colorectal cancer cells 
following irradiation. Bioinformatics analysis predicted that pathways and 
processes involved in radiation response were similar to those predicted in 
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acquired drug resistance. Adding to previous studies describing a role for 
members of the let-7 family in regulating KRAS signalling and radiation response, 
the present study also identified a number of miRNAs, including miR-224, that 
were differentially expressed in irradiated KRAS WT and mutant cells and that 
may modulate KRAS-mediated radiation resistance. A major priority to this work 
is also to conduct more detailed chemo-radiation experiments in isogenic KRAS 
WT and mutant colorectal cancer cells and paired 5-FU or oxaliplatin resistant 
and sensitive colorectal cancer cells.  
The similarities in the pathways and processes associated with miRNAs 
differentially expressed in acquired 5-FU and oxaliplatin resistance, and also in 
the acute response to radiation suggest that cells undergo a similar stress 
response (long term or acute) in both experiments. However, it does also raise 
questions on whether these pathways and processes are enriched as a result of 
the predicted targets of a specific list of miRNAs, or whether it is likely that most 
miRNA lists would lead to similar enrichment of the aforementioned pathways 
and processes, perhaps due to the large number of genes that a single miRNA 
can target. Nevertheless, as discussed previously, many of the aforementioned 
pathways and processes have been experimentally validated in previous studies.  
The present study has suggested some potential markers and modulators of 
disease progression and resistance to drug and radiotherapy. The natural 
progression of this work will be to validate the most promising candidates in 
cancers from cohorts of colorectal patients who have received chemotherapy 
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and/or radiotherapy. The identification of these cohorts is a task that is already 
underway.  
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Appendix A: TLDA microRNA ‘A’ layout 
Appendix E: List of miRNAs expressed in colorectal cancers, normal mucosa and 
adenomas 
Appendix G: The correlation of miR-224 expression with gene expression data 
from Affymetrix data in 41 colorectal cancers analysed in Section 3.3.3 
Appendix H: Predicted gene targets of the 12 miRNAs differentially expressed in 
HCT116 KRAS WT and mutant cells 
Appendix I: Predicted miR-224 target genes 
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resistant cells relative to their respective parental cells 
Appendix K: Genes commonly or uniquely differentially expressed in drug 
resistant cells compared to parental cells. 
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Appendix B: Inter-patient variability in the expression of individual miRNAs 
 
 
Figure B1 
317 
 
 
 
Figure B1: Inter-patient variability in the expression of individual miRNAs. TLDA miRNA ‘A’ 
cards (Life Technologies) were used to profile the expression of 377 miRNAs in 12 colorectal 
cancers, as detailed in Section 2.2.9.8. The expression of the second set of 55 miRNAs on the 
TLDA card, relative to the control miRNA let-7a, is shown. Each bar represents a single point 
determinant of relative expression. 
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Figure B2: Inter-patient variability in the expression of individual miRNAs. TLDA miRNA ‘A’ 
cards (Life Technologies) were used to profile the expression of 377 miRNAs in 12 colorectal 
cancers, as detailed in Section 2.2.9.8. The expression of the third set of 55 miRNAs on the TLDA 
card, relative to the control miRNA let-7a, is shown. Each bar represents a single point 
determinant of relative expression. 
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Figure B3: Inter-patient variability in the expression of individual miRNAs. TLDA miRNA ‘A’ 
cards (Life Technologies) were used to profile the expression of 377 miRNAs in 12 colorectal 
cancers, as detailed in Section 2.2.9.8. The expression of the fourth set of 55 miRNAs on the TLDA 
card, relative to the control miRNA let-7a, is shown. Each bar represents a single point 
determinant of relative expression. 
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Figure B4: Inter-patient variability in the expression of individual miRNAs. TLDA miRNA ‘A’ 
cards (Life Technologies) were used to profile the expression of 377 miRNAs in 12 colorectal 
cancers, as detailed in Section 2.2.9.8. The expression of the fifth set of 55 miRNAs on the TLDA 
card, relative to the control miRNA let-7a, is shown. Each bar represents a single point 
determinant of relative expression. 
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Figure B5: Inter-patient variability in the expression of individual miRNAs. TLDA miRNA ‘A’ 
cards (Life Technologies) were used to profile the expression of 377 miRNAs in 12 colorectal 
cancers, as detailed in Section 2.2.9.8. The expression of the sixth set of 55 miRNAs on the TLDA 
card, relative to the control miRNA let-7a, is shown. Each bar represents a single point 
determinant of relative expression. 
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Figure B6: Inter-patient variability in the expression of individual miRNAs. TLDA miRNA ‘A’ 
cards (Life Technologies) were used to profile the expression of 377 miRNAs in 12 colorectal 
cancers, as detailed in Section 2.2.9.8. The expression of the final set of 47 miRNAs on the TLDA 
card, relative to the control gene let-7a, is shown. Each bar represents a single point determinant 
of relative expression. 
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Appendix C: Electropherograms generated from the 12 normal colorectal mucosa 
samples obtained from Tayside Tissue bank 
 
RNA was extracted from 12 normal colorectal mucosa samples, patient-matched to 
colorectal cancers described in Table F1 (Appendix F). The 3 normal mucosa samples 
used for TLDA miRNA profiling were chosen based on their high RNA yield and integrity 
(RIN) relative to other samples following RNA extraction as assessed by methods 
described in Section 2.2.8.4. The electropherograms below were generated by the 
Bioanalyzer 2100 and display RNA concentration (ng/µl), the 18s and 28s ribosomal 
subunit ratios (28s/18s) and RNA integrity number (RIN). 
In the present study, patient samples 3356 (Patient 3; RIN of 10), 3362 (Patient 4; RIN of 
10) and 3371 (Patient 9; RIN of 9.8) were used due to their very high RIN. Sample 4324 
(Patient 12) which also had a RIN of 10 was not used due to the low RNA concentration 
(44 ng/µl). 
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Appendix D: Electropherograms generated from the 12 colorectal adenomas obtained 
from Tayside Tissue bank  
RNA was extracted from 12 colorectal adenoma samples that displayed low or high 
grades of dysplasia as described in Table D1. The six samples (3 low grade, 3 high grade) 
used for TLDA miRNA profiling were chosen based on their high RNA yield and integrity 
(RIN) relative to other samples following RNA extraction as assessed by methods 
described in Section 2.2.8.4. The electropherograms below were generated by the 
Bioanalyzer 2100 and display RNA concentration (ng/µl), the 18s and 28s ribosomal 
subunit ratios (28s/18s) and RNA integrity number (RIN). 
In the present study, patient samples 5932 (RIN of 8.2), 5472 (RIN of 8.1) and 5284 (RIN 
of 7.8) were chosen from the low grade adenoma group. Patient samples 3817 (RIN of 
5.3), 3904 (RIN of 8.9) and 3680 (RIN of 5.7) were chosen from the high grade adenoma 
group.  
Table D1: List of colorectal adenomas received from Tayside Tissue Bank 
Patient ID Histology Grade of dysplasia  
2419 Tubulovillous High 
3680 Tubulovillous High 
3817 Tubulovillous High 
3904 Tubulovillous High 
4601 Tubulovillous Low 
4682 Tubulovillous High 
5284 Tubulovillous Low 
5472 Tubulovillous Low 
5918 Tubular/Tubulovillous Low 
5932 Tubular Low 
6002 Tubulovillous Low 
6301 Tubulovillous High 
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Appendix F: The patient details and KRAS/BRAF mutation status of colorectal cancers 
used in the present study 
 
Table F1: Patient details and the staging and KRAS/BRAF mutation status of colorectal 
cancers described and analysed in Section 3.3.3 (Figure 3.3) 
Patient 
Patient 
ID Age Sex 
Dukes' 
Stage TMN Stage 
KRAS/BRAF 
mutation status 
1 3180 76 F B T3 N0 MX WT 
2 3197 83 M C T3 N1 MX WT 
3 3356 78 M B T4 N0 MX WT 
4 3362 63 F A T1 N0 MX WT 
5 3300 72 F B T3 N0 MX BRAF mutant 
6 3365 74 M C1 T4 N2 MX BRAF mutant 
7 4063 85 F B T3 N0 MX BRAF mutant 
8 4367 87 F C1 T4 N1 MX BRAF mutant 
9 3371 69 F C T3 N2 MX KRAS mutant 
10 3467 71 M B T3 N0 MX KRAS mutant 
11 4060 54 M A T1 N0 MX KRAS mutant 
12 4324 69 F C1 T3 N2 MX KRAS mutant 
 
Colorectal cancers and matched normal mucosa from patients 3, 4 and 9 used for TLDA analysis 
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Table F2: Patient details and the staging and KRAS/BRAF mutation status of colorectal 
cancers described and analysed in Section 3.3.3 (Figure 3.4) 
Patient 
ID Age Sex 
Dukes' 
Stage TMN Stage 
KRAS/BRAF mutation 
status 
3605 65 M C1 T4 N1 MX WT 
4036 79 F B Not known WT 
4124 53 F B T3 N0 MX WT 
4216 82 M B T3 N0 MX WT 
4223 80 F B T3 N0 MX WT 
4248 83 F C2 T4 N2 MX WT 
4257 68 F A T2 N0 MX WT 
4327 76 M A T2 N0 MX WT 
4388 75 F C T4 N1 MX WT 
4431 78 F B T4 N0 MX WT 
3433 81 F B T3 N0 MX BRAF mutant 
3828 79 M C T3 N1 MX BRAF mutant 
4335 76 M B T3 N0 MX BRAF mutant 
4562 63 F B T3 N0 MX BRAF mutant 
4576 60 M B T3 N0 MX BRAF mutant 
3143 63 M B T3 N0 MX KRAS mutant 
3216 75 M C1 T3 N1 MX KRAS mutant 
3462 79 F B T3 N0 MX KRAS mutant 
3686 82 M C T4 N2 MX KRAS mutant 
3759 80 F C1 T3 N1 MX KRAS mutant 
3829 74 M C T3 N1 MX KRAS mutant 
4076 83 F B T2 N0 MX KRAS mutant 
4113 82 M C T4 N1 MX KRAS mutant 
4238 64 F C T3 N1 MX KRAS mutant 
4349 73 M C1 T2 N1 MX KRAS mutant 
4392 83 F C1 T3 N1 MX KRAS mutant 
4426 88 F B T3 N0 MX KRAS mutant 
4439 47 F B T3 N0 MX KRAS mutant 
4467 77 M B T3 N0 MX KRAS mutant 
 
 
 
 
 
 
335 
 
 
 
Appendix L: Pathways and processes associated with differentially expressed genes in 
drug resistant cells  
Table L1: Pathways and processes associated with genes under-expressed in both 5-FU 
and oxaliplatin resistant DLD-1 cells   
 
Pathway Name p value Ratio 
1 Cell cycle_Role of APC in cell cycle regulation 5.10E-09 17/31 
2 Cell cycle_Start of DNA replication in early S phase 4.62E-08 16/31 
3 Cell cycle_Spindle assembly and chromosome separation 4.62E-08 16/31 
4 Cell cycle_Chromosome condensation in prometaphase 2.64E-07 12/20 
5 Cell cycle_Role of Nek in cell cycle regulation 5.49E-07 14/28 
6 Cell cycle_The metaphase checkpoint 2.56E-06 15/35 
7 LRRK2 in neurons in Parkinson's disease 4.14E-06 14/32 
8 Cell cycle_Role of 14-3-3 proteins in cell cycle regulation 9.46E-06 11/22 
9 dATP/dITP metabolism 1.33E-05 18/53 
10 ATP/ITP metabolism 1.50E-05 24/84 
 
 
Process Name p  value Ratio 
1 Cell cycle_Mitosis 1.07E-16 60/174 
2 Cell cycle_Core 1.85E-15 45/113 
3 Cell cycle_S phase 1.93E-13 49/145 
4 Cell cycle_G2-M 1.09E-12 59/203 
5 Translation_Translation initiation 2.48E-12 50/159 
6 Cytoskeleton_Spindle microtubules 7.20E-08 32/106 
7 Cell cycle_G1-S 6.17E-07 40/161 
8 DNA damage_DBS repair 1.09E-06 30/107 
9 DNA damage_Checkpoint 1.16E-06 33/124 
10 Cytoskeleton_Intermediate filaments 1.25E-05 23/80 
 
Table L2: Pathways and processes associated with genes over-expressed in both 5-FU 
and oxaliplatin resistant DLD-1 cells 
 
 
Pathway Name p value Ratio 
1 Protein folding and maturation_Angiotensin system maturation 1.20E-04 9/31 
 
 
 
 
 
Process Name p value Ratio 
1 Signal transduction_Leptin signaling 1.75E-04 15/86 
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Table L3: Pathways associated with genes under-expressed in both 5-FU and oxaliplatin 
resistant HCT116 cells 
 
Pathway Name p value Ratio 
1 Development_Role of IL-8 in angiogenesis 4.10E-05 4/52 
2 G-protein signaling_G-Protein alpha-i signaling cascades 8.77E-05 3/23 
3 Transport_ACM3 in salivary glands 1.00E-04 3/24 
4 Transport_Alpha-2 adrenergic receptor regulation of ion channels 1.60E-04 3/28 
5 
Regulation of lipid metabolism_Regulation of lipid metabolism via 
LXR, NF-Y and SREBP 1.78E-04 3/29 
6 Membrane-bound ESR1: interaction with G-proteins signaling 3.15E-04 3/35 
7 Muscle contraction_Relaxin signaling pathway 3.72E-04 3/37 
8 Amitraz-induced inhibition of Insulin secretion 4.10E-04 2/8 
9 
Regulation of lipid metabolism_Insulin regulation of fatty acid 
metabolism 5.82E-04 3/43 
 
No significantly associated processes 
 
Table L4: Pathways associated with genes over-expressed in both 5-FU and oxaliplatin 
resistant HCT116 cells 
 
Pathway Name p value Ratio 
1 Cell adhesion_ECM remodeling 2.20E-06 6/51 
2 Transcription_Role of AP-1 in regulation of cellular metabolism 2.02E-04 4/38 
3 Immune response_IL-1 signaling pathway 3.29E-04 4/43 
4 
Regulation of lipid metabolism_Stimulation of Arachidonic acid 
production by ACM receptors 4.27E-04 4/46 
 
 
Process Name p value Ratio 
1 Proteolysis_Connective tissue degradation 2.19E-05 7/119 
2 Inflammation_Kallikrein-kinin system 6.27E-05 7/140 
3 Reproduction_Feeding and Neurohormone signaling  9.04E-05 8/201 
4 Proteolysis_ECM remodeling 3.27E-04 5/83 
5 Inflammation_Amphoterin signaling 1.34E-03 5/113 
6 Cell cycle_G1-S Interleukin regulation 1.89E-03 5/122 
7 Immune response_Th17-derived cytokines 3.09E-03 4/83 
 
 
